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Thiopeptins are highly decorated thiopeptide antibiotics similar in structure to 
thiostrepton A and harbor two unusual features. All thiopeptins contain a thioamide, a rare 
moiety among natural products, and a subset of thiopeptins present with a piperidine in the 
core macrocycle rather than the more oxidized dehydropiperidine or pyridine rings 
typically observed in the thiopeptides. Here, we report the identification of the thiopeptin 
biosynthetic gene (tpn) cluster in Streptomyces tateyamensis and the gene products, 
TpnLMNW.  
TpnW shows sequence similarity to transaminases and is likely involved in the 
biosynthesis of the 4-(1-hydroxyethyl)quinoline-2-carboxylic acid (HEQ) moiety of 
thiopeptin. HEQ is derived from L-tryptophan and the second step of HEQ biosynthesis 
requires a transaminase that catalyzes the conversion of 2-methyl-L-tryptophan to 3-(2-
methylindolyl)pyruvate. In vitro reconstitution of TpnW activity confirmed that this 
enzyme is a 2-methyl-L-tryptophan aminotransferase. TpnW is able to utilize 
3-indolylpyruvate, p-hydroxyphenylpyruvate, and phenylpyruvate as α-keto acid acceptors 
but not pyruvate, oxaloacetate, or α-ketoglutarate. 
TpnMN share homology to YcaO and TfuA proteins, respectively, responsible for 
thioamidation of peptidic substrates. Heterologous expression of TpnMN in the 
thiostrepton A producer, Streptomyces laurentii (S. laurentii), led to the production of a 
metabolite with a mass matching a thioamidated thiostrepton A. Structural characterization 
of this metabolite is still required to determine if it contains a thioamide suggested by the 
proposed functions of TpnMN. 
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 TpnL shows sequence similarity to (deaza)flavin-dependent oxidoreductases. 
Heterologous expression of TpnL in the thiostrepton A producer, S. laurentii, led to the 
production of a piperidine-containing analog. Binding studies revealed TpnL preferentially 
binds the deazaflavin cofactor, coenzyme F420, and in vitro reconstitution of TpnL activity 
confirmed that this enzyme is an F420H2-dependent dehydropiperidine reductase. The 
identification of TpnL and its activity establishes the basis for the piperidine-containing 
series a thiopeptides, one of the five main structural groups of this diverse family of 






































Thiopeptides (examples shown in Figure 1.1 1-6), or polythiazolylpeptides, are 
ribosomally-synthesized and post-translationally modified peptides (RiPPs) with extensive 
chemical modifications that impart potent antibacterial, antimalarial, and anticancer 
properties.1-3 Thiopeptides are distinguished from other peptide metabolites by their six-
membered nitrogenous heterocycle that completes a rigid macrocyclic core found in all 
thiopeptides. The macrocyclic scaffold is decorated by azol(in)es and dehydrated amino 
acids such as dehydroalanine (Dha) and dehydrobutyrine (Dhb). Some thiopeptides present 






Figure 1.1: Examples of thiopeptides isolated from various Gram-positive bacteria; Sch 
18640 (1), thiostrepton A (2), Sch 40832 (3), thiomuracin A (4), micrococcin P1 (5), and 
nosiheptide (6).4-10 The central nitrogenous heterocycle that completes the main 
macrocycle common in all thiopeptides is in blue. Some thiopeptides have a second loop 




Since the discovery of the first thiopeptide, micrococcin (5), in 1948, dozens of 
thiopeptides were isolated from Gram-positive bacteria of both terrestrial and marine 
origin.7, 11-13 The complex structure of thiopeptides, however, has made structural 
characterization a difficult task. It was not until 2009, over fifty years after its discovery, 
that the structure of micrococcin P1 (identical to 5, Figure 1.1) was elucidated.
10 A total 
synthesis of a reference compound was shown to be spectroscopically and polarimetrically 
identical to 5, enabling the assignment of the absolute configuration of micrococcin.10 
Thiostrepton A (2), a prototypical thiopeptide, was first isolated from Streptomyces azureus 
in 1954 and later isolated from Streptomyces laurentii.8, 14-16 X-ray crystallographic 
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experiments and detailed NMR studies during the 1970s and 1980s, followed by 
multidimensional NMR methods confirmed its structural assignment in 1989.17-20 Despite 
advances in spectroscopic techniques, many thiopeptides still remain uncharacterized.1 
This is in part due to difficulties in obtaining crystallographic data which has left some 
stereochemical and connectivity assignments ambiguous. Efforts to structurally 
characterize thiopeptides, however, have led to the development of more efficient methods 
to synthesize these complex natural products, spurred an investigation of the structural 
basis of its biological activities, and have bolstered the development of thiopeptide analogs.  
Despite impressive biological activities of thiopeptides, clinical use of these drugs 
has been limited in large part due to low bioavailability caused by their low aqueous 
solubilities. Therefore, there is interest in the discovery, design, and production of 
thiopeptide analogs with improved pharmacokinetic parameters. While the chemical 
syntheses of thiopeptides such as promothiocin A (Figure 1.3, 8), microccocin P1 5, and 
thiostrepton A 2 have been accomplished, it remains uneconomical and impractical for 
industrial scale use due to low net yield and the need for lengthy multistep syntheses.10, 21-
22 Nonetheless, some thiopeptides are commercially available as isolates from bacterial 
cultures. Accordingly, semisynthetic and biosynthetic engineering strategies appear to be 
viable approaches in developing and producing clinically useful thiopeptide antibiotics. 
For example, the semisynthetic modifications of nocathiacin I 7 (Figure 1.2), thiostrepton 
A 2, and GE2270 A (Figure 1.3, 9) have produced promising analogs.23-27 Nocathiacin I 7, 
isolated from the fermentation broth of Norcadia sp. ATCC 202099, was subjected to a 
series of modifications on the dehydroalanine tail and the hydroxypyridine core.23-24 A 
structure-activity relationship study of 7 found that the dehydroalanine tail region tolerated 
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basic residues such as tertiary amines and tertiary amides over acidic residues such as 
hydroxyls.23-24 A nocathiacin I analog (Figure 1.2, 7a), with a terminal morpholine group 
and a methoxypyridine core, exhibited over ten-fold increase in water solubility while 
retaining comparable biological activities with 7.24 In addition to its antibacterial activities 
against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis, the 





Figure 1.2: Structures of nocathiacin I (7) and its derivative (7a) with a terminal 




The derivatization of GE2270 A 9 has led to the discovery of an analog (Figure 1.3, 
9a) with a much narrower antibiotic spectrum and the drug is currently under phase IIb 
clinical trials as a topical ointment effective against antibiotic-resistant strains of 
Propionibacterium acnes.25 Meanwhile, GE37468 A (Figure 1.3, 10), thiocillin I (Figure 
1.3, 11) and thiostrepton A 2 biosynthetic machineries appear to tolerate certain 
modifications on the peptide substrate (as well as the quinaldic acid moiety of thiostrepton 





Figure 1.3: Additional examples of thiopeptides: promothiocin A (8), GE2270 A (9) and 
its analog (9a), GE37468 A (10), thiocillin I (11), and siomycin A (12). The central 
nitrogenous heterocycle that completes the main macrocycle common in all thiopeptides is 




Both semisynthetic and biosynthetic engineering strategies depend on the isolation 
of thiopeptides from bacterial fermentation cultures. Therefore, our capacity to derivatize 
these compounds is dependent on our knowledge of the thiopeptide biosynthetic machinery 
and our ability to manipulate the biosyntheses of these complex metabolites. Great effort 
has been made in characterizing thiopeptide biosynthetic pathways since the discovery of 
the thiocillin 11, thiostrepton A 2, and siomycin (Figure 1.3, 12) biosynthetic gene clusters 
in 2009.37-39 Many aspects of thiopeptide biosyntheses remain unclear, including the 
formation of the central nitrogenous heterocycle integral to all thiopeptides and the timing 
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in which modifications are installed on the thiopeptide framework. The remainder of this 
chapter will introduce our current understanding of thiopeptides, with a focus on their 
biosyntheses. 
 
1.2 Structural classification of thiopeptides 
To date, over 100 distinct thiopeptides have been identified and are classified as 
structural series a-e based on the oxidation state of the central, six-membered nitrogenous 
ring in the core macrocycle (Figures 1.1-1.4).1, 40 Series a thiopeptides such as Sch 18640 1, 
isolated from Micromonospora arborensis, contain a fully reduced piperidine ring while 
thiostrepton A 2, isolated from Streptomyces azureus and Streptomyces laurentii, siomycin 
A 12, isolated from Streptomyces sioyaensis, and other series b thiopeptides are observed 
with a dehydropiperidine core.9, 41-42 The series c thiopeptide contains an unusual 
dihydroimidazopiperidine moiety and Sch 40832 3, isolated from Micromonospora 
cabonacea var. africana, is the sole known member of this structural class.6 
Thiomuracin A 4, isolated from Nonomuraea sp. Bp3714-39, micrococcin P1 5, isolated 
from Micrococcus and Bacillus species, promothiocin A 8, isolated from Streptomyces sp. 
SF2741, GE2270 A 9, isolated from Planobispora rosea, GE37468 A 10, isolated from 
Streptomyces sp. ATCC 55365, thiocillin I 11, isolated from Bacillus cereus G-15, and 
other series d thiopeptides present with an aromatic pyridine ring.5, 10, 43-45 Nosiheptide 6, 
isolated from Streptomyces actuosus, nocathiacin I 7, isolated from Nocardia sp. ATCC 
202099, and other series e members contain an hydroxypyridine core.4, 46 All known 
members of series a, b, and c thiopeptides possess a second, quinaldic acid-containing 




Figure 1.4: The structural classes of thiopeptides (series a-e) depend on the oxidation state 





1.3 Biological activities of thiopeptides 
 Thiopeptides inhibit the growth of Gram-positive bacteria such as methicillin-
resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus 
pneumoniae by inhibiting prokaryotic ribosomal peptide synthesis.47-49 Two separate 
modes of action exist. One group includes thiostrepton A 2, nosiheptide 6, nocathiacin I 7, 
and thiocillin I 11; these thiopeptides bind to the GTPase-associated center of the 50S 
ribosomal subunit.47, 50-52 This region utilizes GTP-hydrolysis to drive translocation of the 
tRNA-mRNA complex during mRNA translation. When bound to the ribosome, 
thiopeptides interfere with the conformational changes associated with translocation to the 
next codon, inhibiting protein translation.52 In a second mode of action, thiopeptides such 
as thiomuracin A 4, GE2770 A 9, and GE37468 A 10, bind to EF-Tu and block the binding 
of aminoacyl-tRNA to EF-Tu.5, 43, 53 The GTPase EF-Tu delivers aminoacyl-tRNA to the 
A site of the ribosome, a prerequisite for elongation of the nascent polypeptide chain on 
the ribosome. Thiopeptides such as 4 and 9 therefore prevent the formation of the EF-Tu-
GTP-aminoacyl-tRNA complex and inhibit protein translation.53 
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 Some thiopeptides, in addition to their antibacterial activity, have been shown to 
exhibit antiplasmodial and anticancer activity.3, 54 Thiostrepton A 2 inhibits Plasmodium 
falciparum growth by binding to the GTPase-associated domain of the prokaryotic 
ribosome-like translational machinery in the apicoplasts as well as binding to the 20S 
proteasome to inhibit protein degradation, a necessary component for cellular upkeep.55-57 
Most apicomplexan parasites, such as Plasmodium species, carry an organelle called an 
apicoplast that is essential for the parasite’s survival.58 While it is still unclear, this 
organelle may be involved in fatty acid, isoprenoid, and/or heme biosyntheses that may be 
indispensable for Plasmodium parasites.58 Apicoplasts are theorized to be vestigial 
prokaryotic plastids analogous to mitochondria in eukaryotic cells and the apicoplasts 
house their own translational machinery that is separate from the nucleus and the 
mitochondrion.59 Thus, the inhibitory activity of thiostrepton A 2 on protein translation 
extends beyond prokaryotes to certain pathogenic eukaryotes that house prokaryotic 
translational machinery in the cell. 
Thiostrepton A 2 exhibits its anticancer activity by binding to the Forkhead box M1 
(FOXM1) transcription factor, inhibiting the binding of FOXM1 to promoter regions of 
genes involved in cell proliferation and cell cycles that are overexpressed in human solid 
cancers.3 2 was found to decrease expression levels of genes involved in proliferation of 
human breast cancer cell lines without any effect on expression of other housekeeping 
genes that were analyzed in the same cell line.3 In addition, 2 inhibits proteasome activity 
to induce apoptosis in cancer cells.60 The modulation of transcription factors by small 
molecules remain a challenge in modern medicine in part due to the difficulties of purifying 
transcription factors that tend to co-purify with DNA and due to a lack of known molecules 
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that bind to transcription factors.61 Many of these proteins are thought to function as a 
“complexes within a network of interactions” and modulation of protein-protein 
interactions have gained interest as promising therapeutic targets to treat cancers with 
aberrant transcription of oncogenes.61-62 Thiostrepton A 2 is the first known instance of a 
natural product binding directly to a transcription factor to inhibit transcription.3 Sitting at 
the larger end of small molecules, the large, rigid, and peptidic structure of thiopeptides 
may be attuned to disrupt protein-protein interactions. 
 
1.4 Thiostrepton A 
 Thiostrepton A 2 (Figure 1.1) is an extensively studied dehydropiperidine-
containing series b thiopeptide produced by Streptomyces azureus ATCC 14921 
(S. azureus) and Streptomyces laurentii ATCC 31255 (S. laurentii).7-8 Like other series a 
and b thiopeptides, thiostrepton A 2 has a quinaldic acid-containing loop in addition to its 
core macrocycle. Thiostrepton A 2 has been shown to possess potent antibacterial, 
antiplasmodial, and anticancer activity.3, 48, 55 While thiostrepton A 2 has been approved by 
the FDA as an antibiotic ointment for animal use, approval of 2 for human use has been 
stymied due to the low aqueous solubility that is common among all thiopeptides. 
 The thiostrepton biosynthetic gene (tsr) cluster was identified in S. laurentii by 
Kelly and coworkers and Liu and coworkers in 2009.37-38 Soon after these publications, 
thiomuracin A 4, nosiheptide 6, GE2270 A 9, and thiocillin I 11 biosynthetic gene clusters 
were identified; as a result, these studies established that thiopeptides were RiPPs, derived 
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from a genetically-encoded precursor peptide.5, 39, 63 The biosyntheses of thiostrepton A 2 
and other thiopeptides are discussed later in this chapter. 
 
1.5 Thiopeptins 
 The thiopeptins (Figure 1.5, 13-16) are a complex of series a (thiopeptins A1a 13 
and Ba 14) and series b (thiopeptins A1b 15 and Bb 16) thiopeptides produced by 
Streptomyces tateyamensis ATCC 21389 (S. tateyamensis) and have structures highly 
similar to thiostrepton A 2.40, 49, 64-65 Both 2 and the thiopeptins 13-16 are 17 amino acids 
long, differing only in the first residue (Val in the thiopeptins and Ile in thiostrepton A 2), 
and both incorporate a second, quindalic acid containing loop. The thiopeptins 13-16 are, 
however, distinguished from thiostrepton A 2 by a thioamide moiety in 13-16 and the 
piperidine ring found in thiopeptins A1a 13 and Ba 14 (Figure 1.5). Like many other 
thiopeptides, thiopeptins inhibit prokaryotic ribosomal translation and share similar 
antibacterial activities to thiostrepton A 2.49, 66 The thiopeptin biosynthetic genes have not 







Figure 1.5: The structures of thiostrepton A 2 and the thiopeptins 13-16. The 
(dehydro)piperidine ring is in blue, the quinaldic acid moiety in red, and the (thio)amide in 
green. The amino acid residue numbering system of thiostrepton A 2 is indicated on its 
structure. Abbreviations: dehydroalanine (Dha), dehydrobutyrine (Dhb), 




1.6 Thiopeptide biosynthesis  
 Thiopeptides are derived from genetically-encoded precursor peptides and undergo 
a cascade of post-translational modifications.2 The precursor peptide is comprised of two 
parts. The N-terminal leader peptide region is important for substrate recognition by much 
of the post-translational machinery and is cleaved during peptide maturation, and the C-
terminal core peptide is the region that is transformed into the thiopeptide.2 In addition to 
the precursor peptide, a minimum of six proteins (TbtB-G) corresponding to the proteins 
encoded by the thiomuracin A 4 biosynthetic gene (tbt) cluster are required for the 
biosynthesis of the thiopeptide scaffold, and the activities of TbtB-G have been 
demonstrated in vivo (Scheme 1.1-1.3).67 TbtEFG work in tandem to install the 
thiazol(in)es that decorate the thiopeptide scaffold (Scheme 1.1). The cyclodehydration of 
cysteine residues to thiazolines is catalyzed by TbtF, a leader peptide binding protein, and 
TbtG, an F-protein dependent cyclodehydratase, via an ATP-dependent process that 
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activates the amide backbone.68-69 Thiazolines are aromatized to thiazoles by the action of 
TbtE, an FMN-dependent thiazoline dehydrogenase.67 A similar pair of reactions is 
expected to convert serines to oxazoles, found in certain thiopeptides such as GE2270 A 9 
and GE37468 A 10. Azo(lin)e formation is expected to be one of the first steps in 
thiopeptide biosynthesis as TbtFG accepts the unmodified precursor peptide, TbtA, as a 





Scheme 1.1: Azoline formation of thiopeptides. Cysteines are cyclized to form 





After azol(in)e formation, TbtBC, a split LanB-type dehydratase, catalyzes the 
dehydration of serine residues to Dha (Scheme 1.2).67 TbtB shows homology to the 
glutamylation domain of the NisB lanthipeptide dehydratase which uses glutamyl-tRNAGlu 
to activate the serine residue as an ester, and TbtC shows homology to the glutamate 
elimination domain of NisB.71 A similar reaction is expected for the dehydration of 
threonine residues to form Dhb. Dehydration likely occurs after azole formation as TbtBC 
does not accept the unmodified precursor peptide TbtA, but does accept a modified TbtA 






Scheme 1.2: Dehydroalanine and dehydrobutyrine formation of thiopeptides catalyzed by 
the split LanB-like dehydratases. Tbt homologs that are encoded in the tsr cluster are shown 




TbtD encodes a formal [4+2] cyclase that forms the series d pyridine core of 
thiomuracin 4 from two Dha residues.67, 72 This cyclization resembles the Diels-Alder 
reaction utilized among synthetic chemists to introduce a substituted cyclohexene ring 
while controlling the stereochemistry of the substituents.73 The regio- and stereo- selective 
control of the Diels-Alder reaction is particularly useful in challenging syntheses of 
complex natural products where only a particular diastereomer may elicit a desired 
biological activity. There is great interest in the biocatalysis community for enzymatic 
Diels-Alder reactions which may provide cleaner and more efficient pathways to 





Scheme 1.3: Core macrocycle formation of thiopeptides between two Dha residues 
catalyzed by a [4+2] cyclase. TbtD has been shown to be a stand-alone pyridine synthase 
involved in thiomuracin 4 biosynthesis.67, 72 The TbtD homolog TsrE from the tsr cluster 
is proposed to form the dehydropiperidine ring in thiostrepton A 2. R1-R4 represent the rest 




There are disagreements, however, whether these [4+2] thiopeptide cyclases found 
in nature represent a true, pericyclic Diels-Alderase or if these reactions proceed through a 
different, step-wise mechanism.74 In solution, the aza-Diels-Alder reaction between a 2-
aza-1,3-butadiene and a dienophile may react readily without activation if the electronic 
demand of the HOMO-LUMO interaction of the two systems are small.75 For example, the 
reaction may be favorable between an electron-poor diene and an electron-rich dienophile, 
and vice versa. Many aza-Diels-Alder cycloadditions, however, require activation by a 
Lewis acid catalyst to form an iminium cation at the 2-aza-1,3-butadiene and the reaction 





Figure 1.6: Possible stepwise mechanism of a Lewis acid (LA) catalyzed cycloaddition 




The thiopeptide diene and dienophile are both surrounded by electron-donating 
substituents and this [4+2] cycloaddition likely requires activation of the dienophile or the 
2-aza-1,3-butadiene for the reaction to proceed at physiological conditions, require 
modifications to the peptide substrate so that the cycloaddition is more favorable, or 
alternatively, it may proceed via a non-Diels-Alder route. In fact, many of the aza-Diels-
Alder strategies employed for the total syntheses of various thiopeptides have necessitated 
a modified peptide substrate for the cycloaddition.22, 78-80 If the cycloaddition proceeds 
without additional modifications to the peptide substrate, the thiopeptide [4+2] 
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cycloaddition may similarly follow an acid-catalyzed stepwise pathway that has been 
suggested for other aza-Diels-Alder reactions. Kelly and coworkers have proposed a 
general acid base catalyzed stepwise mechanism in which the neighboring thiazole 
functions as an electron sink (Figure 1.7).37 Further studies of the thiopeptide [4+2] 






Figure 1.7: Proposed biosynthesis of the thiopeptide dehydropiperidine. R1-R4 represent 





The TbtD-catalyzed cycloaddition of two Dha residues is followed by dehydration 
and elimination of the leader peptide to form the series e pyridine ring of thiomuracin A 4 
(Scheme 1.3). It is unclear how a similar process would lead to the dehydropiperidine rings 
of series b thiopeptides whilst retaining the leader peptide. TbtABCDEFG comprise the 
minimum set of proteins required for the formation of the thiopeptide core scaffold. 
 
1.7 Biosynthesis of thiostrepton A 
 In addition to its dehydropiperidine-containing core macrocycle, thiostrepton A 2 
contains a second macrocycle that includes a quinaldic acid moiety. The tsr cluster encodes 
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homologs of TbtB-G, the minimum set of proteins encoded in the tbt cluster that are 
required for core macrocycle formation (Schemes 1.1-1.3): TsrA (the precursor peptide), 
along with TsrCD (the split LanB-type dehydratase), TsrE ([4+2] cyclase), TsrF (thiazoline 
dehydrogenase), TsrG (F-protein leader peptide binding domain), and TsrH (F-protein 
dependent cyclodehydratase). TsrCDEFGH are expected to transform TsrA to a 
thiostrepton precursor containing the core macrocycle decorated with thiazol(in)es and 
dehydrated amino acids. 
 The quinaldic acid moiety is derived from L-tryptophan and TsrMNQSV are 
expected to convert the amino acid into 4-(1-hydroxyethyl)quinoline-2-carboxylic acid 
(HEQ (21)) by a process that includes an oxidative ring expansion (Scheme 1.4).34, 37, 81-82 
The first step of this process is catalyzed by TsrM, a radical SAM and cobalamin-dependent 
methyltransferase.81 L-Tryptophan (17) is converted to 2-methyl-L-tryptophan (18) using 
methyl-co(III)balamin as a methyl donor.81 Next, TsrV, a pyridoxal 5’-phosphate (PLP)-
dependent aminotransferase catalyzes the conversion of 2-methyl-L-tryptophan 18 to 3-(2-
methylindolyl)pyruvate (19).37 Next, TsrQ, an FADH2-dependent oxygenase, initiates ring 
opening and rearrangement of the indole ring.82 A tsrS-deletion mutant of S. laurentii still 
produced thiostrepton A, although at trace amounts, leaving the role of TsrS unclear in 
HEQ 21 biosynthesis.34 TsrN, an NADPH-dependent reductase converts the ketone of 





Scheme 1.4: Proposed biosynthesis of 4-(1-hydroxyethyl)quinoline-2-carboxylate 
(HEQ 21) in the thiostrepton biosynthetic pathway.34, 37, 81-82 TsrS is proposed to be 





 HEQ 21 is likely activated by TsrJ, an adenylyltransferase, and an ester bond is 
formed between the activated carboxylic acid of 21 and Thr12 of the thiostrepton A 
scaffold (Scheme 1.5). Once tethered to Thr12, HEQ is epoxygenated by the action of TsrI, 
a cytrochrome P450.83-84  Next, TsrB catalyzes leader peptide cleavage and subsequent 





Scheme 1.5: Proposed coupling of HEQ 21 to a thiostrepton biosynthetic intermediate and 
the formation of the quinaldic acid-contianing loop of thiostrepton A 2. The HEQ-derived 
moieties are in red while the thiostrepton scaffold is abbreviated by dashed lines in certain 




 Additional modifications are performed by TsrKPTU. TsrK, a cytochrome P450, 
catalyzes the two hydroxylations of Ile10.84 The C-terminus of thiostrepton is likely 
methylated by TsrP, to from a methylester (22) (Scheme 1.6).37, 86 The methylation may be 
important in the dehydration of the serine residue at the C-terminus (Dha17). The pKa of 
the serine α hydrogen is likely between 25 and 50 when adjacent to a carboxylate but the 
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pKa decreases to ~25 when adjacent to a carboxymethyl ester. The increase in acidity of 
the C-H bond may facilitate the elimination of water on the terminal residue. Dehydration 
of that serine to dehydroalanine is expected to occur early in thiostrepton biosynthesis, after 
azole formation on the unmodified precursor peptide.67, 70 Therefore, methylation of the C-
terminus of thiostrepton likely occurs very early in its biosynthesis, possibly on the 
unmodified precursor peptide or on the precursor peptide with at least one azole. The 
carboxymethyl ester at the C-terminus is further modified by an esterase, TsrU, that 
catalyzes the hydrolysis of the methylester back to a carboxylate (Scheme 1.6).37, 86 Finally, 
TsrT, an amidotransferase, catalyzes the formation of the C-terminal amide (Scheme 1.6).37, 
86 Deletion mutants of TsrU accumulated a mature thiopeptide with a C-terminal 
methylester 22, while a TsrT mutant accumulated a mature thiopeptide with a C-terminal 
carboxylic acid (23), suggesting that the deesterification and amidation of the C-terminus 
occur late in thiostrepton biosynthesis.37, 86  
The modifications at the C-terminus affect the bioactivity and solubility of the 
thiostrepton analogs. While the methylester species 22 was shown to be slightly more 
effective against Bacillus subtilis than the amidated thiostrepton A 2, the aqueous solubility 
of 22 was diminished.86 On the other hand, the carboxylic acid species 23 retained 
comparable aqueous solubility with 2 but was slightly less effective against Bacillus 




Scheme 1.6: Modifications of the thiostrepton C-terminus by TsrUT to form the amide 





Notably, the thiazoline found in thiostrepton A 2 and many of the thiazolines found 
among the structurally characterized thiopeptides (Sch 18640 1, Sch 40832 3, siomycin 12, 
thiopeptins 13-16, and the cyclothiazomycins (Figure 1.8, 24)) are in the D-configuration 
despite their origin from L-cysteine.9, 19, 41, 87-88 Thiazolines are predicted to be formed in 
the L-configuration and subsequently epimerized to the D-configuration in certain 
thiopeptides. Though the thiostrepton 2, siomycin 12, and cyclothiazomycin 24 
biosynthetic gene clusters have been characterized, obvious epimerase candidates have not 
been identified.37-38, 89 Thus, the origin of epimerization of these thiopeptide thiazolines 
remain uncertain. Arndt and coworkers demonstrated that the thiostrepton A 2 thiazoline 
readily epimerizes under basic conditions if the second, quinaldic acid-containing ring is 
closed.90 The D-configuration of the thiazoline is thermodynamically favored over the 
L-configuration by approximately 2 kcal mol-1 due to the ring strain imposed by the second 
macrocycle.90 It is, however, still unclear if a dedicated enzyme catalyzes this 
epimerization via general-base catalysis or if the epimerization can be attributed as an 
additional role to an encoded product of the tsr cluster that already has an assigned function. 
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Sch 18640 1, thiostrepton A 2, Sch 40832 3, siomycin 12, and the thiopeptins 13-16 all 
possess a second, quinaldic acid-containing ring and, accordingly, a thiazoline in the D-
configuration. Meanwhile, the cyclothiazomycins 24 do contain a second macrocycle, 
albeit an unusual thioether bridge between a dehydroalanine on the core macrocycle and a 
C-terminal cysteine thiol on the “tail” region of 24. The cyclothiazomycins 24 contain a 
thiazoline in the D-configuration on the core macrocycle and a mixture of the L- and D-
configurations on the second macrocycle formed by the thioether (Figure 1.8).89 On the 
other hand, kocurin (Figure 1.8, 25) does not contain a second macrocycle and, accordingly, 
contains a thiazoline in the L-configuration.88 GE37468 A 10 (Figure 1.3) is highly similar 
in structure to kocurin 25, but the configuration of the thiazoline in GE37468 A 10 has not 
been determined. 
Interestingly, kocurin 25 and GE37468 A 10 are the only characterized thiopeptides 
that contain thiazolines in their core macrocycles without a second ring in their structures. 
The prolyl moiety found in the kocurin 25 and GE37468 A 10 core macrocycles likely 
introduces additional ring strain, and a thiazoline may better accommodate that added strain 
over a rigid thiazole. Further studies are required to establish the requirements for the 







Figure 1.8: The structures of the cyclothiazomycins A-C (24) and kocurin (25). The 




1.8 Dehydropiperidine and piperidine biosynthesis 
 The nitrogenous heterocycle common among thiopeptides originates from two 
dehydrated serine residues based on isotopic labeling studies.44, 91-93 The pyridine of series 
d and e thiopeptides is derived from a dedicated pyridine synthase.67, 72 The formal [4+2] 
cyclization is followed by dehydration to form a dihydropyridine intermediate, followed 
by elimination of the leader peptide to form the aromatic heterocycle (Figure 1.9).72 For 
the series b thiopeptides, the pyridine, or a prior biosynthetic intermediate, needs to be 
reduced to the dehydropiperidine ring. There are, however, no obvious candidate 
reductases that can serve this role in known series b thiopeptide biosynthetic gene 
clusters.37-38 In addition, it is unclear why the N-terminal portion of series a-c thiopeptides 
is retained after the dehydration of the core macrocycle. While the formation of the 
dehydropiperidine ring remains unclear, the piperidine ring of series a thiopeptides could 
be formed by the reduction of the dehydropiperidine ring. In this context, piperidine 
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formation may be accomplished by actions of NAD(P)H-, flavin-, or other reductive 





Figure 1.9: The proposed steps of the series d thiopeptide pyridine formation by TbtD and 
its possible relation to series a piperidine and b dehydropiperidine formation. R1-R4 




1.9 Reductive coenzymes 
 Redox coenzymes play a central role in primary and secondary metabolism across 
all three domains of life. Cellular processes that involve one- and two-electron redox 
reactions are associated with the four major energy metabolism systems in biology: aerobic 
respiration, denitrification, photosynthesis, and sulfur respiration.94 While these processes 
depend on a number of cofactors that vary across archaea, bacteria, and eukaryotes, the 
niacin coenzymes nicotinamide adenine dinucleotide (phosphate) (NAD(P)+ and their 
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reduced forms NAD(P)H), and flavin coenzymes, flavin mononucleotide (FMN and its 
reduced form FMNH2) and flavin adenine dinucleotide (FAD and its reduced form FADH2), 
play a central role in metabolism as electron donors and acceptors (Figure 1.10).94-96 In 
addition, nicotinamide and flavin cofactors are heavily utilized in secondary metabolism 





Figure 1.10: The structures of redox coenzymes FMN, FAD, NAD(P)+, and F420. The 
oxidized and reduced forms of each coenzyme are shown on the left and right, respectively. 
The part of the cofactor that is directly involved in two-electron transfer are in blue. 
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Some organisms, notably methanogens and actinobacteria, utilize a deazaflavin 
cofactor where the N5 of the flavin isoalloxazine ring is replaced with a carbon. Cofactor 
F420 is an 8-hydroxy-7-desmethyl-5-deazariboflavin derivative which owes its name to a 
characteristically strong absorbance at 420 nm (Figure 1.10). The deazaflavin cofactor 
contains a polyglutamate tail and a 2-phospho-L-lactate moiety attached to the ribityl group. 
The number of glutamate residues tethered to the lactate moiety is species-specific and 
typically ranges between zero and eight. 99-100 The F420 produced by methanogens that do 
not produce cytochromes have two or three glutamate residues, F420 produced by 
methylotrophic methanogens, which are capable of producing cytochromes, have four or 
five glutamate residues, and actinobacteria produce F420 with five to seven glutamate 
residues tethered to the 2-phospho-L-lactyl moiety.99-101 The physiological significance of 
the differences in the polyglutamate tail length are not well understood. The glutamate tail 
does not affect the redox potential of the cofactor and, therefore, does not affect its 
chemical reactivity.102 Tail length, however, has been shown to affect the affinity of the 
(non-cofactor) substrate to the enzyme (KM) and the turnover rate (kcat) of certain proteins 
in mycobacteria.103   
Despite its structural similarity to flavins, F420 acts as a two-electron (hydride) 
carrier like NAD(P)+ (Figure 1.10).104 Without the nitrogen at the N5 to effectively 
delocalize an unpaired electron, F420 is unable to form a stable semiquinone species 
required for one-electron transfer by FMN and FAD coenzymes.105 Moreover, the 
substitution of N5 with carbon makes F420 a strong reductant. With a standard reduction 
potential of -340 mV, F420 is a stronger reducing agent than other common redox cofactors 
such as FMN (-190 mV), FAD (-220 mV), and NAD(P)+ (-320 mV).102, 106-107 In 
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accordance with its reductive strength, F420-dependent enzymes are involved in challenging 
reactions such as the reduction of methenyltetrahydromethanopterin to 
methyltetrahydromethanopterin during methanogenesis, sulfite reduction, and the 





Scheme 1.7: The F420H2-dependent reduction of (a) methenyltetrahydromethanopterin to 
methyltetrahydromethanopterin by archaea and (b) potential antituberculosis drug PA-824 





F420-dependent pathways are widely found in actinobacteria species such as 
Mycobacterium tuberculosis (M. tuberculosis) and Mycobacterium smegmatis 
(M. smegmatis), yet little is known about the role of the deazaflavin cofactor in the 
metabolism of actinobacteria. Conservation of F420-dependent genes in Mycobacterium 
leprae, the causative agent of leprosy with a heavily reduced genome, may suggest a 
significant role of F420 in Mycobacterium metabolism.
112 Although F420 is not essential to 
mycobacteria, F420 production is linked to the ability of pathogenetic mycobacteria to 
withstand oxidative and nitrosative stress.113-115 In fact, in vitro studies have found that 
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F420-deficient M. smegmatis strains were two- to four-times more sensitive to first-line 
antimycobacterial drugs such as isoniazid, rifampin, and ethambutol and over 100-times 
more sensitive to other antimicrobial agents such as nalidixic acid and malachite green.114 
Thus, F420-dependent pathways have garnered attention as an attractive drug target for the 
selective inhibition of pathogenic Mycobacterium that are notoriously difficult to treat. 
 
1.10 Biosynthesis of cofactor F420 
 F420 biosynthesis diverges from the early steps of the flavin biosynthetic pathway. 
L-Tyrosine and 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione, a biosynthetic 
intermediate of riboflavin, is condensed by F0 synthase to form F0, a biosynthetic precursor 
to F420 (Scheme 1.8).
116 F0 synthase marks the first dedicated step in F420 biosynthesis and 
is encoded as two polypeptides (CofG and CofH) in archaea and a single polypeptide 
(FbiC) in bacteria.116-117 Both domains contain a radical SAM active site. CofH initiates 
the reaction by abstracting a hydrogen atom from the amine of L-tyrosine to form a 
p-hydroxybenzyl radical which is then coupled to the 5-position of the pyrimidine moiety 
of 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione to form a p-hydroxybenzylated 
pyrimidinedione adduct.118 Next, CofG abstracts a hydrogen from the p-hydroxybenzyl 
moiety to facilitate ring closure with the pyrimidinedione moiety to form F0.
118 
 Next, a 2-phospho-L-lactate transferase (CofD in archaea and FbiA in bacteria) 
attaches a phospho-L-lactyl moiety on to F0 to form F420-0.
119-120 The final step in F420 
biosynthesis is the polyglutamylation of F420-0 catalyzed by a γ-glutamyl ligase (CofE in 
archaea and FbiB in bacteria). CofE and the N-terminal domain of FbiB are homologous 
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to each other, but the bacterial γ-glutamyl ligase, FbiB, contains an additional C-terminal 
domain that is not present in the γ-glutamyl ligases of archaea.121-122 While both domains 
of FbiB are required for activity, the CofE-like N-terminal domain of FbiB appears to 
contain the active site. The C-terminal domain of FbiB contains a groove of positively 
charged residues which may be involved in binding the polyglutamate-tail observed in F420 
produced by bacteria. FbiB from M. tuberculosis produced cofactor F420 containing a 
mixture of glutamate tail lengths, with seven being the most common.122 It is not yet known 










Scheme 1.8: The proposed biosynthetic pathway of coenzyme F420 in archaea 




1.11 Scope of this work 
 At least fifteen thiopeptide biosynthetic gene clusters have been identified since 
2009, and the functions of many proteins involved in thiopeptide biosynthesis have been 
described.35, 37-39, 44, 63, 67, 89, 123-130 Thiopeptides, however, are a diverse family of natural 
products with an abundance of interesting chemical modifications for which the 
biosynthetic origins remain unclear. In particular, the formation of the central nitrogenous 
heterocycle in series a-b remains enigmatic. The thiopeptins are a complex of thiopeptides 
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with either a piperidine (series a) or a dehydropiperidine (seires b) ring in the core 
macrocycle and an unusual thioamide moiety. In this work, the thiopeptin biosynthetic 
gene cluster is identified along with two enzymes of this pathway: TpnW, a L-tryptophan 
transaminase and TpnL, an unusual F420H2-dependent dehydropiperidine reductase. The 
characterization of TpnL as a dehydropiperidine reductase establishes the basis for the 
piperidine-containing series a thiopeptides. These insights expand our understanding of 
complex chemical transformations in biological systems and provide us with biosynthetic 
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CHAPTER 2: IDENTIFICATION OF THE THIOPEPTIN BIOSYNTHETIC 





Adapted from: Ichikawa, H.; Bashiri, G.; Kelly, W.L. Biosynthesis of the thiopeptins and 
the identification of an F420H2-dependent dehydropiperidine reductase. J. Am. Chem. Soc. 
2018, 140, 10749-10756. 





 All members of the thiopeptins (13-16) contain an unusual thioamide moiety and 
thiopeptins A1a 13 and Ba 14 contain a piperidine ring in the core macrocycle (Figure 2.1). 
The biosynthetic gene cluster responsible for the production of the thiopeptins has not yet 






Figure 2.1: The structures of the thiopeptins. The (dehydro)piperidine ring is in blue and 




The thioamide is of particular interest as it is a rare modification in naturally-
occurring metabolites. In addition to the thiopeptins, methanobactin, closthioamide, and 
thioviridamide are among the few examples that have been identified and the biological 
significance of the thioamide moieties of these compounds is not well understood (Figures 
2.1 and 2.2).1-3 The hexaoxa analog of the antibiotic closthioamide, closamide, lost activity 
against test bacterial strains, suggesting the thioamides are critical for its activity and this 










In contrast to the rarity of thioamides in nature, thioamides have been utilized in 
medicinal chemistry to improve resistance of some peptidic drugs to proteolytic 
degradation over their amide counterparts.4 In addition, certain thioamidated drugs have 
been shown to increase the potency of a drug compared to its parent compound.5 The 
polythioamide analog of an opioid neuropeptide Leu-enkephalin is ten-fold more active 
over its amide equivalent and the affinity of the thioamidated Leu-enkephalin for the 
σ-opioid receptor is increased by more than five-fold.6 Thioamide-containing drugs have 
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also been used to treat tuberculosis. Ethionamide and prothionamide are thioamide analogs 
of isoniazid (Figure 2.3). All three drugs are thought to inhibit InhA, the NADH-dependent 
enoyl-ACP reductase involved in mycolic acid biosynthesis, by strongly binding an 
isonicotinyl-NAD adduct that is formed in the cell (Figure 2.4).7 While similar in structure, 
isoniazid and the thioamidated prodrugs are activated by different pathways. Heme-
dependent catalase-peroxidase KatG abstracts the hydrazine moiety of isoniazid to form an 
isonicotinyl radical that reacts with NAD+ to form an isonicotinyl-NAD adduct (Figure 
2.4).8 Certain mutations in katG confer resistance to isoniazid but not to ethionamide, 
suggesting either a different binding mode of the thioamidated analogs with KatG or a 
different activator of the analogs.9 Ethionamide has been shown to be activated by an 
NADPH- and O2-dependent flavin monooxygenase, EtaA, via formation of an S-oxide 
intermediate that is possibly oxidized to a sulfinic acid-containing reactive species.7, 10 The 
ethionamide-derived NAD adduct has been shown to bind to InhA and mutations in inhA 
have been linked to ethionamide resistance by Mycobacterium tuberculosis (M. 









While isoniazid is still an important antituberculosis drug today, it is ineffective 
against many other mycobacteria species such as Mycobacterium leprae (M. leprae), the 
causative agent of leprosy.12 M. leprae and other isoniazid-resistant mycobacteria either 
lack katG or have a truncated katG homolog encoded in its genome and it is thought 
M. leprae is unable to activate isoniazid to form the isonicotinyl-NAD adduct that inhibits 
InhA.13 Ethionamide and prothionamide, however, are effective against M. leprae. The 
formation of a prothionamide-derived NAD adduct was detected in the presence of 
prothionamide, NAD+, and an EtaA-homolog in M. leprae and the NAD adduct showed 
strong inhibition of InhA in M. leprae (Figure 2.4).11 The case of isoniazid and its 
thioamide derivatives shows how a simple modification of the chemical structure, such as 
the replacement of an amide with a thioamide, can alter how the drug is activated in the 





Figure 2.4: Possible pathways of InhA inhibition by prodrugs isoniazid and prothionamide. 
A) KatG-dependent activation of isoniazid, and B) EtaA-dependent activation of 
prothionamide, both which leads to the formation of an isonicotinyl-NAD adduct that 
inhibits InhA in certain mycobacteria species. 
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Detailed understanding of the biological activities associated with structural 
features in natural products and the biosynthetic machinery that installs these moieties are 
useful in the design, discovery, and production of novel metabolites with improved 
activities. Thiopeptides, like the thiopeptins, contain a wealth of unusual and complex 
chemical moieties installed on a peptidic substrate by a cascade of post-translational 
modifications.14-17 The biosynthetic role of each enzyme that installs a novel modification 
onto a thiopeptide may be elucidated by a series of gene inactivation, heterologous 
expression, and in vitro enzyme activity reconstitution experiments. Characterization of 
these enzymes may lead to a development of useful biological tools to modify thiopeptides 
and other peptidic substrates. In addition, evaluation of the biological activities of 
thiopeptide analogs and biosynthetic intermediates produced in these experiments may 
provide us with insight to the structure-activity relationships of the thiopeptides.  
In the interest of uncovering how the unusual piperidine and thioamide structural 
features are installed on thiopeptins and the potential biological effects of these 
modifications, we report the identification of the thiopeptin biosynthetic gene (tpn) cluster, 
and the putative functions of each open reading frame (orf). Based on bioinformatic 
analysis of 23 orfs of the tpn cluster, we propose that the thioamide is likely installed by 
the combined actions of TpnM, a YcaO-like protein, and TpnN, a TfuA-like protein, while 
the piperidine is installed by TpnL, a flavin/deazaflavin-dependent oxidoreductase. In 
support of the involvement of the tpn cluster in thiopeptin production, we present the initial 
characterization of TpnW, a transaminase that is involved in the biosynthesis of 4-(1-
hydroxyethyl)quinoline-2-carboxylic acid (HEQ), a critical feature of the quinaldic acid-
containing loop found in series a-c thiopeptides. The bioinformatic analysis of the tpn 
47 
 
cluster and the identification of TpnW as a 2-methyl-L-tryptophan transaminase present 
the basis for thiopeptin production in S. tateyamensis. 
 
2.2 Materials and methods 
2.2.1 General 
All reagents, unless otherwise specified, were purchased from standard commercial 
sources and used as provided. 2-Methyl-L-tryptophan was enzymatically synthesized from 
2-methylindole and L-serine according to previously described methods.18 High-
performance liquid chromatography (HPLC) analyses were performed on a Beckman 
Coulter System Gold HPLC using an analytical Phenomenex Luna 5µm C18(2) 250 x 4.6 
mm column (Torrance, CA). All mass spectrometry analyses were performed at the 
Georgia Institute of Technology Bioanalytical Mass Spectrometry Facility. High-
performance liquid chromatography-mass spectrometry (HPLC-MS) analyses were 
performed on a Micromass Quattro LC using a Phenomenex Synergi 4 µm MAX-RP 80 Å 
C18 250 x 2.00 mm column (Torrance, CA). Oligonucleotides were purchased from 
Integrated DNA Technologies, Inc. (Coralville, IA). DNA sequencing analyses were 







2.2.2 Bacterial strains, plasmids, and growth medium 
All primers used are listed in Table A.1 and strains and plasmids used are listed in 
Table A.2. Streptomyces tateyamensis ATCC 21389 (S. tateyamensis) was purchased from 
American Type Culture Collection. Escherichia coli (E. coli) strains were cultured in 
Luria-Bertani medium supplemented with 100 µg/mL ampicillin, 50 µg/mL apramycin, 
12.5 µg/mL chloramphenicol, 50 µg/mL kanamycin, or 50 µg/mL streptomycin. 
Streptomyces strains were cultured in medium supplemented with 50 µg/mL apramycin or 
40 µg/mL streptomycin. 
 
2.2.3 Growth of S. tateyamensis and analysis of thiopeptin production 
A glycerolic mycelium stock of S. tateyamensis was used to inoculate 50 mL potato 
starch-based medium (40 g/L potato starch, 20 g/L cotton seed meal, 10 g/L corn steep 
liquor, 10 g/L yeast extract, 3 g/L CaCO3, 21.8 g/L KH2PO4, 14.3 g/L Na2HPO4 ·12H2O, 
1.7 g/L N-acetyl-DL-methionine) in a 250 mL Erlenmeyer flask. After incubation at 28 °C 
and 220 rpm for 72 hours, 2.5 mL of the starter culture was used to inoculate 50 mL potato 
starch-based medium in a 250 mL Erlenmeyer flask and grown at 28 °C and 220 rpm for 
72 hours. Next, 5 mL of this seed culture was used to inoculate 100 mL potato starch-based 
medium in a 500 mL Erlenmeyer flask, and incubated at 28 °C at 220 rpm for 7 days. The 
whole culture was extracted twice with an equal volume of chloroform. The chloroform 
layers were pooled together, filtered, and the solvent was removed in vacuo. The solid 




2.2.4   Construction of the S. tateyamensis fosmid library and screening for selected 
sequences 
 
 S. tateyamensis genomic DNA was prepared according to the wizard DNA isolation 
kit (Promega, Madison, WI) protocol. De novo genome sequencing was performed at 
Macrogen Korea using a HiSeq 2000 sequencing system. The draft genome was partially 
sequenced to 6.92 Mb on 2,838 contiguous fragments and scanned for a nucleotide 
sequence encoding the thiopeptin core peptide (VASASCTTCICTCSCSS) using 
VectorNTI Advance 11. One match was identified, named as tpnA, and neighboring genes 
shared sequence similarity to thiostrepton (tsr) and siomycin (sio) biosynthetic genes.14, 16 
To facilitate fully assembling the sequence around tpnA, an S. tateyamensis genomic 
fosmid library was constructed using the CopyControl Fosmid Library Production Kit 
(Lucigen, Middleton, WI). 2,304 clones were isolated and stored according to manufacturer 
instructions. The S. tateyamensis fosmid library was screened by polymerase chain reaction 
(PCR) for the desired tpn sequences using the primer pairs HI-1F/HI-1R (for tpnD), HI-
2F/HI-2R (for tpnO), and HI-3F/HI-3R (for tpnU). Two fosmids, HI2B7 and HI2G2, were 
found to harbor the tpn cluster and shotgun libraries of these two fosmids were prepared 
according to the TOPO Shotgun Subcloning Kit (Life Technologies, Carlsbad, CA) 
protocol. Sequencing of the shotgun libraries was performed at Functional Biosciences 
(Madison, WI). Additional DNA sequencing analysis was used to close any remaining gaps 
in the sequences of the fosmids by primer walking. The tpn cluster was included within a 





2.2.5 Bioinformatics analyses of the tpn gene cluster 
Open reading frames (orfs) were determined using FramePlot 4.0 and the orfs were 
compared to other entries in the NCBI database using the protein Basic Local Alignment 
Search Tool (BLAST).   
 
2.2.6 Sporulation of S. tateyamensis 
 A glycerolic mycelium stock of S. tateyamensis was used to inoculate 50 mL ATCC 
172 medium in a 250 mL Erlenmeyer flask. After incubation at 28 °C and 220 rpm for 72 
hours, 400 μL of the culture was inoculated on ISP3 agar. Colonies were observed after 1 
day at incubation at 28 °C and spores were harvested after 10-25 days.  
 
2.2.7 Intergeneric conjugation in S. tateyamensis 
 S. tateyamensis spores were collected from sporulating colonies that were 10-25 
days old from four ISP3 agar plates and a spore suspension was prepared according to 
protocol with a few modifications.19 To each ISP3 agar plate, 9 mL of sterile water was 
added and the surface of the solid culture was gently rubbed with an inoculation loop to 
suspend the spores in the water. The aqueous suspension of spores and mycelium from all 
four plates were pooled together and transferred to a 15 mL conical tube and vortexed for 
1 min to break up spore aggregates. The spore-mycelium mixture was filtered twice 
through a cotton wool column and the isolated spores were checked by examination under 
an optical microscope. The spores were collected by centrifugation at 1000 x g for 10 min 
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at 4 °C. The supernatant was discarded and the spores were resuspended in ~100 μL of 
residual liquid. Intergeneric conjugation with S. tateyamensis spores was performed 
according to protocol.19 An E. coli (ET12567/pUZ80002) strain harboring the appropriate 
pGM160HKss-derived vector was used as the donor for conjugation. 
 
2.2.8 Disruption of tpnA  
The tpnA gene and its flanking regions was amplified by PCR as a 2.5 kb fragment 
from fosmid HI2B7 using the primer pair HI-4F/HI-4R. The amplicon was cloned into 
pSC-B-amp/kan (Agilent, Santa Clara, CA) to yield pTpnA, and the vector was confirmed 
by DNA sequence analysis. pTpnA was digested with HindIII and the resulting 2.5 kb 
fragment was ligated into pGM160HKss to form pGM-tpnA. A 1.4 kb fragment containing 
the aac(3)IV/oriT cassette, amplified from pIJ773 using the primer pair HI-5F/HI-5R, was 
inserted into pGM-tpnA by λ Red-mediated recombination in E. coli BW25113/pKD46 to 
generate pGM-dtpnA. The resulting construct was confirmed by DNA sequence analysis 
and transformed into E. coli ET12567/pUZ8002. 
 S. tateyamensis protoplasts were prepared according to protocol with a few 
modifications.19 A glycerolic mycelium stock of S. tateyamensis was used to inoculate 
50 mL of ATCC 172 medium in a 250 mL Erlenmeyer flask. After incubation at 28 °C and 
220 rpm for 72 hours, 1 mL of the starter culture was used to inoculate 50 mL of ATCC 
172 medium containing 0.25% glycine in a 250 mL Erlenmeyer flask. After incubation at 
28 °C and 220 rpm for 16 hours, the mycelium was harvested at 1000 x g for 10 min. Next, 
the mycelium was washed twice with 15 mL 10.3% (w/v) D-sucrose and resuspended in 
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4 mL lysis (L) buffer (9.09% (w/v) D-sucrose, 0.50% TES buffer pH 7.2, 0.02% (w/v) 
K2SO4, 1.76 x 10
-3% (w/v) trace metals solution (40 mg/L ZnCl2, 200 mg/L FeCl3·6H2O, 
10 mg/L CuCl2·2H2O, 10 mg/L MnCl2·4H2O, 10 mg/L Na2B4O7·10H2O, and 10 mg/L 
(NH4)6Mo7O24·10H2O), 4.41 x 10
-3% (w/v) KH2PO4, 2.20 mM MgCl2·6H2O, 2.20 mM 
CaCl2) with 1.5 mg/mL lysozyme. The suspension was incubated at 30 °C for 30 min, 
gently mixed, and then incubated for 15 min at 30 °C. At this time, 5 mL of L buffer 
(without lysozyme) was added, and the mixture was incubated for another 15 min at 30 °C. 
The protoplast-mycelium mixture was filtered twice through a cotton wool column and the 
isolated protoplasts were checked by examination under an optical microscope. Protoplasts 
were harvested at 1000 x g for 7 min at 4 °C. The supernatant was removed and protoplasts 
were suspended in residual buffer. To 50 µL of protoplast suspension, 10 µL of a 100 
ng/µL solution of pGM-dtpnA in TE buffer (10 mM Tris pH 8.0 and 1 mM 
ethylenediaminetetraacetic acid (EDTA)) isolated from E. coli ET12567/pUZ8002 was 
added, followed immediately by the addition of 0.5 mL room-temperature transformation 
buffer (2.37% (w/v) D-sucrose, 1.8 x 10-3% (w/v) trace metals solution, 0.02% (w/v) K2SO4, 
0.10 M CaCl2, 50 mM Tris-maleic acid buffer pH 8.0, and 40% (w/v) polyethylene glycol 
1000).  To this mixture, 5 mL of room-temperature protoplast (P) buffer (103 g/L D-
sucrose, 0.25 g/L K2SO4, 2.02 g/L MgCl2·6H2O, 2 mL/L trace metals solution, 0.5 x 10
-3% 
(w/v) KH2PO4, 3.68 x 10
-2% (w/v) CaCl2·2H2O, and 5.73 x 10
-2% (w/v) TES buffer pH 
7.2) was immediately added. The protoplasts were harvested at 700 x g for 7 min at 4 °C. 
After removing the supernatant, the protoplasts were suspended in residual buffer and were 
diluted serially with room-temperature protoplast buffer. The transformation mixture was 
plated on ISP3 agar that was supplemented with 10 mM MgCl2 and had dried in a laminar 
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flow hood for 6 hours. After incubation at 28 °C for 18 hours, the agar was overlaid with 
1.25 mg apramycin in 1 mL of water. Plates were incubated at 28 °C for 3-5 days. 
 Mycelia of apramycin-resistant colonies were inoculated in 50 mL of ATCC 172 
medium supplemented with 50 µg/mL apramycin in a 250 mL Erlenmeyer flask and 
incubated at 28 °C and 220 rpm for 72 hours. Whole-cell PCR was used to identify 
transformants harboring pGM-dtpnA using the primer pair HI-4F/HI-4R. A 2.5 kb 
amplicon was expected from wild-type S. tateyamensis, while a 3.7 kb amplicon was 
expected from the transformant. Forced homologous recombination at 39 °C provided the 
tpnA disruption mutant, S. tateyamensis HI1. The tpnA disruption (double crossover) 
mutant was confirmed by PCR analysis. A 2588 bp amplicon was expected from 
S. tateyamensis HI1 using primer pairs HI-26F/HI-26R and a 1871 bp amplicon was 
expected using primer pairs HI-27F/HI-27R. Together, the two amplified regions comprise 
a 4.4 kb region on the S. tateyamensis HI1 chromosome, including the 3.7 kb region 
involved in the disruption of tpnA. Amplicons were not expected from the wild-type 
S. tateyamensis using either primer pairs HI-26F/HI-26R or HI-27F/HI-26R. The 
amplicons from S. tateyamensis HI1 were cloned into pSC-B-kan/amp and the inserts were 
confirmed by DNA sequence analysis. 
 
2.2.9 Additional conditions for S. tateyamensis protoplast preparation 
 In addition to the optimized condition for protoplast preparation described in 
section 2.3.8, other buffers were utilized during protocol development (Table 2.2).  PR5 
buffer (103 g/L D-sucrose, 0.25 g/L K2SO4, 2.03 g/L MgCl2·6H2O, 2 mL/L trace metals 
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solution, 0.5 x 10-3% (w/v) KH2PO4, 3.70 x 10
-2% (w/v) CaCl2·2H2O, and 0.57% (w/v) 
TES buffer pH 7.2), and PR6 buffer (200 g/L D-sucrose, 0.10 g/L K2SO4, 2 mL/L trace 
metals solution, 7.0 x 10-2% (w/v) CaCl2·2H2O, 0.21% (w/v) 
3-(N-morpholino)propanesulfonic acid (MOPS) buffer pH 7.2, and 10 g/L filter-sterilized 
bovine serum albumin) were used instead of the P buffer (described in Section 2.2.8) in 
certain conditions.20 R2YE medium was used in certain conditions in place of the ISP3 
medium as the regeneration medium. 
 
2.2.10 Towards the disruption of tpnL 
The tpnL gene and flanking regions was amplified by PCR as a 2.7 kb fragment 
from fosmid HI2G2 using the primer pair HI-8F/HI-8R. The amplicon was cloned into 
pSC-B-amp/kan (Agilent, Santa Clara, CA) to yield pTpnL, and the vector was confirmed 
by DNA sequence analysis. pTpnL was digested with HindIII, and the resulting 2.5 kb 
fragment was ligated into pGM160HKss to form pGM-tpnL. A 1.4 kb fragment containing 
the aac(3)IV/oriT cassette, amplified from pIJ773 using the primer pair HI-9F/HI-9R, was 
inserted into pGM-tpnL by λ Red-mediated recombination in E. coli BW25113/pKD46 to 
generate pGM-dtpnL. The resulting construct was confirmed by DNA sequence analysis 
and transformed into E. coli ET12567/pUZ8002. 
 S. tateyamensis protoplast preparation and transformation with pGM-dtpnL into 
S. tateyamensis were performed according to the methods described for the disruption of 
tpnA. Mycelia of apramycin-resistant colonies were inoculated in 50 mL of ATCC 172 
medium supplemented with 50 µg/mL apramycin in a 250 mL Erlenmeyer flask and 
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incubated at 28 °C and 220 rpm for 72 hours. Whole-cell PCR was used to identify 
transformants harboring pGM-dtpnL using the primer pair HI-8F/HI-8R. From the wild-
type strain, a 2.7 kb amplicon was expected while a 3.6 kb amplicon was expected from 
the transformant. 
 
2.2.11 Towards the disruption of tpnM  
The tpnM gene and flanking regions was amplified by PCR as a 2.7 kb fragment 
from fosmid HI2G2 using the primer pair HI-10F/HI-10R. The amplicon was cloned into 
pSC-B-amp/kan (Agilent, Santa Clara, CA) to yield pTpnM, and the vector was confirmed 
by DNA sequence analysis. pTpnM was digested with HindIII, and the resulting 2.7 kb 
fragment was ligated into pGM160HKss to form pGM-tpnM. A 1.4 kb fragment containing 
the aac(3)IV/oriT cassette, amplified from pIJ773 using the primer pair HI-11F/HI-11R, 
was inserted into pGM-tpnM by λ Red-mediated recombination in E. coli 
BW25113/pKD46 to generate pGM-dtpnM. The resulting construct was confirmed by 
DNA sequence analysis and transformed into E. coli ET12567/pUZ8002. 
 S. tateyamensis protoplast preparation and transformation with pGM-dtpnM were 
performed according to the methods described for the disruption of tpnA. Mycelia of 
apramycin-resistant colonies were inoculated in 50 mL of ATCC 172 medium 
supplemented with 50 µg/mL apramycin in a 250 mL Erlenmeyer flask and incubated at 
28 °C and 220 rpm for 72 hours. Whole-cell PCR was used to identify transformants 
harboring pGM-dtpnM using the primer pair HI-10F/HI-10R. From the wild-type strain, a 
2.7 kb amplicon was expected while a 3.1 kb amplicon was expected from the transformant. 
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2.2.12 Towards the disruption of tpnN 
The tpnN gene and flanking regions was amplified by PCR as a 3.2 kb fragment 
from fosmid HI2G2 using the primer pair HI-12F/HI-12R. The amplicon was cloned into 
pSC-B-amp/kan (Agilent, Santa Clara, CA) to yield pTpnN, and the vector was confirmed 
by DNA sequence analysis. pTpnN was digested with HindIII, and the resulting 3.2 kb 
fragment was ligated into pGM160HKss to form pGM-tpnN. A 1.4 kb fragment containing 
the aac(3)IV/oriT cassette, amplified from pIJ773 using the primer pair HI-13F/HI-13R, 
was inserted into pGM-tpnN by λ Red-mediated recombination in E. coli 
BW25113/pKD46 to generate pGM-dtpnN. The resulting construct was confirmed by 
DNA sequence analysis and transformed into E. coli ET12567/pUZ8002. 
 S. tateyamensis protoplast preparation and transformation with pGM-dtpnN were 
performed according to the methods described for the disruption of tpnA. Mycelia of 
apramycin-resistant colonies were inoculated in 50 mL of ATCC 172 medium 
supplemented with 50 µg/mL apramycin in a 250 mL Erlenmeyer flask and incubated at 
28 °C and 220 rpm for 72 hours. Whole-cell PCR was used to identify transformants 
harboring pGM-dtpnN using the primer pair HI-12F/HI-12R. From the wild-type strain, a 
3.2 kb amplicon was expected while a 3.8 kb amplicon was expected from the transformant. 
 
2.2.13 Towards the disruption of tpnR 
The tpnR gene and flanking regions was amplified by PCR as a 3.1 kb fragment 
from fosmid HI2G2 using the primer pair HI-14F/HI-14R. The amplicon was cloned into 
pSC-B-amp/kan (Agilent, Santa Clara, CA) to yield pTpnR, and the vector was confirmed 
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by DNA sequence analysis. pTpnR was digested with HindIII, and the resulting 3.1 kb 
fragment was ligated into pGM160HKss to form pGM-tpnR. A 1.4 kb fragment containing 
the aac(3)IV/oriT cassette, amplified from pIJ773 using the primer pair HI-15F/HI-15R, 
was inserted into pGM-tpnR by λ Red-mediated recombination in E. coli 
BW25113/pKD46 to generate pGM-dtpnR. The resulting construct was confirmed by 
DNA sequence analysis and transformed into E. coli ET12567/pUZ8002. 
 S. tateyamensis protoplast preparation and transformation with pGM-dtpnR were 
performed according to the methods described for the disruption of tpnA. Mycelia of 
apramycin-resistant colonies were inoculated in 50 mL of ATCC 172 medium 
supplemented with 50 µg/mL apramycin in a 250 mL Erlenmeyer flask and incubated at 
28 °C and 220 rpm for 72 hours. Whole-cell PCR was used to identify transformants 
harboring pGM-dtpnR using the primer pair HI-14F/HI-14R. From the wild-type strain, a 
3.1 kb amplicon was expected while a 3.8 kb amplicon was expected from the transformant. 
 
2.2.14 Towards the genetic complementation of S. tateyamensis HI1 
The tpnA gene was amplified from fosmid HI2B7 by PCR using the primer pair 
HI-16F/HI16R. The amplicon was digested with NdeI and EcoRI and ligated into 
pSET1520ss to give pSET1520ss-TpnA. The resulting plasmid was confirmed by DNA 
sequencing analysis. After the isolation of pSET1520ss-TpnA from E. coli 
ET12567/pUZ8002, the plasmid was used to transform protoplasts of S. tateyamensis HI1. 
S. tateyamensis HI1 protoplast preparation and transformation with pSET1520ss-TpnA 
were performed according to the methods described for the disruption of tpnA with one 
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exception. After the transformant was plated on ISP3 plates, the agar was overlaid with 
1.25 mg streptomycin and 1.25 mg apramycin in 2 mL of H2O. Mycelia of streptomycin- 
and apramycin-resistant colonies were inoculated into 50 mL of ATCC 172 medium 
supplemented with 50 µg/mL streptomycin and 50 µg/mL apramycin in a 250 mL 
Erlenmeyer flask and incubated at 28 °C and 220 rpm for 72 hours. Whole-cell PCR was 
used to identify transformants harboring pSET1520ss-TpnA using the primer pair 
HI-16F/HI-16R. A 198 bp amplicon was expected from the transformants while an 
amplicon was not expected from S. tateyamensis HI1. 
 
2.2.15 Expression and purification of TpnW  
The tpnW gene and its flanking regions was amplified from HI2B7 by primer pairs 
HI-17F/HI-17R. The amplicon was ligated into pSC-B-amp/kan (Agilent, Santa Clara, CA) 
to form ptpnW and the vector confirmed by DNA sequence analysis. The gene tpnW was 
amplified by PCR from ptpnW using the primer pair HI-18F/HI-18R. The amplicon was 
ligated into pSC-B-amp/kan to yield ptpnW2 and the insert was confirmed by DNA 
sequence analysis. The plasmid was digested with NdeI and EcoRI, and the resulting tpnW 
fragment ligated into pET28b(+) to form pET28b-tpnW. The construct was confirmed by 
DNA sequence analysis. E. coli BL21(DE3) containing pET28b-tpnW was incubated 
overnight at 37 °C and 220 rpm in 10 mL of Luria-Bertani medium supplemented with 
50 µg/mL kanamycin. 20 mL of the overnight culture was used to inoculate 2 L of Luria-
Bertani medium supplemented with 50 µg/mL kanamycin. The culture was incubated at 
37 °C and 220 rpm until the optical density at 600 nm (OD600) = 0.6, at which point the 
temperature was decreased to 15 °C and TpnW expression was induced with the addition 
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of 0.4 mM isopropyl-β-D-thiogalactopyranoside (IPTG). Cultures were incubated for an 
additional 48 hours. Harvested cells were resuspended in 50 mL of lysis buffer (20 mM 
Tris pH 8.0, 500 mM NaCl, 2 mM imidazole, 10% glycerol, 1 mg/mL lysozyme, 10 µg/mL 
deoxyribonuclease, 2 mM MgCl2). Cells were disrupted by sonication (10 rounds of 10 s 
pulses followed by a 60 s pause) and the lysate clarified by centrifugation at 14,000 x g for 
30 min at 4 °C. The cell-free extract was incubated with 1.5 mL of Ni-NTA (Qiagen, 
Germantown, MD) slurry for 20 min. The slurry was poured into a column, and the resin 
was washed with 15 mL wash buffer (20 mM Tris pH 8.0, 500 mM NaCl, 20 mM 
imidazole, 10% glycerol, 2 mM MgCl2). Next, the resin was washed with 15 mL wash 
buffer with 40 mM imidazole. Protein was eluted with 15 mL elution buffer (20 mM Tris 
pH 8.0, 500 mM NaCl, 300 mM imidazole, 10% glycerol, 2 mM MgCl2) collecting 5 mL 
fractions. Fractions containing the protein were pooled together and dialyzed against 2 x 
2 L storage buffer (50 mM Tris pH 8.0, 300 mM NaCl, 10% glycerol, 2 mM MgCl2, 2 mM 
dithiothreitol). TpnW was concentrated with a 10,000 Da molecular weight cut-off Amicon 
Ultra centrifugal filter (Millipore, Burlington, MA). Protein concentration was determined 
by the method of Bradford using bovine serum albumin as a standard.21 Purified TpnW 
was flash frozen in liquid nitrogen and stored at –80 °C. 
 
2.2.16 In vitro reconstitution of TpnW activity  
A 200 µL reaction mixture containing 1.5 µM TpnW, 1 mM 2-methyl-L-tryptophan 
18 (Scheme 2.1), 1 mM of an α-keto acid acceptor (pyruvate, oxaloacetate, α-ketoglutarate, 
phenylpyruvate, p-hydroxyphenylpyruvate, or 3-indolylpyruvate 30), 100 µM pyridoxal 
5’-phosphate, 100 mM potassium phosphate buffer pH 7.8, and 3% DMSO 
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(2-methyl-L-tryptophan and the α-keto acid were added from stock solutions in DMSO) 
was prepared in an HPLC-MS vial. The reaction mixture was incubated under argon in the 
dark at 25 °C for 30 min, quenched with liquid nitrogen, and stored at –80 °C until ready 
for analysis. 100 µL of each sample was analyzed by HPLC or HPLC-MS. An HPLC 
gradient was developed from 5% acetonitrile in water with 0.1% formic acid to 95% 
acetonitrile in water with 0.1% formic acid over 30 min. Absorbance was monitored at 
280 nm. 
 
2.3 Results and discussion 
2.3.1 Production of thiopeptins by S. tateyamensis 
 To verify that S. tateyamensis produces the thiopeptin complex, the strain was 
cultivated in a manner similar to a previously described method.22 Metabolites that matched 
the mass of thiopeptins A1a, Ba, A1b, and Bb (Figure 2.1, 13-16) were identified in the crude 
culture extract of S. tateymanesis by HPLC-MS analysis (Figure B.1). A similar mixture 
of thiopeptin congeners was identified from the culture extract in previous reports. Initially, 
Miyairi and coworkers identified thiopeptin B as the major component of the complex with 
minor components A1-A4, based on separation of thiopeptin components by silica gel, UV-
visible and IR spectroscopy, and mass characterization by gas chromatography vapor 
pressure method.23 No structural characterization was provided at this stage and the “a” 
and “b” designations that indicate the oxidation state of the nitrogenous heterocycle were 
applied later in a detailed structural characterization of the thiopeptins by Hensens (Figures 
2.1, 13-16 and 2.5, 26-29).17 It is unclear if the numerical designations of thiopeptins A1-
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A4 given by Miyairi match the thiopeptin designations A1a/b-A4a/b given by Hensens. The 
masses of thiopeptins A1-A4 or their relative trend in mass differences among the congeners 
do not match A1a/b-A4a/b. In addition, thiopeptin B was separated in two distinct fractions, 
Ba and Bb in later sutides.
17, 23 Miyairi and coworkers did not characterize thiopeptin A2 
due to insufficient yield, and this derivative was not observed by Hensens in later studies.17 
Thiopeptins A3a, A4a, A3b, and A4b (26-29) are truncated at the C-terminus relative to 13-16 
and they may be artifacts of the purification process or caused by degradation upon storage. 
During the course of siomycin structure elucidation, a truncated analog was observed from 
acid hydrolysates, and 26-29 may have resulted from thiopeptins A1a/b-A2a/b in a similar 
manner during purification, storage, or analysis.24 The thiopeptin congener designations 










Isolation and characterization of each thiopeptin derivative would be essential and 
are needed as standards for thiopeptin production and biosynthetic studies. For example, a 
gene deletion study of a thiopeptin biosynthetic gene that is responsible for piperidine 
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formation may result in abolishment of production of piperidine-containing 13 and 14 and 
an accumulation of dehydropiperidine-containing 15 and 16 by the mutant strain. The 
availability of standards would be key in identifying the exact mixture of metabolites. 
Additionally, compounds produced by the mutants may be highly similar in structure and 
difficult to distinguish from 13-16 in a crude culture extract. A co-injection of a crude 
culture extract from a mutant with a thiopeptin standard may accelerate identification of 
new metabolites and intermediates. Furthermore, thiopeptides have complex MS and NMR 
spectra. The availability of reference spectra would facilitate the structural characterization 
of a potential thiopeptin derivative. 
Thiopeptin production by S. tateyamensis, however, was difficult to reproduce. 
Despite repeated efforts to maintain cell stocks that produced thiopeptin, its production 
ceased periodically. The loss of thiopeptin production in S. tateyamensis may be due to 
mutations and deletions in the chromosome. Genetic instability has been observed in 
certain streptomycetes, and is markedly prevalent among genes involved in sporulation, 
pigment production, antibiotic resistance, and antibiotic production.25-27 Streptomyces 
glaucescens strain GLA0 (S. glaucescens), for example, is naturally resistant to 
streptomycin. Antibiotic-sensitive S. glaucescens strains, however, can arise spontaneously 
at a frequency of 0.2 to 1.4% by growth on agar media alone or after cold storage.28 
Reversion to wild-type streptomycin resistance levels was observed at a frequency of 10-5, 
and the cause of its reversion is not understood. Chromosome rearrangements may have 
led to polar effects on the expression of the S. glaucescens streptomycin resistance gene or 
point mutations may be contributors.29 Mutations of genes involved in aerial mycelium 
formation and sporulation have been implicated in the drastic loss of secondary metabolite 
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production.30-34 The products of bldABCDFGH are required for aerial mycelium formation 
in Streptomyces, and bldA mutations are associated with a “bald” non-sporulating 
phenotype and abolishment of secondary metabolite production.35-37 BldA encodes for a 
tRNALeu and bldA mutants are unable to translate genes with the rare Streptomyces leucine 
codon TTA.34 In fact, only 145 of 7825 genes (< 2%) identified in the Streptomyces 
coelicolor genome contain a TTA codon.38 This rare codon, however, is frequently found 
in regulatory genes that control cell differentiation and antibiotic production.33 “Bald” 
mutants of S. coelicolor are unable to produce the antibiotics actinorhodin and 
undecylprodigosin as the biosyntheses of these two metabolites are dependent on the 
expression of transcription factors ActII and RedZ, respectively, that contain the rare codon 
TTA.32, 39 Site-directed mutagenesis of the TTA codon of actII to TTG restored 
actinorhodin production in the “bald” mutants, establishing the relationship between the 
use of the rare TTA codon and antibiotic production.33 Genes that regulate Streptomyces 
morphology, such as whiABCDEFGHI involved in sporulation, may also be involved in a 
regulatory cascade of secondary metabolism.35 Strains that contain a whi mutation are 
known as “white” mutants as aerial mycelia and spores lose their pigmentation and appear 
white.40 “Bald” and “white” mutants of Streptomyces avermitilis, the producer of the 
anthelmintic avermectins, were found to appear at a frequency of 2.4% from the wild-type 
strain under growth on solid media.41 These “bald” and “white” strains showed reduction 
or the complete loss of avermectin production.41 
When grown on ISP3 agar, S. tateyamensis initially appeared dusty and pinkish-
grey. S. tateyamensis, however, often displayed characteristics of “bald” and “white” 
colonies that may carry a bldA or whi mutation. Colonies that were both “white” and “bald”, 
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those that were “white” but not “bald”, and even the colonies that retained a dusty, pinkish-
grey appearance all lost its ability to produce the thiopeptin complex (Figure 2.6). Only the 
glycerolic mycelium stock prepared from the lyophilized stock purchased from ATCC 
retained some thiopeptin production (Figure 2.6). Despite repeated efforts, thiopeptide 
production diminished or was lost over time. Comparison of DNA sequences of the bld 
and whi genes of S. tateyamensis colonies that have lost the ability to produce the 
thiopeptins may reveal mutations and or deletions in the aforementioned genes that are not 
present in S. tateyamensis colonies that produce the thiopeptins. Genomic analysis may 
reveal chromosomal rearrangements and other alterations to the S. tateyamensis genome 
and shed light to why thiopeptin production was abolished in S. tateyamensis. Although 
we were unable to develop a reproducible thiopeptin production protocol and to obtain 
thiopeptin standards, S. tateyamensis is a known producer of the thiopeptins and efforts to 





Figure 2.6: HPLC analyses of crude culture extracts from (a-c) S. tateyamensis colonies 
that presented with a pink pigment on solid media and crude culture extracts of (d-f) S. 
tateyamensis prepared from a glycerolic mycelium stock from the lyophilized ATCC 
sample. Compounds suspected to be thiopeptins based on the UV-vis absorbance profile 
are indicated by asterisks. Absorbance was monitored at 254 nm. 
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2.3.2 Identification of the thiopeptin biosynthetic gene cluster 
To pinpoint the genes responsible for 13-16 biosyntheses, the S. tateyamensis 
genome was partially sequenced to 6.92 Mb on 2,838 contiguous fragments and scanned 
for a nucleotide sequence that could encode the core peptide (VASASCTTCICTCSCSS). 
The gene encoding the thiopeptin precursor peptide, tpnA, was identified but the tpn locus 
included gaps in the sequence and ambiguous sequences in the draft genome assembly. To 
assist in sequencing of the tpn cluster, an S. tateyamensis genomic fosmid library was 
prepared. While a fosmid can accommodate an insert up to ~40 kb, an entire thiopeptide 
gene cluster, it is more likely that overlapping fragments of the tpn gene cluster will be 
found on multiple fosmids. Based on the draft genome sequence, the boundaries of the tpn 
locus appeared to be around tpnU (similar to tsrQ of the thiostrepton biosynthetic gene 
cluster) on the 5’ end of the gene cluster and near tpnO (similar to tsrM) on the 3’ end. 
Therefore, the fosmid library was screened for the 5’-end (tpnU), 3’-end (tpnO), and a 
central region (tpnD, similar to tsrE) of the tpn gene cluster in order to identify any fosmids 
that contained, at minimum, a partial tpn locus. Fosmid HI2B7 was found to contain tpnD 
and tpnU (Figure 2.7 and 2.8) while HI2G2 was found to contain tpnO (Figure 2.9 and 
2.10). Fosmids HI2B7 and HI2G2 were sequenced and, together, found to span the entire 
tpn locus. The tpn cluster encompasses 23 open reading frames (tpnA-W) very similar in 
composition and organization to the thiostrepton biosynthetic gene (tsr) cluster (Figure 







Figure 2.7: PCR screen of the S. tateyamensis genomic fosmid library for tpnD. Fosmids 
from the S. tateyamensis genomic fosmid library are named “HIxxx”. JP8D9 is a fosmid 
from the S. laurentii genomic fosmid library and is used as a control. Primer pairs 
HI-1F/HI-1R were used for amplification. (M) 100 bp molecular weight ladder, (1) HI2A7, 
(2) HI2B7, (3) HI2C7, (4) HI2D7, (5) HI2E7, (6) HI2F7, (7) HI2G7, (8) HI2H7, (9) JP8D9, 
(10) pCC1FOS, and (11) S. tateyamensis gDNA. A 0.7 kb amplicon was expected from 







Figure 2.8: PCR screen of the S. tateyamensis genomic fosmid library for tpnU. Fosmids 
from the S. tateyamensis genomic fosmid library are named “HIxxx”. JP8D9 is a fosmid 
from the S. laurentii genomic fosmid library and used as a control. Primer pairs HI-3F/HI-
3R were used for amplification. (M) 100 bp molecular weight ladder, (1) HI2A6, (2) HI2B6, 
(3) HI2C6, (4) HI2D6, (5) HI2E6, (6) HI2F6, (7) HI2G6, (8) HI2H6, (9) HI2A7, (10) 
HI2B7, (11) HI2C7, (12) HI2D7, (13) HI2E7, (14) HI2F7, (15) HI2G7, (16) HI2H7, (17) 
JP8D9, (18) pCC1FOS, and (19) S. tateyamensis gDNA. A 0.8 kb amplicon was expected 





Figure 2.9: PCR screen of the S. tateyamensis genomic fosmid library for tpnO. Fosmids 
from the S. tateyamensis genomic fosmid library are named “HIxxx”. JP8D9 is a fosmid 
from the S. laurentii genomic fosmid library and used as a control. Primer pairs HI-2F/HI-
2R were used for amplification. (M) 100 bp molecular weight ladder, (1) HI2A5, (2) HI2B5, 
(3) HI2C5, (4) HI2D5, (5) HI2E5, (6) HI2F5, (7) HI2G5, (8) HI2H5, (9) HI2B2, (10) 
HI2C2, (11) HI2D2, (12) HI2E2, (13) HI2F2, (14) HI2G2, (15) HI2H2, (16) JP8D9, (17) 
pCC1FOS, and (18) S. tateyamensis gDNA. A 0.6 kb amplicon was expected from 






Figure 2.10: PCR amplification of tpnDOU from fosmid HI2G2. (M) 100 bp molecular 
weight ladder, (1-3) amplification of tpnU from HI2G2, (4) amplification of tpnD from 
S. tateyamensis gDNA, (5-7) amplification of tpnD from HI2G2, (8) amplification of tpnU 
from S. tateyamensis gDNA, (9-11) amplification of tpnO from HI2G2, (12) amplification 
of tpnO from S. tateyamensis gDNA. The expected amplicon sizes: 0.8 kb for tpnU, 0.7 kb 




Figure 2.11: The organization of the thiopeptin (tpn) and thiostrepton (tsr) biosynthetic 
gene clusters. Homologous genes are indicated by dashed lines. Gene products that are 
likely involved in core macrocycle formation are in blue, those involved in HEQ formation 
are in red, those involved in other modifications to the thiopeptide scaffold are in grey, and 
those with either unknown, transport, or regulatory functions are in white. The span of the 
fosmid inserts that contain a partial tpn locus (HI2B7 and HI2G2) are indicated by solid 




2.3.3 The deduced functions of the tpn cluster 
The gene products of the tpn cluster were compared to proteins from the NCBI 
database using protein BLAST to identify their proposed functions (Table 2.1). Based on 
sequence similarity to proteins encoded in the tsr and other thiopeptide biosynthetic gene 
clusters, the predicted thiopeptin precursor peptide TpnA, together with TpnBCDEFG, 
comprise the minimum set of proteins expected to assemble the core thiopeptide scaffold. 
The thiazol(in)es are likely installed by TpnEFG. TpnF and TpnG are similar to leader 
peptide binding proteins and YcaO domain-containing cyclodehydratases, respectively, 
that operate in concert to form thiazoline rings from the amide backbone and cysteine 
residues of the thiopeptide.15, 43-44 The dehydrogenase TpnE is expected to oxidize the 
intermediate thiazoline to the thiazole.15, 45 A split LanB-type dehydratase appears to be 
encoded by tpnBC, and likely catalyzes the dehydrations to generate the Dha and 
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dehydrobutyrine residues.15 Two Dha residues are likely coupled together by a putative 











Tsr Homologa Closest Homologa 
Orf-5 Transporter 
 
--- Arsenic transporter (WP_030553753.1; 
85/90); Kitasatospora aureofaciens 
Orf-4 ABC transporter permease 
 
--- ABC transporter permease 
(WP_035847761.1; 69/79); Kitasatospora 
azatica 
Orf-3 ABC transporter ATP-binding 
protein 
--- ATP transporter ATP-binding protein 
(WP_083977627.1; 84/92); Kitasatospora 
azatica 
Orf-2 Sensor histidine kinase 
 
--- Hypothetical protein (WP_083977629.1; 
69/75); Kitasatospora azatica 
Orf-1 LuxR family transcriptional 
regulator 
--- DNA-binding response regulator 




--- Hypothetical protein (WP_091614342.1; 
63/72); Amycolatopsis saalfeldensis 
TpnV SnoaL-like cyclase TsrS 
(ACN52308.1; 
66/78) 
SnoaL-like polyketide cyclase (SEO89837.1; 






Acyl-CoA dehydrogenase (SEO89852.1; 







(SEO89872.1; 76/81); Amycolatopsis 
saalfeldensis 





DUF2867 domain-containing protein 
(WP_091614353.1; 72/85); Amycolatopsis 
saalfeldensis 
TpnR α/β-Hydrolase fold family 
protein 
--- Pimeloyl-ACP methyl ester carboxylesterase 
(SEO89904.1; 62/74); Amycolatopsis 
saalfeldensis 





Thiocillin/thiostrepton family thiazolyl 
peptide (WP_091614358.1; 81/88); 
Amycolatopsis saalfeldensis 
TpnQ Thiopeptin macrocyclase TsrB 
(ACN52292.1; 
58/72) 
Pimeloyl-ACP methyl ester carboxylesterase 
(SEO89930.1; 73/82); Amycolatopsis 
saalfeldensis 
TpnB LanB-type dehydratase 




Hypothetical protein (WP_091614364.1; 
67/75); Amycolatopsis saalfeldensis 
TpnC LanB-type dehydratase 





Hypothetical protein (WP_091614367.1; 
71/81); Amycolatopsis saalfeldensis 
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Table 2.1 (continued) 
 
TpnD Thiopeptide [4+2] cyclase TsrE 
(ACN52295.1; 
74/85) 
Hypothetical protein (WP_091614370.1; 
85/92); Amycolatopsis saalfeldensis 
TpnE Thiazoline dehydrogenase TsrF 
(ACN52296.1; 
58/65) 
Hypothetical protein (WP_091614372.1; 
72/78); Amycolatopsis saalfeldensis 





Hypothetical protein (WP_091614375.1; 






Ribosomal protein S12 methylthiotransferase 
accessory factor (SEO90054.1; 73/78); 
Amycolatopsis saalfeldensis 
TpnH 4-(1-Hydroxyethyl)quinoline-2-




Cytochrome P450 (SEO90075.1; 72/80); 
Amycolatopsis saalfeldensis 
TpnI Adenylyltransferase TsrJ 
(ACN52300.1; 
61/70) 
Long-chain fatty acid-CoA ligase 
(WP_091614382.1; 79/87); Amycolatopsis 
saalfeldensis 
TpnJ Isoleucine hydroxylase TsrK 
(ACN52301.1; 
55/66) 
Cytochrome P450 (WP_091614385.1; 
73/81); Amycolatopsis saalfeldensis 
TpnK LanB-type dehydratase 




Hypothetical protein (WP_091614387.1; 
60/69); Amycolatopsis saalfeldensis 
TpnL Flavin/deazaflavin 
oxidoreductase 
--- Pyridoxamine 5’-phosphate oxidase 
(SEO90151.1; 70/78); Amycolatopsis 
saalfeldensis 
TpnM YcaO domain-containing 
protein 
--- Hypothetical protein (WP_091614389.1; 
78/84); Amycolatopsis saalfeldensis 
TpnN TfuA-like protein --- Hypothetical protein (WP_091614392.1; 
72/79); Amycolatopsis saalfeldensis 











SDR family NAD(P)-dependent 
oxidoreductase (WP_091614398.1; 74/82); 
Amycolatopsis saalfeldensis 
Orf1 Universal stress protein 
 
--- Universal stress protein (WP_097239522.1; 
77/84); Streptomyces sp. 1331.2 
Orf2 β-Lactamase 
 
--- Serine hydrolase (WP_030274042.1; 67/75); 
Streptomyces sp. NRRL B-24484 
Orf3 Hypothetical protein 
 
--- Hypothetical protein (WP_053175376.1; 
40/57); Streptomyces virginiae 
Orf4 Major facilitator superfamily 
transporter 
--- MFS transporter (WP_100887175.1; 85/92); 
Kitasatospora sp. OK780 
Orf5 DNA-binding response 
regulator 
--- DNA-binding response regulator 
(WP_042413556.1; 97/98); Streptacidiphilus 
anmyonenis 






The quinaldic acid moiety of 2, and likely of 13-16 (Figure 2.1), is derived from 
L-tryptophan. TpnOPUVW are expected to convert the amino acid into 
4-(1-hydroxyethyl)quinoline-2-carboxylic acid (HEQ 21) by a process that includes an 
oxidative ring expansion (Scheme 1.4).14, 46-47 TpnO is similar to TsrM, a radical SAM and 
cobalamin-dependent methyltransferase that generates 2-methyl-L-tryptophan as the first 
step in this process.48 The second step is catalyzed by an aminotransferase.14 TpnW shares 
homology with histidinol-phosphate transaminases but demonstrates only 40% identity 
(50% similarity) with the thiostrepton pathway transaminase, TsrV.14 Since there is no 
other open reading frame in the tpn locus that shows homology to an aminotransferase, 
TpnW is a candidate 2-methyl-L-tryptophan transaminase. TpnU shows homology to the 
FADH2-dependent oxygenase, TsrQ, that initiates ring opening and rearrangement of the 
indole ring.47 TpnV shows homology to TsrS, a SnoaL-like cyclase suggested to be 
involved in HEQ 21 biosynthesis, although its function is unclear.46 TpnP shows sequence 
homology to the NADPH-dependent reductase TsrN that reduces the ketone of 
4-acetylquinoline-2-carboxylate to the alcohol of HEQ.46 
The quinaldic acid-containing macrocycle is likely installed in the thiopeptin scaffold 
by the actions of TpnHIQ.49-51 TpnI is similar to adenylyltransferases and is expected to 
attach HEQ 21 to Thr12 of the peptide, likely followed by TpnH-catalyzed 
epoxygenation.14, 49, 51 TpnQ, similar to the macrocyclase TsrB, is a candidate to mediate 
macrocyclization of the quinaldic acid-containing loop through attack of the core peptide’s 
N-terminus upon the epoxide.50 The thiopeptins from S. tateyamensis possess either a 
methylester (Figure 2.1, 13 and 15) or a carboxylic acid (Figure 2.1, 14 and 16) at their C-
termini; none containing the C-terminal amide observed in 2 have been reported. 
72 
 
Accordingly, a homolog encoding the thiostrepton amidotransferase, TsrT, is absent.14 
TpnT is similar to TsrP and may function as a carboxymethyltransferase to produce the C-
terminal methyl ester.14, 52 A homolog of the methylesterase TsrU is not present in the tpn 
cluster.52 Instead, TpnR, with similarity to other α/β-hydrolases likely serves this role. 
Three genes of the tpn cluster, tpnLMN, do not share homology with known thiopeptide 
biosynthetic genes and are therefore candidates for the thioamide and piperidine features 
unique to 13-16. TpnMN show sequence similarity to YcaO proteins and TfuA-like 
proteins, respectively, and are similar to the TvnHI pair encoded in the thioviridamide gene 
cluster, another thioamidated metabolite.53 Involvement of a YcaO-TfuA pair in the 
posttranslational thioamidation of methyl-coenzyme A reductase in Methanosarcina 
acetivorans was recently established.54-55 The YcaO protein activates the peptide backbone 
in an ATP-dependent manner similar to the YcaO-domain containing cyclodehydratases 
involved in thiazoline formation.55 Although the function of the TfuA protein is unclear, 
both the YcaO and TfuA proteins are required for the thioamidation of the peptide 
substrate.55 It is therefore likely that TpnM (YcaO protein) and TpnN (TfuA protein) work 
together to install the thiopeptin thioamide.  
TpnL, on the other hand, shares homology to proteins annotated as FMN-dependent 
pyridoxine/pyridoxamine 5’-phosphate oxidases and other enzymes of the 
flavin/deazaflavin oxidoreductase subgroup B (FDOR-B).56 The only remaining thiopeptin 
modification unaccounted for is a reduction to produce the piperidine ring of the series a 





2.3.4 Disruption of open reading frames of the tpn cluster 
 To confirm the involvement of the tpn cluster in thiopeptin biosynthesis, insertional 
mutants of tpnALMNR in S. tateyamensis were pursued. Inactivation of a gene essential to 
thiopeptin biosynthesis would abolish its production and affirm the involvement of the tpn 
cluster in the pathway. In addition, accumulation of any biosynthetic intermediates would 
shed light on the role and timing of a particular modification mediated by the inactivated 
gene. A λ Red-mediated recombination strategy was used to insert the aac(3)IV/oriT 
cassette in E. coli into each tpn gene being targeted for disruption.57 The aac(3)IV gene 
confers resistance to apramycin and is used to apply selective pressure for the bacterium to 
retain the plasmid while oriT is required for intergeneric conjugation between E. coli and 
Streptomyces. The disrupted gene would then be incorporated into the S. tateyamensis 
chromosome through homologous recombination. The tpnA insertional mutant 
S. tateyamensis HI1, for example, was constructed using the λ Red-mediated 
recombination strategy (Figure 2.12). To rule out polar effects on thiopeptide production 
that may have been caused by modifications to the S. tateyamensis chromosome, we 
attempted to genetically complement the tpnA insertional mutant with a functional copy of 




Figure 2.12: Strategy used to construct the tpnA mutant, S. tateyamensis HI1. (A) The 
pIJ773 disruption cassette was amplified by PCR with primer pair HI-5F/HI-5R containing 
a 39 nt region around tpnA at the 5’ ends of the primers and a 20 nt P1 or P2 sequence at 
the 3’ ends of the primers. (B) Homologous recombination between the PCR product and 
pGM-tpnA generated pGM-dtpnA. (C) Homologous recombination between pGM-dtpnA 




 While many methods exist to introduce DNA into Streptomyces, intergeneric 
conjugation of plasmids from E. coli into streptomycetes is frequently used for its 
simplicity in protocol over protoplast transformation, which requires species-specific 
protocol optimization.19 For conjugation experiments, Streptomyces spore germlings are 
used so that a homogeneous cell population can be subjected to genetic manipulation under 
more consistent and reproducible conditions. Due to the complex life cycle of Streptomyces 
species, physiological homogeneity is difficult to achieve and even a young mycelium 
culture can contain a heterogeneous population.19 
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 A variety of conditions were explored to generate S. tateyamensis spores suitable 
for intergeneric conjugation with E. coli. Sporulation of S. tateyamensis was assayed on 
ISP4, ATCC 184, ISP7, and calcium-malate agar, but robust spore formation was not 
observed. ISP3 solid media produced thick, dusty, and gray growth and the spores were 
harvested after 10, 15, 20, and 25 days. Mycelium heat shocked at 50 °C for 10 min did 
not grow on either ISP3 or MS agar, allowing us to confirm the presence of S. tateyamensis 
spores and their viability. Both heat-shocked and untreated spores germinated on ISP3 agar, 
but seemed to grow quicker on ISP3 medium supplemented with 10 mM MgCl2. Spores 
also germinated on maltose sugar (MS) solid medium supplemented with 10 mM MgCl2. 
Spores harvested after 10-25 days were used for conjugation with E. coli harboring a 
pGM160HKss plasmid. Unfortunately, our protocols were not successful in introducing 
foreign DNA into S. tateyamensis spores.  
S. tateyamensis protoplast transformation was also pursued. Protoplasts are 
bacterial cells that lack a cell wall, leaving the plasma membrane as the outermost barrier. 
The lack of a rigid, secondary outer cell wall is thought to make the transfer of genetic 
material into the cell more efficient. Protoplast generation of Gram-positive bacteria has 
been demonstrated as the cell wall is easily removed with lysozyme treatment and may be 
an applicable method in producing S. tateyamensis protoplasts.59 To complement lysozyme 
treatment, bacteria may be cultured in media containing penicillin or glycine to weaken the 
integrity of the cell wall by preventing optimal cross-linking in the peptidoglycan. 
Penicillin irreversibly inhibits DD-transpeptidase, which catalyzes cross-link formation in 
peptidoglycan.60-61 Glycine weakens the bacterial cell wall at high concentrations (0.5-
3.0%), by competing with D-alanine for incorporation into peptidoglycan; D-alanine is 
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involved in cross-linking in the cell wall of all bacteria, and the replacement of D-alanine 
with glycine disrupts the integrity of the cell wall.62-63 The age and/or physiological state 
of the mycelium used to prepare the protoplasts can have an effect on transformation 
frequencies in individual species.57 Streptomyces lividans protoplasts prepared from late 
exponential phase of the mycelium stage (36-40 h) were found to yield transformants, 
whereas younger mycelium (18 h) of Streptomyces parvulus was found to be viable for 
transformation.19, 64 In addition to the importance of the growth phase of the mycelium at 
the time of protoplast transformation, several factors can greatly influence transformation 
efficiencies, including the temperature at which the mycelium and protoplasts are kept 
during preparation and transformation, the concentration of protoplasts, the composition 
and dryness of the regeneration medium, the organism from which the plasmid is isolated, 
and the temperature at which protoplasts are regenerated.19, 57, 65  
 S. tateyamensis protoplasts were prepared at various growth phases of the 
mycelium, glycine concentrations, and cell wall lysis buffers (Table 2.2). Cultures 
incubated for 16 and 24 hours with 0.25% glycine did provide protoplasts which 
regenerated on dried ISP3 solid medium. Conditions 18 and 19 (Table 2.2) were selected 
for protoplast transformation as these conditions yielded a homogeneous sample of 
protoplasts in initial transformation efforts. In later trials, however, condition 21 and 22 









Table 2.2: Conditions used to prepare S. tateyamensis protoplasts. The protoplasts used for 





















1 40 hours 0.5 % P + 1 
mg/mL 
lysozyme 
30 min Mostly mycelium R2YE No growth 
2 40 hours 0.5 % P + 1 
mg/mL 
lysozyme 
30 min Mostly mycelium Dried ISP3 No growth 
3 40 hours 0.5 % P + 1 
mg/mL 
lysozyme 
30 min Mostly mycelium ISP3 No growth 
4 40 hours 0.5 % P + 1 
mg/mL 
lysozyme 
60 min Mostly mycelium R2YE No growth 
5 40 hours 0.5 % P + 1 
mg/mL 
lysozyme 
60 min Mostly mycelium Dried ISP3 No growth 
6 40 hours 0.5 % P + 1 
mg/mL 
lysozyme 
60 min Mostly mycelium ISP3 No growth 
7 40 hours 0.5 % L + 1 
mg/mL 
lysozyme 
60 min Mixture of 
mycelium and 
protoplasts 
R2YE No growth 
8 40 hours 0.5 % L + 1 
mg/mL 
lysozyme 
60 min Mixture of 
mycelium and 
protoplasts 
ISP3 No growth 
9 40 hours 0.5 % L + 1 
mg/mL 
lysozyme 
60 min Mixture of 
mycelium and 
protoplasts 
Dried ISP3 Some growth 
after 2 days 
10 40 hours 0.5 % L + 1.5 
mg/mL 
lysozyme 
60 min Mostly 
protoplasts 
R2YE No growth 
11 40 hours 0.5 % L + 1.5 
mg/mL 
lysozyme 
60 min Mostly 
protoplasts 
Dried ISP3 No growth 
12 40 hours 0.5 % L + 2.0 
mg/mL 
lysozyme 
60 min Mostly 
protoplasts 
R2YE No growth 
13 40 hours 0.5 % L + 2.0 
mg/mL 
lysozyme 
60 min Mostly 
protoplasts 
Dried ISP3 No growth 
14 30 hours 0.5 % L + 1.5 
mg/mL 
lysozyme 
60 min Mostly 
protoplasts 
Dried ISP3 Some growth 
15 30 hours 0.75 % L + 1.5 
mg/mL 
lysozyme 
60 min Cell debris Dried ISP3 No growth 
16 30 hours 1.0 % L + 1.5 
mg/mL 
lysozyme 
60 min Cell debris Dried ISP3 No growth 
17 24 hours 0.5 % L + 1.5 
mg/mL 
lysozyme 
60 min Mixture of 
mycelium and 
protoplasts 
Dried ISP3 No growth 
18 24 hours 0.25 % L + 1.5 
mg/mL 
lysozyme 
60 min Protoplasts Dried ISP3 Growth after 2 
days 
19 24 hours 0.25 % L + 1.5 
mg/mL 
lysozyme 
45 min Protoplasts Dried ISP3 Growth after 2 
days 
20 24 hours 0.25 % L + 1.5 
mg/mL 
lysozyme 
30 min Mostly 
Protoplasts 
Dried ISP3 Growth after 2 
days 




Table 2.2 (continued) 
 
21 16 hours 0.25 % L + 1.5 
mg/mL 
lysozyme 
45 min Protoplasts Dried ISP3 Growth after 2 
days 
22 16 hours 0.25 % P + 1.5 
mg/mL 
lysozyme 
60 min Protoplasts Dried ISP3 Growth after 2 
days 
23 16 hours 0.25 % PR5 + 1.5 
mg/mL 
lysozyme 
60 min Protoplasts Dried ISP3 No growth 
24 16 hours 0.25 % PR6 + 1.5 
mg/mL 
lysozyme 
60 min Protoplasts Dried ISP3 No growth 
a The time of culture incubated at 28 °C after inoculation. 
b Protoplast regeneration was distinguished from mycelial growth by overlaying a second, identical plate with 0.01% sodium dodecyl 
sulfate (SDS). SDS inhibits the growth of protoplasts but does not significantly affect mycelium growth. The number of colonies on 
plates with and without SDS were compared to determine if protoplasts had regenerated on solid media. Protoplasts were regenerated 




Protoplasts of many Streptomcyes species are transformed by plasmid DNA at high 
frequency in the presence of polyethylene glycol (PEG).66 The w/v of the PEG solution 
seems to influence transformation frequency rather than the molecular weight of the PEG 
used.19 While the exact mechanism of PEG-mediated DNA transformation is not known, 
DNA collapses into a globular form in PEG solutions and compacted DNA may be more 
efficiently taken up by a cell via endocytosis over its coiled counterpart.67 S. tateyamensis 
protoplast transformation was performed under various conditions (Table 2.3) and 
transformation was successful using conditions 2 and 21 (Table 2.3). In later trials to 
transform S. tateyamensis, neither condition yielded transformants. Protoplast 
transformation using 10% PEG1000 and 100 mM MgCl2 in the transformation buffer with 
pGM-dtpnL did yield apramycin-resistant colonies, suggesting the transfer of a plasmid 
with an apramycin resistance gene (such as aac3(IV) in pGM-dtpnL) into S. tateyamensis. 
However, a PCR-based screen for pGM-dtpnL in the candidate transformants did not 
identify any harboring the plasmid.  
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Transformation of Streptomyces may be significantly impacted by the presence of 
restriction-modification (RM) systems in the organism.68 Protoplasts are fragile and may 
leak nucleases that degrade foreign DNA introduced during transformation. The addition 
of calf thymus DNA before, but not after, the addition of plasmid DNA was found to 
increase the transformation frequency 10-fold in Streptomyces ambofaciens 
(S. ambofaciens).65 Calf thymus DNA may provide competitive protection against 
endonucleolytic cleavage of plasmid DNA. In addition, transformation frequency was 
increased by 103 in S. ambofaciens and in Streptomyces griseus (S. griseus) using plasmid 
DNA isolated from S. ambofaciens and S. griseus, respectively.65, 68 Many Streptomyces 
species have species-specific methyltransferases that methylate their own DNA and protect 
themselves from endonucleases that cleave incoming bacteriophage DNA.69-70 For 
example, plasmids isolated from E. coli were unable to be introduced into S. griseus until 
the plasmid was methylated in vitro with HpaII and SssI.68 The transformation efficiency 
increased by 105 using HpaII-methylated plasmid DNA, comparable to transformation 
levels observed using plasmids isolated from S. griseus.68 Dam-methylated plasmids are 
cleaved by restriction endonucleases of many Streptomcyes species and accordingly, the 
plasmids used to transform S. tateyamensis were isolated from a Dam-deficient E. coli 
strain (E. coli ET12567).68, 71 This method by MacNeil and coworkers was successful in 
introducing a plasmid into Streptomyces avermitilis, later shown to be applicable for 
Streptomyces laurentii by Kelly and coworkers, but not for S. tateyamensis.14, 72 DNA 
introduced to S. tateyamensis may require a different methylation pattern than those 
generated in E. coli ET12567 to overcome RM systems present in S. tateyamensis. RM 
systems can be a great obstacle for interspecies DNA transfer. 
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Table 2.3: Transformation conditions for S. tateyamensis protoplasts. Conditions that 



















1 18 20 25 0.5 yes no 
2 18 20 25 1 yes yes 
3 18 20 4 0.5 yes no 
4 18 20 4 1 yes no 
5 21 10 25 0.5 yes no 
6 21 10 25 1 yes no 
7 21 10 25 10 yes no 
8 21 20 25 0.5 yes no 
9 21 20 25 1 yes yes 
10 21 20 25 10 yes yes 
11 21 20 4 0.5 yes no 
12 21 20 4 1 yes no 
13 21 20 4 10 yes no 
14 21 40 25 0.5 yes no 
15 21 40 25 1 yes no 
16 21 40 25 10 yes no 
17 21 55 25 0.5 yes no 
18 21 55 25 1 yes no 
19 21 55 25 10 yes no 
20 21 10 + 100 mM 
MgCl2 
25 1 yes noc
 
21 21 10 + 100 mM 
MgCl2 
25 10 yes noc 
22 21 20 + 100 mM 
MgCl2 
25 1 yes no 
23 21 20 + 100 mM 
MgCl2 
25 10 yes no 
24 21 40 + 100 mM 
MgCl2 
25 1 yes no 
25 21 40 + 100 mM 
MgCl2 
25 10 yes no 
26 22 20 25 1 yes no 
27 22 20 25 5 yes no 
28 22 20 25 10 yes no 
29 22 40 25 1 yes no 
30 22 40 25 5 yes no 
31 22 40 25 10 yes no 
32 22 55 25 1 yes no 
33 22 55 25 5 yes no 
34 22 55 25 10 yes no 
a Protoplast preparation conditions shown in Table 2.2. 
b PEG1000 concentration in the transformation buffer along with other additives. 
c Apramycin-resistant transformants were observed, suggesting the acquisition of pGM-dtpnL. The presence of the plasmid in these 




Conditions to transform S. tateyamensis were unable to be optimized. Only the tpnA 
mutant was successfully produced. S. tateyamensis transformants that harbored 
pGM-dtpnA were screened by whole cell culture PCR and the double crossover mutant, 
S. tateyamensis HI1, was confirmed by PCR and DNA sequencing analysis (Figures 2.13 
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and 2.14). The crude culture extract of the tpnA mutant, S. tateyamensis HI1, seemed to 
lack many of the compounds suspected to be the thiopeptins (Figure 2.15 and B.2). To rule 
out polar effects on thiopeptin production that may have been caused by the modifications 
on the S. tateyamensis chromosome, we attempted to genetically complement 
S. tateyamensis HI1 with a functional copy of tpnA expressed under the constitutive 
promotor ermE*.58 A direct relationship between the expression of tpnA and thiopeptin 
production can be demonstrated if thiopeptin production is restored in S. tateyamensis HI1 
by in trans expression of tpnA. Genetic complementation of S. tateyamensis HI1, however, 
was unsuccessful. In addition, thiopeptin production was difficult to reproduce in 
S. tateyamensis, as mentioned earlier in this chapter, causing the results of these genetic 
experiments to be difficult to interpret. Therefore, alternate strategies to assess the 






Figure 2.13: Whole cell culture PCR analysis of potential S. tateyamensis pGM-dtpnA 
transformants. (M) 1 kb molecular weight ladder and (Colonies 1-20) 
potential S. tateyamensis pGM-dtpnA transformants. A 3625 bp product was amplified 
from S. tateyamensis pGM-dtpnA (tpnA::aprR/oriT) transformants and pGM-dtpnA 
(pGM160HKss-tpnA::aprR/oriT) while a 2469 bp product was amplified from wild-type 
S. tateyamensis. S. laurentii was used as a control. Primer pair HI-4F/HI-4R was used for 






Figure 2.14: PCR analysis of the tpnA mutant, S. tateyamensis HI1. (M) 1 kb molecular 
weight ladder. (1-10) S. tateyamensis HI1 (11) wild-type S. tateyamensis (12) S. laurentii 
(13) wild-type S. tateyamensis gDNA (14-21) S. tateyamensis HI1 (22) wild-type S. 
tateyamensis (23) S. laurentii (24) wild-type S. tateyamensis gDNA. A 2588 bp product 
was amplified from (1-10) using primer pair HI-26F/HI-26R and a 1871 bp product was 
amplified from (14-21) using primer pair HI-27F/HI-27R from S. tateyamensis HI1. No 
product was expected to be amplified from either (11-13) using primer pair HI-26F/HI-
26R or (22-24) using primer pair HI-27F/HI-27R. An amplicon (~600 bp) is observed in 
some reactions (14-15, 22, and 24) with primer pair HI-27F/HI-27R which likely resulted 





Figure 2.15: HPLC analysis of (a) S. tateyamensis and (b) S. tateyamensis HI1 crude 
culture extracts. Absorbance was monitored at 254 nm. Compounds suspected to be 









2.3.5 Transaminase activity of TpnW 
Transamination of 2-methyl-L-tryptophan (17) is a required step in the biosynthesis 
of the HEQ 21 moiety of the thiopeptins.14 TpnW shares homology with histidinol-
phosphate transaminases but shows only modest homology with the thiostrepton pathway 
transaminase, TsrV.14 To determine if TpnW could be involved in 13-16 biosynthesis, we 
expressed TpnW in E. coli, purified the protein (Figure 2.16), and reconstituted its activity 
in vitro. TpnW does convert 2-methyl-L-tryptophan 18 to 3-(2-methylindolyl)pyruvate 
(19) in the presence of aromatic α-keto acid acceptors 3-indolylpyruvate (30), 
p-hydroxyphenylpyruvate, and phenylpyruvate, but not in the presence of pyruvate, 
oxaloacetate, or α-ketoglutarate (Scheme 2.1 and Figures 2.17-2.18). Similar preferences 
for α-keto acid acceptors were observed with TsrV.14, 47 These results indicate that TpnW 
is a 2-methyl-L-tryptophan aminotransferase involved in HEQ 21 biosynthesis for 13-16 
and supports the involvement of the tpn gene cluster in thiopeptin biosynthesis. It is not 
clear if TpnW has a preferred α-keto acid acceptor or if TpnW has a relaxed substrate 
preference. Further biochemical studies, such as substrate binding and kinetic experiments, 











Scheme 2.1: Transamination of 2-methyl-L-tryptophan 18 with 3-indolylpyruvate 30 and 





Figure 2.17: HPLC analyses of TpnW transamination activity after a 30 minute reaction 
time. (a) L-Tryptophan 17 standard; (b) 2-methyl-L-tryptophan 18 standard; 
(c) 3-indolylpyruvate 30 standard; (d) 30 after 30 min incubation in phosphate buffer; (e) 
18 and 30; (f) 18, 30, and PLP; (g) 18, 30, PLP, and TpnW. Absorbance was monitored at 
280 nm. A new metabolite presumed to correspond to 3-(2-methylindolyl)pyruvate 19 was 
observed at tR ~19.5 min and the product 17 was observed at tR ~10.2 min in the intact 
reaction. The presence of an ion corresponding to the expected m/z of 19 in the reaction 





Figure 2.18: HPLC analyses of TpnW transamination activity with various α-keto acids. 
Transamination of 2-methyl-L-tryptophan 18 was performed with various α-keto acid 
acceptors: (a) pyruvate, (b) oxaloacetate, (c) α-ketoglutarate, (d) phenylpyruvate, (e) 
p-hydroxyphenylpyruvate, and (f) 3-indolylpyruvate 30. The formation of a new metabolite 
at tR ~19.5 min presumed to be 3-(2-methylindolyl)pyruvate 19 was observed in the 
presence of the aromatic α-keto acids phenylpyruvate, p-hydroxyphenylpyruvate, and 













 The thiopeptin biosynthetic gene (tpn) cluster was identified in S. tateyamensis 
based on in silico comparisons of encoded products of the tpn cluster to homologous 
proteins found on the NCBI database, as well as to other known thiopeptide biosynthetic 
genes. The structure of thiostrepton A 2 and the thiopeptins 13-16 are highly similar and, 
accordingly, many of the encoded products of the tpn cluster show amino acid sequence 
similarities to thiostrepton biosynthetic proteins. In support of the involvement of the tpn 
cluster in thiopeptin biosynthesis, TpnW was shown to catalyze the transamination of 
2-methyl-L-tryptophan 18 to 3-(2-methylindolyl)pyruvate 19, the second step in HEQ 21 
biosynthesis from L-tryptophan 17.  
Homologs of the thiostrepton biosynthetic gene cluster that are present in the tpn 
cluster can account for nearly all modification to the thiopeptin scaffold. TpnLMN, 
however, do not show sequence homology to known thiopeptide biosynthetic proteins. 
TpnL shows homology to flavin/deazaflavin oxidoreductases and is a candidate for 
piperidine formation. TpnMN show homology to YcaO domain-containing proteins and 
TfuA-like proteins, respectively, that effect thioamidation and are proposed to have similar 
activities in thiopeptin biosynthesis. The roles of TpnLMN in thiopeptin biosynthesis will 
be investigated through heterologous expression of TpnLMN in a host organism that 
produces a thiopeptide similar to thiopeptin and, for TpnL, in vitro biochemical assays that 
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 The thiopeptin biosynthetic gene (tpn) cluster contains 23 open reading frames 
(orfs), tpnA-W, and tpnLMN do not share homology to other known thiopeptide 
biosynthetic genes. These three orfs are candidates for their involvement in thioamide and 
piperidine formation, the two distinguishing features of the thiopeptins. In addition, tpnR 
encodes a predicted α/β-hydrolase that does not show homology to other known thiopeptide 
biosynthetic genes and may serve as an esterase that hydrolyzes the C-terminus 
carboxymethyl of a thiopeptin biosynthetic intermediate. To investigate the roles of 
tpnLMNR in thiopeptin biosynthesis, we attempted to inactivate each gene in Streptomyces 
tateyamensis ATCC 21389 (S. tateyamensis) and examine the effects of the gene 
inactivations on the biosynthesis of thiopeptin. Despite repeated efforts, conditions to 
reliably modify the S. tateyamensis genome were unable to be optimized.  
 Instead, an alternate approach was taken to investigate the roles of tpnLMNR. 
Thiostrepton A 2, a thiopeptide produced by Streptomyces laurentii ATCC 31255 
(S. laurentii), is highly similar in structure to the thiopeptins and we hypothesized that the 
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products of tpnLMNR may intercept the appropriate thiostrepton biosynthetic intermediate 
in S. laurentii as a substrate, generating a new metabolite, and shedding light on the 
function of these proteins. Thiostrepton A 2 production by S. laurentii has been shown to 
be reproducible in the Kelly lab.1-3 In addition, the genomic manipulation of S. laurentii 
has been demonstrated and conditions previously reported by Kelly and coworkers.4-6 
Together, these two capabilities offer a separate strategy to examine tpn genes. Thus, 
TpnLMNR were heterologously expressed in S. laurentii. The S. laurentii strain that 
heterologously expressed TpnL produced a new piperidine-containing metabolite, 
thiostrepton Aa. This thiostrepton analog was structurally characterized and was evaluated 
for its aqueous solubility and antibacterial properties. 
 
3.2 Materials and methods 
3.2.1 General 
All reagents, unless otherwise specified, were purchased from standard commercial 
sources and used as provided. High-performance liquid chromatography (HPLC) analyses 
were performed on a Beckman Coulter System Gold HPLC using an analytical 
Phenomenex Luna 5µm C18(2) 250 x 4.6 mm column (Torrance, CA). All mass 
spectrometry analyses were performed at the Georgia Institute of Technology Bioanalytical 
Mass Spectrometry Facility. High-performance liquid chromatography-mass spectrometry 
(HPLC-MS) analyses were performed on a Micromass Quattro LC using a Phenomenex 
Synergi 4 µm MAX-RP 80 Å C18 250 x 2.00 mm column (Torrance, CA). High resolution 
electrospray ionization mass spectrometry (HR-ESI-MS) and subsequent MS/MS analyses 
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were performed on a Thermo Fisher Scientific LTQ Orbitrap XL ETD with flow injection 
analysis. NMR analyses were performed on a Bruker Avance IIIHD 800 at the Georgia 
Institute of Technology NMR Center. Oligonucleotides were purchased from Integrated 
DNA Technologies, Inc. (Coralville, IA). DNA sequencing analyses were performed by 
Eurofins MWG Operon USA (Louisville, KY). 
 
3.2.2 Bacterial strains, plasmids, and growth medium 
All primers used are listed in Table A.1 and strains and plasmids used are listed in 
Table A.2. Streptomyces tateyamensis ATCC 21389 (S. tateyamensis) and Streptomyces 
laurentii ATCC 31255 (S. laurentii) were purchased from American Type Culture 
Collection. Escherichia coli (E. coli) strains were cultured in Luria-Bertani medium 
supplemented with 100 µg/mL ampicillin, 50 µg/mL apramycin, 12.5 µg/mL 
chloramphenicol, 50 µg/mL kanamycin, or 50 µg/mL streptomycin. S. laurentii strains 
containing pSET1520-derived vectors were cultured in media supplemented with 
50 µg/mL apramycin. 
 
3.2.3 Growth of S. laurentii and analysis of thiostrepton production 
Growth of S. laurentii strains were carried out in a three step process as previously 
described.2 First, a glycerolic mycelium stock was used to inoculate 50 mL of tryptic soy 
broth in a 250 mL Erlenmeyer flask, and the resulting culture was incubated at 28 °C and 
220 rpm for 72 hours. 2.5 mL of this culture was used to inoculate 50 mL of seed medium 
(15 g/L D-glucose, 15 g/L soybean flour, 15 g/L soluble starch) in a 250 mL Erlenmeyer 
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flask and cultured at 28 °C and 220 rpm for 72 hours. Next, 5 mL of the seed medium was 
used to inoculate 100 mL of fermentation medium (50 g/L D-glucose, 11 g/L yeast extract, 
15 g/L tryptic soy broth, 1 mL/L trace elements solution (5 g/L CoCl2·6H2O, 0.5 g/L 
Na2MoO4, 0.5 g/L H3BO3, 1.0 g/L CuSO4·2H2O, 1.0 g/L ZnSO4·7H2O)) in a 500 mL 
Erlenmeyer flask. The culture was incubated at 28 °C and 220 rpm for 5 days for the initial 
studies of the S. laurentii heterologous expression strains HI0-HI7 and 8 days for latter 
studies involving S. laurentii HI0 and HI1. The whole culture was extracted twice with an 
equal volume of chloroform. The chloroform layers were pooled together, filtered, and the 
solvent was removed in vacuo. The solid residue was dissolved in 4 mL of chloroform. 
Samples were analyzed by HPLC and developed with a gradient of 0 to 100% acetonitrile 













3.2.4 Transformation of S. laurentii with pSET1520 and cultivation of S. laurentii HI0 
The plasmid pSET1520 was transformed into E. coli ET12567/pUZ8002, and 
introduced into S. laurentii by intergeneric conjugation.2, 7 Colonies resistant to apramycin 
were selected, gDNA was isolated from each colony, and S. laurentii HI0 (S. laurentii 
harboring pSET1520) was confirmed by PCR analysis (Figure 3.1) using the primer pair 
HI-19F/HI-19R and sequencing analysis of the amplified product. S. laurentii HI0 was 





Figure 3.1: Confirmation of S. laurentii HI0 by PCR. The primers used were HI-19F and 
HI-19R, which anneal to sites on either side of the pSET1520 multiple cloning site. (M) 1 
kb molecular weight ladder; (1) S. laurentii HI0; (2) S. laurentii; (3) S. laurentii HI1; (4) 
pSET1520. The expected 659 bp products were amplified from S. laurentii HI0 and 








3.2.5 Expression of TpnL in S. laurentii 
The gene encoding TpnL was amplified by PCR from HI2G2 using the primer pair 
HI-20F/HI-20R. The PCR product was ligated into pSC-B-amp/kan to form pSC-B-tpnL, 
and the genomic insert was confirmed by DNA sequence analysis. The vector was digested 
with EcoRI and NdeI, the insert ligated into pSET1520 to form pSET1520-tpnL, and the 
insert was confirmed by DNA sequence analysis. Following transformation into E. coli 
ET12567/pUZ8002, pSET1520-tpnL was introduced into S. laurentii by intergeneric 
conjugation.2, 7 Colonies resistant to apramycin were selected, gDNA was isolated from 
each colony, and S. laurentii HI1 (S. laurentii harboring pSET1520-tpnL) was confirmed 
by PCR analysis (Figure 3.2) using the primer pair HI-20F/HI-20R and sequencing analysis 
of the amplified product. S. laurentii HI1 was cultured and evaluated for thiostrepton 





Figure 3.2: Confirmation of S. laurentii HI1 by PCR. The primers used were HI-20F and 
HI-20R, which anneal to tpnL. (M) 1 kb molecular weight ladder; (1) S. laurentii HI1; (2) 
S. laurentii; (3) pSET1520-tpnL; (4) pSET1520. The expected 519 bp products were 




3.2.6 Expression of TpnM in S. laurentii 
The gene encoding TpnM was amplified by PCR from HI2G2 using the primer pair 
HI-21F/HI-21R. The PCR product was ligated into pSC-B-amp/kan to form pSC-B-tpnM, 
and the genomic insert was confirmed by DNA sequence analysis. The vector was digested 
with EcoRI and NdeI, the insert ligated into pSET1520 to form pSET1520-tpnM, and the 
insert was confirmed by DNA sequence analysis. Following transformation into E. coli 
ET12567/pUZ8002, pSET1520-tpnM was introduced into S. laurentii by intergeneric 
conjugation.2, 7 Colonies resistant to apramycin were selected, gDNA was isolated from 
each colony, and S. laurentii HI2 (S. laurentii harboring pSET1520-tpnM) was confirmed 
by PCR analysis (Figure 3.3) using the primer pair HI-21F/HI-21R and sequencing analysis 
of the amplified product. S. laurentii HI2 was cultured and evaluated for thiostrepton 





Figure 3.3: Confirmation of S. laurentii HI2 by PCR. The primers used were HI-21F and 
HI-21R, which anneal to tpnM. (M) 1 kb molecular weight ladder; (1) S. laurentii HI2; (2) 
S. laurentii; (3) pSET1520-tpnM. The expected 1.2 kb products were amplified from 




3.2.7 Expression of TpnN in S. laurentii 
The gene encoding TpnN was amplified by PCR from HI2G2 using the primer pair 
HI-22F/HI-22R. The PCR product was ligated into pSC-B-amp/kan to form pSC-B-tpnN, 
and the genomic insert was confirmed by DNA sequence analysis. The vector was digested 
with EcoRI and NdeI, the insert ligated into pSET1520 to form pSET1520-tpnN, and the 
insert was confirmed by DNA sequence analysis. Following transformation into E. coli 
ET12567/pUZ8002, pSET1520-tpnN was introduced into S. laurentii by intergeneric 
conjugation.2, 7 Colonies resistant to apramycin were selected, gDNA was isolated from 
each colony, and S. laurentii HI3 (S. laurentii harboring pSET1520-tpnN) was confirmed 
by PCR analysis (Figure 3.4) using the primer pair HI-22F/HI-22R and sequencing analysis 
of the amplified product. S. laurentii HI3 was cultured and evaluated for thiostrepton 
production as described in 3.2.3. 
 
 
Figure 3.4: Confirmation of S. laurentii HI3 by PCR. The primers used were HI-22F and 
HI-22R, which anneal to tpnN. (M) 1 kb molecular weight ladder; (1) S. laurentii HI3; (2) 
S. laurentii; (3) pSET1520-tpnN. The expected 1.3 kb products were amplified from 




3.2.8 Expression of TpnR in S. laurentii and cultivation of S. laurentii HI4 
The gene encoding TpnR was amplified by PCR from HI2B7 using the primer pair 
HI-23F/HI-23R. The PCR product was ligated into pSC-B-amp/kan to form pSC-B-tpnR, 
and the genomic insert was confirmed by DNA sequence analysis. The vector was digested 
with EcoRI, the insert ligated into pSET1520 to form pSET1520-tpnR, and the insert was 
confirmed by DNA sequence analysis. Following transformation into E. coli 
ET12567/pUZ8002, pSET1520-tpnR was introduced into S. laurentii by intergeneric 
conjugation.2, 7 Colonies resistant to apramycin were selected, gDNA was isolated from 
each colony, and S. laurentii HI4 (S. laurentii harboring pSET1520-tpnR) was confirmed 
by PCR analysis (Figure 3.5) using the primer pair HI-23F/HI-23R and sequencing analysis 
of the amplified product. S. laurentii HI4 was cultured and evaluated for thiostrepton 
production as described in 3.2.3. 
 
 
Figure 3.5: Confirmation of S. laurentii HI4 by PCR. The primers used were HI-23F and 
HI-23R, which anneal to tpnR. (M) 1 kb molecular weight ladder; (1) S. laurentii HI4; (2) 
S. laurentii; (3) pSET1520-tpnR. The expected 1.0 kb products were amplified from 




3.2.9 Expression of TpnLM in S. laurentii 
The genes encoding TpnLM were amplified by PCR from HI2G2 using the primer 
pair HI-20F/HI-21R. The PCR product was ligated into pSC-B-amp/kan to form 
pSC-B-tpnLM, and the genomic insert was confirmed by DNA sequence analysis. The 
vector was digested with EcoRI and NdeI, the insert ligated into pSET1520 to form 
pSET1520-tpnLM, and the insert was confirmed by DNA sequence analysis. Following 
transformation into E. coli ET12567/pUZ8002, pSET1520-tpnLM was introduced into 
S. laurentii by intergeneric conjugation.2, 7 Colonies resistant to apramycin were selected, 
gDNA was isolated from each colony, and S. laurentii HI5 (S. laurentii harboring 
pSET1520-tpnLM) was confirmed by PCR analysis (Figure 3.6) using the primer pair HI-
20F/HI-21R and sequencing analysis of the amplified product. S. laurentii HI5 was 





Figure 3.6: Confirmation of S. laurentii HI5 by PCR. The primers used were HI-20F and 
HI-21R, which anneal to the 5’-end of tpnL and the 3’-end of tpnM, respectively. (M) 1 kb 
molecular weight ladder; (1-3) S. laurentii HI5; (4-6) S. laurentii; (7) pSET1520-tpnLM. 




3.2.10 Expression of TpnMN in S. laurentii 
The genes encoding TpnMN were amplified by PCR from HI2G2 using the primer 
pair HI-21F/HI-22R. The PCR product was ligated into pSC-B-amp/kan to form 
pSC-B-tpnMN, and the genomic insert was confirmed by DNA sequence analysis. The 
vector was digested with EcoRI and NdeI, the insert ligated into pSET1520 to form 
pSET1520-tpnMN, and the insert was confirmed by DNA sequence analysis. Following 
transformation into E. coli ET12567/pUZ8002, pSET1520-tpnMN was introduced into 
S. laurentii by intergeneric conjugation.2, 7 Colonies resistant to apramycin were selected, 
gDNA was isolated from each colony, and S. laurentii HI6 (S. laurentii harboring 
pSET1520-tpnMN) was confirmed by PCR analysis (Figure 3.7) using the primer pair HI-
21F/HI-22R and sequencing analysis of the amplified product. S. lasurentii HI6 was 





Figure 3.7: Confirmation of S. laurentii HI6 by PCR. The primers used were HI-21F and 
HI-22R, which anneal to the 5’-end of tpnM and the 3’-end of tpnN, respectively. (M) 1 kb 
molecular weight ladder; (1-3) S. laurentii HI6; (4-6) S. laurentii; (7-9) pSET1520-tpnMN. 




3.2.11 Expression of TpnLMN in S. laurentii 
The genes encoding TpnLMN were amplified by PCR from HI2G2 using the 
primer pair HI-20F/HI-22R. The PCR product was ligated into pSC-B-amp/kan to form 
pSC-B-tpnLMN, and the genomic insert was confirmed by DNA sequence analysis. The 
vector was digested with EcoRI and NdeI, the insert ligated into pSET1520 to form 
pSET1520-tpnLMN, and the insert was confirmed by DNA sequence analysis. Following 
transformation into E. coli ET12567/pUZ8002, pSET1520-tpnLMN was introduced into 
S. laurentii by intergeneric conjugation.2, 7 Colonies resistant to apramycin were selected, 
gDNA was isolated from each colony, and S. laurentii HI7 (S. laurentii harboring 
pSET1520-tpnLMN) was confirmed by PCR analyses (Figure 3.8) using the primer pair 
HI-20F/HI-22R and sequencing analysis of the amplified product. S. laurentii HI7 was 





Figure 3.8: Confirmation of S. laurentii HI7 by PCR. The primers used were HI-20F and 
HI-22R, which anneal to the 5’-end of tpnL and the 3’-end of tpnN, respectively. (M) 1 kb 
molecular weight ladder; (1-3) S. laurentii HI7; (4-6) S. laurentii; (7-9) 




3.2.12 Purification and characterization of thiostrepton Aa (31) 
From 1 L of S. laurentii HI1 culture, 3 mL of crude extract was prepared and 
thiostrepton Aa 31 was purified by HPLC. A Phenomenex 5µm C18(2) Luna 
250 x 10.00 mm column was used to develop a gradient of 0% to 50% acetonitrile in water 
over 60 min at 7 mL/min. The purified metabolite was analyzed by HR-ESI-MS (observed: 
m/z 1666.5157 [M+H]+, calculated: m/z 1666.5158), ESI-MS/MS, and NMR (Figures 
B.13-B.23 and Tables B.1-B.3). 
 
3.2.13 Determination of thiostrepton Aa (31) solubility  
The solubility of thiostrepton Aa 31 was determined following a previously 
described method.5 A 100 µL mixture containing 50 µM thiostrepton A 2 or 
thiostrepton Aa 31, 50 mM Tris pH 7.5, and 10% DMSO was incubated at 25 °C for 2 hours 
with rotary shaking. Samples were prepared in triplicate. The mixtures were centrifuged at 
14,000 x g for 10 min at 4 °C. The absorbance of the supernatant was analyzed at 280 nm. 
Thiostrepton remaining in solution was quantified using the molar absorptivity of 
thiostrepton at 280 nm, 0.027 µM-1cm-1.8 
 
3.2.14 Antimicrobial activity of thiostrepton Aa (31) 
The minimum inhibitory concentrations (MICs) of thiostreptons A 2 and Aa 31 
against Bacillus sp. ATCC 27859 (Bacillus sp.), vancomycin-resistant Enterococcus 
faecium ATCC 12952 (VRE), methicillin-resistant Staphylococcus aureus ATCC 33591 
109 
 
(MRSA), and Escherichia coli ATCC 27856 (E. coli) were determined using previously 
described methods.4 Cell growth was monitored by comparing the OD600 at the time of 
treatment and after 18 hours incubation at 37 °C. A difference in OD600 was considered 
growth. DMSO was used as a control in all assays. To determine the relative inhibition of 
cell growth, the difference in OD600 was normalized against the DMSO control. MIC was 
defined as the lowest concentration at which no difference in OD600 was observed. 
 
3.2.15 In vitro coupled transcription-translation assay 
The half maximum inhibitory concentration (IC50) of thiostrepton A 2 and 
thiostrepton Aa 31 against prokaryotic ribosomal translation was determined using the 
E. coli S30 Extract System for Circular DNA and the Luciferase Assay System (Promega, 
Madison, WI) according to a previously described method with one modification.5 The 
concentration of the template DNA, pBESTluc, was reduced from 50 ng/µL to 5 ng/µL in 










3.3 Results and Discussion 
3.3.1 Heterologous expression of TpnLMNR in S. laurentii 
 TpnLMNR were heterologously expressed, either individually or coexpressed in 
combination with the others, in S. laurentii under the control of the constitutive ermE* 
promotor of the pSET1520 plasmid (Table 3.1).9-10 The strains were cultured in liquid 
media and the crude culture extracts were analyzed by HPLC and HPLC-MS for a 
piperidine-containing analog of thiostrepton A (31) ([M+2H]2+ calculated m/z 834), a 
thioamide-containing analog of thiostrepton A (32) ([M+2H]2+ calculated m/z 841), or a 
piperidine- and thioamide-containing analog (33) ([M+2H]2+ calculated m/z 842) (Table 
3.1, Figures 3.9-3.20, and B.5-B.12). Wild-type S. laurentii, S. laurentii HI0, and 
S. laurentii HI4 each produced 2 and the proposed analogs 31-33 were not detected 
(Figures 3.10-3.11, 3.14 and Figures B.4-B.5, B.9). S. laurentii HI0 is a negative control 
and alterations to thiostrepton production are not expected. S. laurentii HI4 expresses TpnR, 
a predicted α/β-hydrolase that may hydrolyze the C-terminal methyl ester of a 
thiopeptin/thiostrepton biosynthetic intermediate. Wild-type S. laurentii already expresses 
the thiostrepton methylesterase, TsrU.2 If our prediction about TpnR function is correct, it 
is not surprising that no new thiostrepton analogs were observed in S. laurentii HI4. All 
other S. laurentii strains still produced thiostrepton A 2, but strains that expressed TpnL (S. 
laurentii HI1, S. laurentii HI5, and S. laurentii HI7) also produced a new metabolite (31 
[M+2H]2+ calculated m/z 834) with a mass increased by 2 Da relative to 2 and a slightly 
earlier HPLC retention time compared to 2 (Table 3.2, Figure 3.11, 3.15, 3.17 and Figures 
B.6, B.10, and B.12). S. laurentii HI1 produced 31 at 76.97 ± 40.87 mg/L and 2 at 4.82 ± 
3.03 mg/L, nearly 9-fold less than the titer of 2 produced by the wild-type strain at 41.63 
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± 22.26 mg/L. HPLC co-injection of the crude culture extracts of S. laurentii HI1, S. 
laurentii HI5, and S. laurentii HI7 resulted in a co-elution of 31, suggesting that all three 
strains produced the same metabolite (Figures 3.18-3.20). S. laurentii HI6, which expresses 
both TpnMN but not TpnL, did not produce 31 (Figure 3.15 and B.11). The only common 
gene expressed in all three strains that produced 31 is tpnL, and therefore tpnL is likely to 
be responsible for this new metabolite. 
 The strain that coexpressed TpnM and TpnN (S. laurentii HI6) produced a 
compound with a mass matching a thioamidated thiostrepton analog 32 (Figure B.11, tR ~ 
21.84 min, observed m/z 840.9 [M+2H]+, calculated m/z 840.7), but S. laurentii HI6 did 
not produce either of the piperidine-containing analogs 31 or 33. The strain that 
coexpressed TpnLMN (S. laurentii HI7) produced a compound with a mass similar to a 
piperidine- and thioamide-containing thiostrepton analog 33 (Figure B.12, tR ~ 29.01 min, 
observed m/z 842.4 [M+2H]+, calculated m/z 841.8). The proposed thiostrepton A analogs 
detected in S. laurentii strains that expressed TpnMN and TpnLMN match predicted 
functions of the proteins. The YcaO-TfuA pair, TpnM and TpnN, is predicted to work in 
concert to thioamidate the peptidic substrate, and accordingly, a new metabolite with a 
mass matching a thioamide-containing thiostrepton analog 32 was observed in S. laurentii 
HI6, which coexpresses TpnMN (Figure B.11), but not in S. laurentii HI2, S. laurentii HI3, 
or S. laurentii HI5 which express TpnM, TpnN, or TpnLM, respectively (Figure B.7-B.8). 
In addition, TpnL appears to mediate formation of a piperidine-containing thiostrepton 
analog 31. Accordingly, a new metabolite with a mass matching a piperidine- and 
thioamide-containing thiostrepton analog 33 was observed in S. laurentii HI7 which 
coexpresses TpnLMN but not in other strains which either lacked the expression of TpnL 
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or a TpnMN pair. Compounds presumed to be 32 and 33 need to be isolated and structurally 
characterized to confirm if they contain a thioamide moiety suggested by the proposed 





































Table 3.1. S. laurentii strains evaluated in this chapter 
Strain Name Expression Vector Gene(s) 
Expressed 
New Metabolite Observed HPLC HPLC-MS 
S. laurentii     Figure B.4 
S. laurentii HI0 pSET1520   Figure 3.10 Figure B.5 
S. laurentii HI1 pSET1520-TpnL tpnL Thiostrepton Aa 31 Figure 3.11 Figure B.6 
S. laurentii HI2 pSET1520-TpnM tpnM  Figure 3.12 Figure B.7 
S. laurentii HI3 pSET1520-TpnN tpnN  Figure 3.13 Figure B.8 
S. laurentii HI4 pSET1520-TpnR tpnR  Figure 3.14 Figure B.9 
S. laurentii HI5 pSET1520-TpnLM tpnLM 31         (unconfirmed)a Figure 3.15 Figure B.10 
S. laurentii HI6 pSET1520-TpnMN tpnMN 32?       (unconfirmed)a Figure 3.16 Figure B.11 
S. laurentii HI7 pSET1520-TpnLMN tpnLMN 31, 33? (unconfirmed)a Figure 3.17 Figure B.12 
a
Compound presumed to be 31 produced by S. laurentii HI5 and S. laurentii HI7 co-elutes with 31, which was isolated from S. laurentii 





Figure 3.9: The structures of potential thiostrepton analogs (2, 31-33) that could be 
produced by S. laurentii HI0-HI7. The dehydro(piperidine) ring is in blue and the 




Table 3.2: S. laurentii strains which produced thiostrepton Aa 31 
Strain Name HPLC HPLC Retention 
Time of 31 
HPLC-MS HPLC-MS Retention 
Time of 31 
S. laurentii HI1 Figure 3.11 22.85 min Figure B.6 24.91 min 
S. laurentii HI5 Figure 3.15 27.60 min Figure B.10 25.42 min 







Figure 3.10: HPLC analyses of (a) thiostrepton A 2, (b) culture extract of S. laurentii HI0, 
and (c) co-injection of 2 and the culture extract of S. laurentii HI0. Absorbance was 






Figure 3.11: HPLC analyses of (a) thiostrepton A 2, (b) culture extract of S. laurentii HI1, 
and (d) co-injection of 2 and the culture extract of S. laurentii HI1. Absorbance was 
monitored at 254 nm. Thiostrepton A 2 is indicated by (○) and Thiostrepton Aa 31 is 





Figure 3.12: HPLC analyses of (a) thiostrepton A 2, (b) culture extract of S. laurentii, (c) 
culture extract of S. laurentii HI2, and (d) co-injection of 2 and the culture extract of 






Figure 3.13: HPLC analyses of (a) thiostrepton A 2, (b) culture extract of S. laurentii, (c) 
culture extract of S. laurentii HI3, and (d) co-injection of 2 and the culture extract of 






Figure 3.14: HPLC analyses of (a) thiostrepton A 2, (b) culture extract of S. laurentii, (c) 
culture extract of S. laurentii HI4, and (d) co-injection of 2 and the culture extract of 






Figure 3.15: HPLC analyses of (a) thiostrepton A 2, (b) culture extract of S. laurentii, (c) 
culture extract of S. laurentii HI5, (d) co-injection of 2 and the culture extract of S. laurentii 
HI5, and (e) co-injection of the culture extracts of S. laurentii and S. laurentii HI5. 
Absorbance was monitored at 254 nm. Thiostrepton A 2 is indicated by (○) and 31 is 





Figure 3.16: HPLC analyses of (a) culture extract of S. laurentii, (b) thiostrepton A 2, (c) 
culture extract of S. laurentii HI6, and (d) co-injection of 2 and the culture extract of 
S. laurentii HI6. Absorbance was monitored at 254 nm. Thiostrepton A 2 is indicated by 





Figure 3.17: HPLC analyses of (a) thiostrepton A 2, (b) culture extract of S. laurentii, (c) 
culture extract of S. laurentii HI7, (d) co-injections of 2 and the culture extract of 
S. laurentii HI7, and (e) co-injection of the culture extracts of S. laurentii and S. laurentii 
HI7. Absorbance was monitored at 254 nm. Thiostrepton A 2 is indicated by (○) and 31 is 




Figure 3.18: HPLC analyses of (a) culture extract of S. laurentii HI1, (b) culture extract 
of S. laurentii HI5, and (c) co-injection of the culture extracts of S. laurentii HI1 and 




Figure 3.19: HPLC analyses of (a) thiostrepton A 2, (b) culture extract of S. laurentii, (c) 
culture extract of S. laurentii HI1, (d) culture extract of S. laurentii HI7, (e) co-injection of 
2 and the culture extract of S. laurentii HI7, (f) co-injection of the culture extracts of 
S. laurentii and S. laurentii HI7 and (g) co-injection of the culture extracts of S. laurentii 
HI1 and S. laurentii HI7. Absorbance was monitored at 254 nm. Thiostrepton A 2 is 




Figure 3.20: HPLC analyses of (a) culture extract of S. laurentii HI5, (b) culture extract 
of S. laurentii HI7, and (c) co-injection of the culture extracts of S. laurentii HI5 and 





3.3.2 Structural characterization of thiostrepton Aa (31) 
31 was isolated from S. laurentii HI1 (Figure 3.21) and a molecular formula of 
C72H88N19O18S5 was determined by HR-ESI-MS (observed m/z 1666.5157 [M+H]
+, 
calculated m/z 1666.5158) which suggests the addition of 2 hydrogen atoms to thiostrepton 
A 2 (Figure B.13a). Additional MS/MS and NMR analyses (COSY, HSQC, HMBC, 
DEPT-135, and ROESY) were used to elucidate the structure of 31 (Figures B.13-B.23 and 
Table B.1-B.3). A 1H chemical shift at δH = 4.68-4.66 ppm (Pip-2) is obscured by other 
resonances, but its COSY correlations with two piperidine protons (Pip-3-HA δH = 2.12-
2.08 ppm and Pip-3-HB δH = 1.70-1.65 ppm) suggest a newly introduced proton on the 
nitrogenous heterocycle that is unobserved in the dehydropiperidine-containing 
thiostrepton A 2. In addition, a broad singlet at δH = 4.05 ppm (Pip-5-NH) does not show 
an HSQC correlation, but does reveal COSY correlations to the protons of the piperidine 
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ring at the 2, 3, and 6 positions (Pip-2-H δH = 4.68-4.66 ppm, Pip-3-HA δH = 2.12-2.08 ppm, 
and Pip-6-H δH = 4.76 ppm, respectively) suggesting the presence of an amine proton in 
the ring. The Pip-5 amine and Pip-3 protons likely adopt a “W” conformation within the 
ring and long-range 4JHH COSY correlation is expected due to the favorable overlap of 
molecular orbitals in this conformation.11 Taken together, the NMR analyses indicate that 
the dehydropiperidine ring of 2 was reduced by TpnL to form a piperidine ring in 31 
(Scheme 3.1). To determine the configuration of the newly introduced stereocenter at the 
Pip-2 carbon, a ROESY analysis of 31 was conducted (Figures B.22-B.23 and Tables 
B.2-B.3). 1H-1H ROESY correlations between Pip-6-H and Pip-4-HB (δH = 2.63-2.58 ppm) 
and between Pip-4-HB and Pip-2-H of 31 suggest these three atoms are all in axial positions 
of the six-membered piperidine ring (Figures B.22-B.23 and Tables B.2-B.3). Based on the 
previously determined structure of 2, we propose that the newly introduced stereocenter in 
31 presents with the same absolute configuration as is observed in the other series a 









Figure 3.21: HPLC analysis of (a) thiostrepton A 2, (b) thiostrepton Aa 31 isolated from S. 











3.3.3 Aqueous solubility and antibacterial activity of thiostrepton Aa (31) 
Despite the potent antibacterial activities of thiostrepton A 2 and other thiopeptides, 
their low aqueous solubility has dampened the development of thiopeptide antibiotics for 
clinical use.6, 14-15 We made initial investigations of the biological activities of the 
piperidine-containing analog 31 by comparing the solubility and biological activity of 31 
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with thiostrepton A 2. The aqueous solubility of 31 in 10% DMSO (26.01 ± 0.05 µM) is 
slightly improved relative to 21.88 ± 0.05 µM of 2.5 The antibacterial activities of 31 are 
comparable to 2, demonstrating minimum inhibitory concentrations of 0.018-0.098 µg/mL 
against Gram-positive strains (Table 3.3 and Figures B.24-B.26) and, as expected, 31 is 




Table 3.3: Antibiotic activities of thiostrepton A 2 and thiostrepton Aa 31. 
 
 MICa (µg/mL)  
Compound MRSAb VREc Bacillusd E. colie 
Thiostrepton A  2 0.061 0.017 0.023 >0.500 
Thiostrepton Aa 31 0.098 0.018 0.040 >0.500 
Vancomycin 0.78 NDf ND ND 
Chloramphenicol ND 3.9 0.97 3.9 
aMinimum inhibitory concentration.  
bStaphylococcus aureus ATCC 33591.  
cEnterococcus faecium ATCC 12952.  
dBacillus sp. ATCC 27859. 





Since 2, and presumably 13-16, bind to the ribosome and impair its activity, 
inhibition of prokaryotic protein synthesis by 31 was determined using an in vitro 
transcription-translation assay.5, 16 A cell-free E. coli extract containing the cellular 
components necessary for transcription and translation was coupled to a luciferase/luciferin 
reporter system. Luciferin fluorescence was measured in the presence of DMSO (negative 
control), vancomycin (negative control), 2, and 31. A relative decrease in fluorescence 
compared to the negative control suggests inhibition of ribosomal translation activity. 
Under these conditions, the half-maximal inhibitory concentration of 31 was 
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0.26 ± 0.04 µM, similar to 0.50 ± 0.04 µM for 2 and consistent with the activities of the 
two metabolites against the indicator bacterial strains (Figure B.27) The piperidine 
modification does not significantly alter the antibacterial properties of 31 under conditions 
tested, consistent with prior examination of a semisynthetic piperidine-containing 2 
analog.17 
The introduction of a piperidine ring in 31 alters the orientation of the tail (Thz15, 
Dha16, and Dha17) of the thiostrepton analog.17 The crystal structure of thiostrepton A 2 
bound to the L11 ribosomal protein subunit and 23S rRNA subunit of the 50S large 
ribosomal subunit of Deinococcus radiodurans (D. radiodurans) shows the Thz15 of 
thiostrepton A involved in electrostatic interactions with Pro26 of the ribosomal protein 
L11 subunit. In addition, the interaction of L11 and the tail region of thiostrepton appear 
to prevent conformational changes in the L11 subunit required for stable interactions of 
L11 and the L7 ribosomal subunit with EF-G.16 Docking studies of the piperidine-
containing thiostrepton analog 31 with the L11-RNA complex of D. radiodurans 
performed by Arndt and coworkers suggest that 31 may have a similar binding mode as 2 
to the L11 ribosomal subunit and the tail region of 31 may provide an additional hydrogen 
bond interaction with the protein backbone of L11.17 In addition, Arndt and coworkers 
found the KD of a piperidine-containing thiostrepton analog to the L11-RNA subunit of 
Thermus thermophilus to be nearly two-fold less than the KD of 2 to the L11-RNA 
subunit.17  
A slight increase in binding affinity of thiostrepton Aa 31 to the ribosomal subunit 
may explain its modest increase in inhibition of prokaryotic translation over 2. It is, 
however, not clear why 31 shows a slightly diminished activity against MRSA and Bacillus 
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compared to 2 while 31 retained similar activity against VRE with 2 (Table 3.3). The 
efficacy of many antibiotics not only depend on their activity against their target, but their 
ability to cross the cellular wall and membrane.18 Most hydrophobic antibiotics, like 
thiopeptides, are thought to permeate the Gram-positive bacterial cell membrane and enter 
the cytoplasm by passive diffusion.19 A slight increase in aqueous solubility may affect 
how 31 passes through the cell membrane of certain bacteria to its biological target. 
 
3.4 Conclusions 
To shed light on the roles of encoded proteins that may be associated with 
thioamide and piperdine formation in the tpn cluster, as well as to circumvent difficulties 
encountered with the genetic modification of S. tateyamensis, tpnLMNR were expressed in 
S. laurentii, a producer of thiostrepton A 2. Heterologous expression of TpnL in S. laurentii 
resulted in the production of a new metabolite thiostrepton Aa 31, a piperidine-containing 
analog of thiostrepton A 2. TpnL appears to be involved in the reduction of the 
dehydropiperidine moiety of thiostrepton A 2 to a piperidine ring. The newly introduced 
stereocenter at the piperidine carbon (Pip-2) is consistent with the configuration reported 
for the series a thiopeptins and suggests a similar enzymatic origin. The piperidine 
modification of thiostrepton Aa 31 did not significantly alter either its aqueous solubility 
or antibacterial activities against the strains evaluated. In addition, possible thioamidated 
thiostrepton analogs were detected in S. laurentii strains that coexpressed TpnMN, but not 
in strains the expressed TpnM or TpnN separately, consistent with our predictions that this 
YcaO-TfuA pair is required for thioamidation. Isolation and structural characterization of 
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 TpnL is an encoded product of the thiopeptin biosynthetic gene (tpn) cluster that 
shows homology to proteins of the flavin/deazaflavin-dependent oxidoreductase subgroup 
B (FDOR-B). The FDOR-B family is a diverse group of small proteins that bind flavin 
mononucleotide (FMN), flavin adenine dinucleotide (FAD), deazaflavin cofactor F420, or 
heme.1 The members of this family share low sequence similarity with each other (~30%) 
but all are predicted to adopt a split β-barrel fold.1-5 These proteins are found in a wide 
range of bacterial phyla and include the ubiquitous pyridoxal 5’-phosphate oxidase 
(PPNOx) involved in vitamin B6 metabolism.
1, 6 Notably, some FDOR-Bs found in 
actinobacteria are thought to bind the unusual cofactor F420 (Figure 4.1) and participate in 









 Only a handful of FDOR-Bs have been biochemically and structurally 
characterized, and many of those that have been characterized thus far are closely involved 
in mycobacterial heme catabolism and virulence. MSMEG_6519 from Mycobacterium 
smegmatis (M. smegmatis) and HugZ from Heliobacter pylori bind and oxidize heme to 
biliverdin, a linear tetrapyrrole (Figure 4.2).1, 3, 11 Both proteins adopt a split β-barrel fold 
and a strictly conserved histidine residue coordinates the propionate side chain of the heme 
molecule.1, 3 In addition to the split β-barrel fold-containing domain, a secondary domain 
is found in heme-binding members of the FDOR-B family.1, 3 The role of this secondary 
domain is unclear as the heme-oxidizing activity of HugZ appears to be contained on the 
split β-barrel fold-containing domain.1, 3 A truncated HugZ mutant lacking the secondary 
domain was catalytically active, and this mutant showed higher turnover rate than the wild-
type HugZ.3   
In addition to the heme-oxidizing enzymes, other FDOR-B proteins have been 
implicated in other aspects of heme catabolism and mycobacterial virulence. 
MSMEG_3880 from M. smegmatis, Rv2074 and Rv1155 from M. tuberculosis reduce 
biliverdin-IXα to bilirubin-IXα using cofactor F420H2 as a hydride source (Figure 4.2).
1, 12 
These three proteins adopt a split β-barrel fold, forming a cofactor F420 binding cleft at the 
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dimer interface.4-5, 13 While there are no strictly conserved motifs or residues, a highly 
conserved lysine residue coordinates the phosphate moiety of FMN, FAD, and F420 among 
certain FDOR-Bs.1 The F420 binding site contains additional basic residues that interact 
with the polyglutamate tail of the cofactor.5 These positively charged residues are unique 






Figure 4.2: The degradation of heme in mycobacteria and in Helicobacter pylori are 
mediated by proteins of the FDOR-B family. In most organisms, the first step of heme 









Homologs of these F420H2-dependent biliverdin reductases are widely distributed 
among actinobacteria and demonstrate high sequence similarity to each other, suggesting 
an important physiological role.12 Biliverdin reductases are notably overexpressed in 
M. tuberculosis and the product bilirubin is a powerful antioxidant.14 10 nM of 
bilirubin-IXα reversed cell death induced by a 10,000-fold excess concentration of H2O2 in 
HeLa cells and brain cultures.15-16 It has been shown that disruption of bilirubin production 
leads to greater levels of reactive oxygen species in M. tuberculosis in non-pathogenic 
environments and higher rates of bacterial cell death.14 Therefore, the F420H2-dependent 
reduction of biliverdin-IXα to bilirubin-IXα may play a critical role not only in the virulence 
of pathogenic mycobacteria but for the general survival of mycobacteria by reducing 
oxidative stress on the bacterium.  
The involvement of FDOR-B proteins in mycobacterial heme degradation 
pathways and the use of an unusual cofactor F420 by biliverdin reductases in M. tuberculosis 
virulence has added interest in F420-dependent pathways and the proteins that bind F420 
towards treatment of pathogenic mycobacteria. Little is known, however, about FDOR-B 
proteins in other actinomycetes, especially the proteins involved in secondary metabolism. 
One of the few characterized examples of an F420-dependent FDOR-B protein is OxyR, a 
reductase from Streptomyces rimosus that is involved in the biosynthesis of tetracycline 
(Figure 4.3).9 Characterization of proteins in the FDOR-B family, such as TpnL in the 












Heterologous expression of TpnL in the dehydropiperidine-containing series b 
thiopeptide thiostrepton A 2 producer, S. laurentii, resulted in the production of 
thiostrepton Aa 31, a piperidine-containing series a analog of 2. Therefore, TpnL is likely 
to mediate the reduction of the dehydropiperidine ring of thiostrepton A 2, and, presumably, 
the dehydropiperidine-containing intermediate of the thiopeptin biosynthetic pathway. To 
establish the role of this protein, TpnL was subjected to a series of bioinformatic and 
biochemical analyses to determine the cofactor necessary for activity, to reconstitute TpnL 
activity, and to demonstrate formation of 31 in vitro. 
 
4.2 Materials and methods 
 
4.2.1 General 
All reagents, unless otherwise specified, were purchased from standard commercial 
sources and used as provided. All primers used are listed in Table A.1 and strains and 
plasmids used are listed in Table A.2. Streptomyces laurentii ATCC 31255 (S. laurentii) 
and Streptomyces tateyamensis ATCC 21389 (S. tateyamensis) were purchased from 
American Type Culture Collection. Escherichia coli (E. coli) strains were cultured in 
Luria-Bertani medium supplemented with 100 µg/mL ampicillin, 50 µg/mL apramycin, 
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12.5 µg/mL chloramphenicol, 50 µg/mL kanamycin, or 50 µg/mL streptomycin. 
S. laurentii containing pSET1520-derived vectors were cultured in media supplemented 
with 50 µg/mL apramycin. High-performance liquid chromatography (HPLC) analyses 
were performed on a Beckman Coulter System Gold HPLC using an analytical 
Phenomenex Luna 5µm C18(2) 250 x 4.6 mm column (Torrance, CA). All mass 
spectrometry analyses were performed at the Georgia Institute of Technology Bioanalytical 
Mass Spectrometry Facility. High-performance liquid chromatography-mass spectrometry 
(HPLC-MS) analyses were performed on a Micromass Quattro LC using a Phenomenex 
Synergi 4 µm MAX-RP 80 Å C18 250 x 2.00 mm column (Torrance, CA). 
Oligonucleotides were purchased from Integrated DNA Technologies, Inc. (Coralville, IA). 
DNA sequencing analyses were performed by Eurofins MWG Operon USA (Louisville, 
KY). Cofactor F420 and F420-dependent glucose-6-phosphate dehydrogenase (FGD) were 
purified as previously described by Ghader Bashiri.17-18 
 
4.2.2   Bioinformatics analyses of TpnL, its homologs and other proteins of the   FDOR-B 
family, and cofactor F420 biosynthetic enzymes FbiABC 
 
The proteins were compared to other entries in the NCBI database using the protein 
Basic Local Alignment Search Tool (BLAST). Multiple sequence alignments and 
phylogenetic analyses were performed using Clustal Omega multiple sequence alignment 
and the EMBOSS-Needle tool on the European Bioinformatics Institute (EMBL-EBI) 
server was used for pairwise sequence alignments. The phylogenetic tree of TpnL and 
homologs was constructed with ClustalW2 - Phylogeny (Simple Phylogeny) tool on the 
EMBL-EBI server using a neighbor-joining algorithm to construct trees from the distance 
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matrix and visualized using the Interactive Tree of Life (iTOL) v4.2.3. Accession numbers 
of the protein sequences used to construct the phylogenetic tree of TpnL homologs are 
listed in Table A.3. 
 
4.2.3 Expression and purification of TpnL 
The gene encoding TpnL was amplified by PCR from fosmid HI2G2 using the 
primer pair HI-23F/HI-23R. The amplicon was digested with HindIII and NdeI, ligated into 
pET28b(+) to form pET28b-tpnL, and confirmed by DNA sequence analysis. E. coli 
BL21(DE3) containing pET28b-tpnL was incubated overnight at 37 °C and 220 rpm in 
10 mL of Luria-Bertani medium supplemented with 50 µg/mL kanamycin. 10 mL of the 
overnight culture was used to inoculate 1 L of Luria-Bertani medium supplemented with 
50 µg/mL kanamycin. The culture was incubated at 37 °C and 220 rpm until OD600 = 0.6, 
at which point the temperature was decreased to 15 °C, and TpnL expression was induced 
with the addition of 0.4 mM IPTG. Cultures were incubated for an additional 48 hours. 
Harvested cells were resuspended in 50 mL of lysis buffer (20 mM Tris pH 8.0, 500 mM 
NaCl, 2 mM imidazole, 10% glycerol, 1 mg/mL lysozyme, 10 µg/mL deoxyribonuclease, 
2 mM MgCl2). Cells were disrupted by sonication (10 rounds of 10 s pulses followed by a 
60 s pause) and the lysate clarified by centrifugation at 14,000 x g for 30 min at 4 °C. The 
cell-free extract was incubated with 1 mL of Ni-NTA (Qiagen, Germantown, MD) slurry 
for 20 min. The slurry was poured into a column, and the resin was washed with 10 mL 
wash buffer (20 mM Tris pH 8.0, 500 mM NaCl, 20 mM imidazole, 10% glycerol, 2 mM 
MgCl2). Protein was eluted with 15 mL elution buffer (20 mM Tris pH 8.0, 500 mM NaCl, 
150 mM imidazole, 10% glycerol, 2 mM MgCl2) collecting 5 mL fractions. Fractions 
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containing the protein were pooled together and dialyzed against 2 x 2 L storage buffer 
(50 mM Tris pH 8.0, 300 mM NaCl, 10% glycerol, 2 mM MgCl2, 2 mM dithiothreitol). 
TpnL was concentrated with a 10,000 Da molecular weight cut-off Amicon Ultra 
centrifugal filter. Protein concentration was determined by the method of Bradford using 
bovine serum albumin as a standard.19 Purified TpnL was flash frozen in liquid nitrogen 
and stored at -80 °C. 
 
4.2.4 Cofactor binding assays  
A 100 µL reaction mixture containing 2 µM TpnL, 100 mM NaCl, 50 mM Tris pH 
7.0 and 0-2 mM cofactor FAD, FMN, or F420 was incubated in the dark at 25 °C for 15 min. 
The samples were excited at 285 nm and the emission wavelength at 340 nm was monitored 
in a 75 µL quartz cuvette by a Shimadzu RF-530/PC spectrofluorophotometer. The 
fluorescence of each sample was collected as an average of 3 scans at high sensitivity, and 
each ligand concentration was repeated in triplicate. The fraction of protein bound to the 
cofactor was derived by 1 – F/F0, where F is the fluorescence of tryptophanTpnL in the 
presence of a particular concentration of cofactor and F0 is the fluorescence of 
tryptophanTpnL in the absence of cofactor. To calculate the KD of the ligands, the data was 
fit into a hyperbolic function using Kaleidagraph 4.0. 
 
4.2.5 In vitro reconstitution of FGD activity 
 A 100 µL reaction mixture containing 50 mM Tris pH 7.0, 300 mM NaCl, 1 mM 
β-mercaptoethanol, 1 mM EDTA, 100 nM FGD, 20 µM F420, and 1 mM glucose-
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6-phosphate (G6P) were incubated at room temperature. FGD was omitted in the negative 
control. The absorbance spectra were taken every 30 seconds over the course of 5 min. 
 
4.2.6 In vitro reconstitution of TpnL activity  
A 200 µL reaction mixture containing 10 µL DMSO, 10 µL of 500 µM thiostrepton 
A 2 in DMSO (25 µM final concentration), 10 µL of 1 M Tris pH 7.5 (50 mM final 
concentration), 144.5 µL of deionized water, 4 µL of 500 µM F420 (10 µM final 
concentration), 5 µL of 100 mM G6P (2.5 mM final concentration), and 14.5 µL of 6.2 µM 
FGD (0.45 µM final concentration), and 2 µL 100 µM TpnL (1 µM final concentration) 
was prepared. Reagents were added in the order described. Before the addition of TpnL, 
however, the 198 µL mixture was pre-incubated at 25 °C for 5 min. Reactions were initiated 
with either TpnL or 2 µL of 50 mM Tris pH 7.5 and incubated at 25 °C for 0-6 hours. 
Reactions were quenched with trifluoroacetic acid (1% final concentration), flash frozen 
with liquid nitrogen, and stored at –80 °C until ready for analysis. 100 µL of each sample 
was analyzed by HPLC using an isocratic condition of 42.5% acetonitrile in water over 
30 min at 2 mL/min. Absorbance was monitored at 254 nm. For kinetic assays, the 
concentration of TpnL was decreased to 25 nM, the concentration of thiostrepton A 2 used 
was between 0.5-10 µM, the volume of DMSO added was adjusted to maintain 10% final 
concentration, and the reactions were quenched after 5 min. In one set of the activity assays, 
the concentration of F420 was increased to 20 µM and 2 µM FGD. Samples were analyzed 
by HPLC as described above. To quantify thiostrepton A 2 and thiostrepton Aa 31 present 
in a reaction mixture by HPLC, the areas under the peaks were compared to a calibration 
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curve prepared for thiostrepton A 2, assuming 2 and 31 have comparable molar 
absorptivities at 254 nm. 
 
4.2.7 PCR amplification of a putative F0 synthase from S. tateyamensis  
A gene fragment encoding a putative F0 synthase was amplified from 
S. tateyamensis using the primer pair HI-24F/HI-24R. The 2.5 kb amplicon was ligated 
into pSC-B-amp/kan and the DNA sequence of the product was determined. 
 
 
4.3 Results and discussion 
4.3.1 TpnL cofactor determination 
 TpnL shows sequence homology to enzymes of the flavin/deazaflavin 
oxidoreductase subgroup B (FDOR-B). An amino acid alignment of TpnL with other 
characterized members of this protein family indicated that TpnL has a conserved lysine 
residue (K55) that is present in most F420-dependent FDOR-Bs (Figure 4.4).
1 In addition, 
K55 is adjacent to several basic residues, a characteristic of the cofactor binding region in 












TpnL            ------MTAEAAFVPIRAALAEAADYWVCTVRADGRPHTVPVWGVWWRDSL--VFSTVGG 52 
Rv1155          ------MARQVFDDKLLAVISGNSIGVLATIKHDGRPQLSNVQYHFDPRKLLIQVSIAEP 54 
Rv2074          --MAMVNTTTRLSDDALAFLSERHLAMLTTLRADNSPHVVAVGFTFDPKTHIARVITTGG 58 
Rv2991          MGTKQRADIVMSEAEIADFVNSSRTGTLATIGPDGQPHLTAMWYAVIDGEI--WLETKAK 58 
MSMEG_3880      MAASRGKATTRLTTDALAFLTERHLAMLTTLRSDGSPHVVAVGFTFDPKTHIARVITTGG 60 
                                   :       : *:  *. *:   :            .      
 
TpnL            SVKARNLRGNARASVHLSSAQE-----VVILDGTAAEVTDEAE-----LAEIGALFDAKY 102 
Rv1155          RAKTRNLRRDPRASILVDADDGWS---YAVAEGTAQLTPPAAAPDDDTVEALIALYRN-I 110 
Rv2074          SQKAVNADR--SGLAVLSQVDGAR---WLSLEGRAAVNSDIDAVRDA------------- 100 
Rv2991          SQKAVNLRRDPRVSFLLEDGDTYDTLRGVSFEGVAEIVEEPEALHRV------------- 105 
MSMEG_3880      SQKAVNAQE--RGVAVLSQVDGAR---WLSLEGKSTVSSDPDAVRDA------------- 102 
                  *: *          :.  :          :* :                          
 
TpnL            AGGA--AGSYDL--VTAR----------QHGMAICAVRAEVVRQWTSDDMFRSRRFSFAA 148 
Rv1155          AGEHSDWDDYRQAMVTDR----------RVL-----LTLPISHVYGLPPGMR-------- 147 
Rv2074          --ELRYAQRYRTPRPNPR----------RVV-----IEVQIERVLGSADLLDRA------ 137 
Rv2991          --GVSVWERYTGPYTDECKPMVDQMMNKRVGVRIV---ARRTRSWDH------RKLGLP- 153 
MSMEG_3880      --ELRYAQRYRTPRVNPR----------RVV-----IEVRIERVLGSSELLDRS------ 139 
                         *                  :             :                  
 
TpnL            DGSLSLAEAGLPAVAEQVA 167 
Rv1155          ------------------- 147 
Rv2074          ------------------- 137 
Rv2991          --HMSVGGSTAP------- 163 
MSMEG_3880      ------------------- 139 
                                    
 
Figure 4.4: Alignment of the amino acid sequences of TpnL and proteins of the 
flavin/deazaflavin oxidoreductase subgroup B (FDOR-B) that bind cofactor F420. Rv1155 
(WP_003898745.1),13 Rv2074 (WP_003899157.1),12 and Rv2991 (NP_217507.1)13 are 
proteins from Mycobacterium tuberculosis H37Rv. MSMEG_3800 (YP_888093.1)21 is a 
protein from Mycobacterium smegmatis MC2 155. The highly conserved lysine residue 
present in most F420-dependent proteins of the FDOR-B subgroup is highlighted in green. 
The motif around the conserved lysine residue contains positively charged residues that 





To determine if TpnL preferentially binds cofactor F420 over other flavins, a 
fluorescence binding experiment was performed. TpnL was heterologously expressed in 
E. coli with an N-terminal His6-tag. The purified protein (Figure 4.5) was colorless, 
suggesting it does not copurify with the flavins present in E. coli, a microorganism that 
does not produce F420. Tryptophan fluorescence quenching in the presence of F420 or the 
flavins was used to indicate cofactor binding to TpnL (Figure 4.6).8 The KD of F420 for 
TpnL (8.5 ± 1.4 µM) is ten times lower than those for FAD and FMN (88.3 ± 24.4 µM and 
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105.9 ± 13.2 µM, respectively). In addition, other common cofactors were analyzed for 
their binding affinities to TpnL. ATP, NADH, and NADPH did not appear to show binding 
affinity towards TpnL, and KD values for these cofactors were not calculated. Although the 
reduced form, F420H2, is most likely the native cofactor for TpnL, this protein does 














Figure 4.6: Binding of cofactors to TpnL as measured by tryptophan fluorescence. 
Cofactor binding was quantified by monitoring the quenching of tryptophan fluorescence. 
F420 binding is indicated by red closed circles (●), FAD by blue open squares (□), FMN by 
green closed triangles (▲), ATP by black x’s (X), NADH by orange open circles (○), and 
NADPH by blue plus signs (+). The excitation wavelength was 280 nm and the emission 




4.3.2 Reconstitution of TpnL activity 
To determine the appropriate substrate for TpnL, we considered the TpnL-mediated 
formation of a piperidine-containing thiostrepton Aa 31 in S. laurentii HI1 (Chapter 3). 
Piperidine formation in series a thiopeptides likely results from the reduction of the 
dehydropiperidine ring of series b thiopeptides. This dehydropiperidine reduction is 
expected to be among the latter maturation steps as the [4+2] condensation that assembles 
the dehydropiperidine-containing core macrocycle occurs after many of the post-
translational modifications on the precursor peptide.22-23 We therefore reasoned that 2, a 
dehydropiperidine-containing series b thiopeptide, may be a substrate of TpnL and the 
hydride source for a reduction may be supplied by cofactor F420 (Scheme 4.1). TpnL shows 
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affinity towards F420 (Figure 4.6) but F420H2, the reduced form of the cofactor is most likely 
the required for TpnL activity. F420H2, however, readily oxidizes in the presence of O2.
24 
To generate the reduced coenzyme F420H2 in situ, F420-dependent glucose-6-phosphate 
dehydrogenase (FGD) and glucose-6-phosphate (G6P) were included in the assay mixture 
with TpnL and 2 (Scheme 4.1).8 The presence of F420 can be determined by its diagnostic 
absorbance at 420 nm and the formation of F420H2 can be observed by an increase in 
absorbance at 320 nm.24-25 Initial studies reconstituting FGD activity show a decrease in 
absorbance at 420 nm and an increase in absorbance at 320 nm, which corresponds to a 





Scheme 4.1: Dehydropiperidine reduction catalyzed by TpnL and the coupled reaction that 







Figure 4.7: UV-visible absorbance spectra of the FGD-catalyzed reduction of 20 μM F420 
to F420H2 by 100 nM FGD over the course of 5 min after the addition of FGD to the reaction 
mixture. The negative control reaction (-FGD) omitted FGD and the absorbance was 
measured after 5 min incubation. The absorbance at 420 nm (indicated by a down arrow) 
is diagnostic for the presence of F420. The absorbance at 320 nm (indicated by an up arrow) 






To confirm that TpnL reduces the thiostrepton dehydropiperidine, we reconstituted 
its activity in vitro. In the absence of either F420 or FGD, conversion of thiostrepton A 2 to 
thiostrepton Aa 31 was not observed (Figure 4.8, a-b). Similarly, in a reaction with both 
F420 and FGD, but lacking TpnL, 31 was not observed (Figure 4.9, e). The conversion of 2 
to 31 was observed only when 2 was incubated with TpnL, F420, and FGD (Figure 4.9, f, tR 
~ 23.4 min, and Figure B.28). An HPLC co-injection of the reconstituted reaction after 
1-hour (Figure 4.9, f-iii) and 31 shows that 31 and the product formed in the TpnL activity 
assay co-elute (Figure 4.9, h) but a co-injection of the reconstituted 1-hour reaction with 2 
shows that the two do not coelute (Figure 4.9, g). The results from this assay demonstrate 
that TpnL catalyzes the reduction of the dehydropiperidine ring of 2 to the piperidine ring 
in 31. Both F420 and FGD are required for TpnL activity, indicating the need for F420H2 as 
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a hydride source for the reduction. While TpnL does utilize F420H2 as a cofactor to reduce 
thiostrepton A, we wondered if another common biological hydride donor such as NADH 
and NADPH could substitute for F420H2 in S. laurentii. TpnL activity was not observed in 
the presence of 600 μM NADH and 600 μM NADPH (Figure 4.10) consistent with the low 
binding affinity observed between the nicotinamide cofactors and TpnL (Figure 4.6). 
Further biochemical and structural studies will be required to determine if TpnL can utilize 
other cofactors such as FMNH2/FADH2, and if TpnL can accept other dehydropiperidine-
containing compounds as substrates.  
 
 
Figure 4.8: HPLC analyses of TpnL activity in (a) the absence of FGD and (b) the absence 
of F420. Reactions incubated for (i) 0 min, (ii) 10 min, and (iii) 60 min. The standards of 
the reaction mixture are shown in (c) G6P, (d) F420, (e) thiostrepton A 2, and (f) thiostrepton 






Figure 4.9: HPLC analyses of TpnL activity. The standards of the reaction components 
are shown in (a) G6P, (b) F420, (c) thiostrepton A 2, and (d) thiostrepton Aa 31. Reactions 
(e) omitting TpnL and (f) containing TpnL incubated for (i) 0 min, (ii) 10 min, (iii) 60 min, 
(iv) 6 hours, and (v) 24 hours. (g) A co-injection of 2 and a 1-hour reaction with TpnL, and 
(h) a co-injection of 31 and a 1-hour reaction with TpnL. Absorbance was monitored at 









Figure 4.10: HPLC analyses of TpnL activity in the presence of nicotinamide cofactors. 
(a) Thiostrepton A 2. (b) Thiostrepton Aa 31. (c) A co-injection of 2 and 31. (d) Reaction 
without TpnL or cofactor. (e) Reaction with 600 μM NADH. (f) A co-injection of the 
reaction with 600 μM NADH and 2. (g) A co-injection of the reaction with 600 μM NADH 
and 31. (h) Reaction without TpnL or cofactor. (i) Reaction with 600 μM NADPH. (j) A 
co-injection of the reaction with 600 μM NADPH and 2. (k) A co-injection of the reaction 
with 600 μM NADPH and 31. The reaction was incubated for 60 min. The absorbance at 











4.3.3 Kinetic assays of TpnL 
To quantify 2 and 31 in the reaction, a calibration curve was prepared to compare 
the area under the HPLC peaks to the mass of 2 applied to the column (Figure 4.11). The 
calibration curve was applied to 31, as well, assuming that the two compounds would share 









To determine the kinetic parameters of TpnL, substrate concentration was varied 
between 0 and 20 μM thiostrepton A 2, below the upper limit of solubility of 2 (21.88 ± 
0.05 µM) under reaction conditions (50 mM Tris pH 7.5 and 10% DMSO). TpnL activity 
appears to be subject to substrate inhibition at concentrations greater than 2 µM 2 (Figure 
4.12). To examine if the in situ generation of F420H2 could be limiting TpnL activity, F420 
reduction by FGD was monitored during the time course of the TpnL assay, and was found 
to be unaffected by TpnL and 2 (Figure 4.13). An additional assessment of TpnL activity 
































using increased concentrations of F420 and FGD (from 10 μM F420 and 0.45 μM FGD to 
20 μM F420 and 2 μM FGD) did not demonstrate a significant alteration of TpnL activity 
(Figure 4.12). The assay conditions examined here prevented a determination of KM, but 
an apparent kcat/KM (2.80 x 10
4 M-1s-1) was derived from the linear region of substrate 





Figure 4.12: Dehydropiperidine reductase activity of TpnL with varying amounts of F420 
and FGD. TpnL activity in the presence of 10 μM F420 and 0.45 μM FGD is shown by blue 
circles (●). Also included are two activity assays of TpnL in the presence of 20 μM F420 
and 2 μM FGD, shown by orange triangles (▲) at two substrate concentrations, 2 and 
10 μM thiostrepton A. The rate of moles thiostrepton Aa 31 produced per mole TpnL per 





Figure 4.13: The reduction of F420 by F420-dependent glucose-6-phosphate dehydrogenase 
(FGD) during the TpnL kinetic assay. (a) The reaction mixture containing 10 μM F420 and 
0.45 μM FGD, the concentrations used for the kinetic analysis of TpnL. During the course 
of the TpnL reaction, at least 89% of the cofactor was in the reduced form, F420H2. (b) The 
reaction mixture containing 20 μM F420 and 2 μM FGD. During the course of the TpnL 
reaction, at least 90% of the cofactor was in the reduced form, F420H2. The reduction of 
F420 to F420H2 was monitored by the loss of absorbance at 420 nm.
28 Each condition was 
repeated in triplicate. The absorbance at 420 nm prior to the addition of FGD is shown at t 
= 0 min, FGD is added at t = 0.2 min (indicated by the vertical grey dashed line), TpnL is 
added at t = 6 min, and the TpnL kinetic assay is quenched at 11 min. The reduction of F420 
in the absence of thiostrepton A 2 is shown with black squares (■), F420 reduction in the 
presence of 2 μM thiostrepton A 2 is shown with red triangles (▲), and F420 reduction in 




 The non-Michaelis-Menten behavior of TpnL activity may be a result of substrate 
inhibition or caused by non-ideal assay conditions. Temperature and pH may need 
optimization for future kinetic studies as it can affect the interactions of TpnL with its 
substrates, 2 and F420H2. The aqueous solubility of thiostrepton A is approximately 20 μM 
in 10% DMSO and 8 μM in 5% DMSO.29 While the physiological concentration range of 
thiostrepton A 2 in S. laurentii or the corresponding substrate in S. tateyamensis is not 
known, its biological activities are in the sub-micromolar range.26, 30 TpnL activity, 
however, appears to increase linearly with substrate concentration up to 2 μM, and, at 
concentrations above 2 μM, TpnL activity appears strongly and sharply inhibited by its 
t = 6 min 
+ TpnL 
t = 11 min 
reaction 
quenched 
t = 6 min 
+ TpnL 





substrate. Under conditions tested, TpnL activity reaches its maximum (5.1 s-1) at 2 μM 
thiostrepton A 2 and decreases nearly 5-fold (1.1 s-1) by 20 μM thiostrepton A 2. Further 
examination of TpnL activity is needed to fully explain its kinetic behavior. 
 
4.3.4 F420 biosynthesis in S. tateyamensis and S. laurentii 
  
TpnL is an F420-dependent dehydropiperidine reductase involved in thiopeptin 
biosynthesis and it is expected that the deazaflavin cofactor is produced by the thiostrepton 
Aa 31 producer, S. laurentii HI1 and the thiopeptin (13-16) producer, S. tateyamensis. 
FbiABC are required for F420 biosynthesis and all three homologs were found in the 
S. laurentii genome (Figures 4.14-4.16). Two fragments of a protein that share homology 
to an F0 synthase, FbiC was found in the draft genome assembly of S. tateyamensis. Primers 
were designed from the two FbiC-like fragments and a single 2.5 kb product was amplified 
from S. tateyamensis (Figure 4.17). This candidate FbiC from S. tateyamensis shows 
63.1% identity and 75.8% similarity to the FbiC from Mycobacterium bovis and 76.2% 
identity and 84.2% similary to the candidate FbiC from S. laurentii (Figure 4.16). The 
aqueous cell extracts and the organic extracts of the cell cultures of S. laurentii, S. laurentii 
HI1, and S. tateyamensis were analyzed by LC-MS for positively and negatively charged 
ions of cofactor F420 with various glutamate tail lengths but F420 could not be identified 
(data not shown). Nonetheless, the presence of FbiABC in S. laurentii and FbiC in S. 




S.laur_FbiA       MRIVVLAGGIGGARFLRGLKKA-------------APDAEITVVGNTGDDIHLFGLKVCP 47 
M.tuber_FbiA      VKVTVLAGGVGGARFLLGVQQLLGLGQFAANSAHSDADHQLSAVVNVGDDAWIHGLRVCP 60 
M.bovis_FbiA      MKVTVLAGGVGGARFLLGVQQLLGLGQFAANSAHSDADHQLSAVVNVGDDAWIHGLRVCP 60 
                  :::.*****:****** *:::                * :::.* *.***  :.**:*** 
 
S.laur_FbiA       DLDTVMYTLGGGIDEEQGWGREGESFTVKEELAAYGVGPEWFGLGDRDFATHIVRTQMLG 107 
M.tuber_FbiA      DLDTCMYTLGGGVDPQRGWGQRDETWHAMQELVRYGVQPDWFELGDRDLATHLVRTQMLQ 120 
M.bovis_FbiA      DLDTCMYTLGGGVDPQRGWGQRDETWHAMQELVRYGVQPDWFELGDRDLATHLVRTQMLQ 120 
                  **** *******:* ::***:..*:: . :**. *** *:** *****:***:******  
 
S.laur_FbiA       AGYPLSAVTEALCARWRPGVRLLPMSDDRVETHVAIE--VDGEQRAVHFQEYWVKMRASV 165 
M.tuber_FbiA      AGYPLSQITEALCDRWQPGARLLPATDDRCETHVVITDPVDESRKAIHFQEWWVRYRAQV 180 
M.bovis_FbiA      AGYPLSQITEALCDRWQPGARLLPATDDRCETHVVITDPVDESRKAIHFQEWWVRYRAQV 180 
                  ****** :***** **:**.**** :*** ****.*   ** .::*:****:**: **.* 
 
S.laur_FbiA       PARAVVPVGAEQATPAPGVLEAIADADVILFPPSNPVVSIGTILAVPGIREAVAAASAPV 225 
M.tuber_FbiA      PTHSFAFVGAEKSSAATEAIAALADADIIMLAPSNPVVSIGAILAVPGIRAALREATAPI 240 
M.bovis_FbiA      PTHSFAFVGAEKSSAATEAIAALADADIIMLAPSNPVVSIGAILAVPGIRAALREATAPI 240 
                  *:::.. ****::: *  .: *:****:*:: *********:******** *:  *:**: 
 
S.laur_FbiA       VGLSPIVGDAPVRGMADKVLAAVGVESTAAAVARHYGS----GLVDGWLVDTVDAGAVAD 281 
M.tuber_FbiA      VGYSPIIGEKPLRGMADTCLSVIGVDSTAAAVGRHYGARCATGILDCWLVHDGDH----- 295 
M.bovis_FbiA      VGYSPIIGEKPLRGMADTCLSVIGVDSTAAAVGRHYGARCATGILDCWLVHDGDH----- 295 
                  ** ***:*: *:*****. *:.:**:******.****:    *::* ***.  *       
 
S.laur_FbiA       VEAAGIRCRAVPLMMTDVDATAAMAREALALAAEAGKTAEPKETKGTGE 330 
M.tuber_FbiA      AEIDGVTVRSVPLLMTDPNATAEMVRAGCDLAGVVA------------- 331 
M.bovis_FbiA      AEIDGVTVRSVPLLMTDPNATAEMVRAGCDLAGVVA------------- 331 
                  .*  *:  *:***:*** :*** *.* .  **. ..              
 
Figure 4.14: Alignment of FbiA (2-phospho-L-lactate transferase) amino acid sequences. 
M.bovis_FbiA: FbiA from Mycobacterium bovis BCG (Q7TWV4.1);31 M.tuber_FbiA: a 
candidate FbiA from Mycobacterium tuberculosis H37Rv (WP_003417087.1);31 and 
S.laur_FbiA: candidate FbiA from S. laurentii (BAU83677.1);32 S.laur_FbiA shows 41.8% 


















S.laur_FbiB        --MTPKGPTARFEVWALDGIPEVAPGDDLAKLIADASPGLADGDVLLVTSKIVSKAEGRV 58 
M.tuber_FbiB       LTGPEHGSASTIEILPVIGLPEFRPGDDLSAAVAAAAPWLRDGDVVVVTSKVVSKCEGRL 60 
M.bovis_FbiB       MTGPEHGSASTIEILPVIGLPEFRPGDDLSAAVAAAAPWLRDGDVVVVTSKVVSKCEGRL 60 
                        :* :: :*:  : *:**. *****:  :* *:* * ****::****:***.***: 
 
S.laur_FbiB        LAATDR--------EAAIDAETVRVVARRGPLRIVETRQGLVMAAAGVDASNTPSGTVLL 110 
M.tuber_FbiB       VPAPEDPEQRDRLRRKLIEDEAVRVLARKDRTLITENRLGLVQAAAGVDGSNVGRSELAL 120 
M.bovis_FbiB       VPAPEDPEQRDRLRRKLIEDEAVRVLARKDRTLITENRLGLVQAAAGVDGSNVGRSELAL 120 
                   : * :         .  *: *:***:**:.   *.*.* *** ******.**.  . : * 
 
S.laur_FbiB        LPEDPDASARRIRDGLRETLNVDVGVLVTDTFGRPWRNGLTDVAIGAAGVRVLDDLRGGT 170 
M.tuber_FbiB       LPVDPDASAATLRAGLRERLGVTVAVVITDTMGRAWRNGQTDAAVGAAGLAVLRNYAGVR 180 
M.bovis_FbiB       LPVDPDASAATLRAGLRERLGVTVAVVITDTMGRAWRNGQTDAAVGAAGLAVLRNYAGVR 180 
                   ** ******  :* **** *.* *.*::***:** **** **.*:****: ** :  *   
 
S.laur_FbiB        DAHGNGLNATITATADELAGAGDLVKGKIDGRPVAVVRGLSHLVKPEPEPESGDAPVAEA 230 
M.tuber_FbiB       DPYGNELVVTEVAVADEIAAAADLVKGKLTATPVAVVRGFGVSD---------------- 224 
M.bovis_FbiB       DPYGNELVVTEVAVADEIAAAADLVKGKLTATPVAVVRGFGVSD---------------- 224 
                   * :** * .* .*.***:*.*.******: . *******:.                    
 
S.laur_FbiB        EGAAEAEGARALVRVAADDMFRLGTSEAVR----EAVTLRRTVRDFTDEPVDPGSVRRAV 286 
M.tuber_FbiB       ----DGSTARQLLRPGANDLFWLGTAEALELGRQQAQLLRRSVRRFSTDPVPGDLVEAAV 280 
M.bovis_FbiB       ----DGSTARQLLRPGANDLFWLGTAEALELGRQQAQLLRRSVRRFSTDPVPGDLVEAAV 280 
                       :.. ** *:* .*:*:* ***:**:.    :*  ***:** *: :**  . *. ** 
 
S.laur_FbiB        AAAVTAPAPHHTTPWRFVLLESEASRTRLLDAMRDAWIADLRADGKTEESVAKRVKRGDV 346 
M.tuber_FbiB       AEALTAPAPHHTRPTRFVWLQTPAIRARLLDRMKDKWRSDLTSDGLPADAIERRVARGQI 340 
M.bovis_FbiB       AEALTAPAPHHTRPTRFVWLQTPAIRARLLDRMKDKWRSDLTSDGLPADAIERRVARGQI 340 
                   * *:******** * *** *:: * *:**** *:* * :** :**   ::: :** **:: 
 
S.laur_FbiB        LRRAPYLIVPCLVMDGAHHYGDARRDAAEREMFVVAAGAGVQNLLVALAAEQLGSAWVSS 406 
M.tuber_FbiB       LYDAPEVVIPMLVPDGAHSYPDAARTDAEHTMFTVAVGAAVQALLVALAVRGLGSCWIGS 400 
M.bovis_FbiB       LYDAPEVVIPMLVPDGAHSYPDAARTDAEHTMFTVAVGAAVQALLVALAVRGLGSCWIGS 400 
                   *  ** :::* ** **** * ** *  **: **.**.**.** ******.. ***.*:.* 
 
S.laur_FbiB        TMFCRDVVRGVLGLPGDWDPMGAVAVGRPAAAPKERPARQAAEFIEVR 454 
M.tuber_FbiB       TIFAADLVRDELDLPVDWEPLGAIAIGYADEPSGLRDPVPAADLLILK 448 
M.bovis_FbiB       TIFAADLVRDELDLPVDWEPLGAIAIGYADEPSGLRDPVPAADLLILK 448 
                   *:*. *:**. *.** **:*:**:*:*        *    **::: :: 
 
Figure 4.15: Alignment of FbiB (coenzyme F420:L-glutamate ligase) amino acid sequences. 
M.bovis_FbiB: FbiB from Mycobacterium bovis BCG (Q7TWV3.1);31 M.tuber_FbiB: 
FbiB from Mycobacterium tuberculosis H37Rv (P9WP79.1);33 S.laur_FbiB: a candidate 
FbiB  from S. laurentii (BAU83678.1).32 S.laur_FbiB shows 51.9% identity and 67.0% 
















F0_synthase_contig1562      ----------MDHMPSTP--PTESSMRRALRRARDGVAVDRTEAAVLLQARGEDLAQLCA 48 
F0_synthase_contig2630      ------------------------------------------------------------ 0 
S.tat_FbiC                  -------------MPSTP--PTESSMRRALRRARDGVAVDRTEAAVLLQARGEDLAQLCA 45 
S.laur_FbiC                 ---MTDHQASHAPSGSSR--PTGNAMRRALRRARDGVALDAGEAAVLLRARGEDLADLVA 55 
M.bovis_FbiC                VPQPVGRKSTALPSPVVPPQANASALRRVLRRARDGVTLNVDEAAIAMTARGDELADLCA 60 
                                                      ** ********     ***    ***  ** * *                                   
 
F0_synthase_contig1562      VAARLRDQGLAAAGRPG-----VITYSKKVFVPLTRLCRDRCHYCTFATVPGKLRRDGHG 103 
F0_synthase_contig2630      ------------------------------------------------------------ 0 
S.tat_FbiC                  VAARLRDQGLAAAGRPG-----VITYSKKVFVPLTRLCRDRCHYCTFATVPGKLRRDGHG 100 
S.laur_FbiC                 TAGRVRDAGLAEAGRAG-----IVTYSKSVFIPLTRLCRDVCHYCTFATVPGKLRRAGHG 110 
M.bovis_FbiC                SAARVRDAGLVSAGRHGPSGRLAISYSRKVFIPVTRLCRDNCHYCTFVTVPGKLRAQGSS 120 
                             * * ** **  *** *        **  ** * ****** ****** *******                                                                 
 
F0_synthase_contig1562      LYLSPDEVLEIARQGAALGCKEALFTLGDRPEDRWPEAREWLDAHGYDDTLAYLRAMAVR 163 
F0_synthase_contig2630      ------------------------------------------------------------ 0 
S.tat_FbiC                  LYLSPDEVLEIARQGAALGCKEALFTLGDRPEDRWPEAREWLDAHGYDDTLAYLRAMAVR 160 
S.laur_FbiC                 AFMSPDEVLDVARKGAALGCKEALITLGDKPEDRWPEAREWLDAHGYDDTIAYVRAMAIR 170 
M.bovis_FbiC                TYMEPDEILDVARRGAEFGCKEALFTLGDRPEARWRQAREWLGERGYDSTLSYVRAMAIR 180 
                                *** *  ** **  ****** **** ** **  *****   *** *  * **** *                                                             
 
F0_synthase_contig1562      VLEETGLLPHLNPGVLGWTDLQRLKPVAPSMGMMLETTATRLWSEPGGPHHGSPDKEPAV 223 
F0_synthase_contig2630      ------------------------------------------------------------ 0 
S.tat_FbiC                  VLEETGLLPHLNPGVLGWTDLQRLKPVAPSMGMMLETTATRLWSEPGGPHHGSPDKEPAV 220 
S.laur_FbiC                 ILEETGLLPHLNPGVLSWTDFQRLKPVAPSMGMMLETTSRRLWEEPGQPHYGSPDKEPAV 230 
M.bovis_FbiC                VLEQTGLLPHLNPGVMSWSEMSRLKPVAPSMGMMLETTSRRLFETKGLAHYGSPDKDPAV 240 
                             ** ***********  *    ****************  **    *  * ***** ***                                                             
 
F0_synthase_contig1562      RLRVLEDAGRSAVPFTTGVLIGIGEDYAERADAFFAIRSVARRYQGVQEVIVQNFRAKPD 283 
F0_synthase_contig2630      ------------------------------------------------------------ 0 
S.tat_FbiC                  RLRVLEDAGRSAVPFTTGVLIGIGEDYAERADAFFAIRSVARRYQGVQEVIVQNFRAKPD 280 
S.laur_FbiC                 RLRVLEDAGRSSVPFTSGLLIGIGETYEERADSLFALRRIARAYHGIQELIIQNFRAKPD 290 
M.bovis_FbiC                RLRVLTDAGRLSIPFTTGLLVGIGETLSERADTLHAIRKSHKEFGHIQEVIVQNFRAKEH 300 
                            ***** ****   *** * * ****   ****   * *         ** * ******                                                              
 
F0_synthase_contig1562      TAMRAMPDAELEELAAAIAVARVVLGPGARIQAPPNLVDA-EYRLIIGAGIDDWGGVSPL 342 
F0_synthase_contig2630      ------------------------------------------------------------ 0 
S.tat_FbiC                  TAMRAMPDAELEELAAAIAVARVVLGPGARIQAPPNLVDA-EYRLIIGAGIDDWGGVSPL 339 
S.laur_FbiC                 TAMRAMPDAEIDDLVATVAVARLIMGPSACLQAPPNLVDS-AYERLIAAGIDDWGGVSPL 349 
M.bovis_FbiC                TAMAAFPDAGIEDYLATVAVARLVLGPGMRIQAPPNLVSGDECRALVGAGVDDWGGVSPL 360 
                            *** * ***      *  ****   **    *******          ** *********                                                             
 
F0_synthase_contig1562      TPDHVNPERPWPQIEELARRTAAEGFELRERLTVYPEYLQRGE----------------- 385 
F0_synthase_contig2630      ------------------------------------------------------------ 0 
S.tat_FbiC                  TPDHVNPERPWPQIEELARRTAAEGFELRERLTVYPEYLQRGEPWLDPRVRPHVEALADP 399 
S.laur_FbiC                 TVDHVNPERPWPALEELARRSEAAGFELRERLCVYPEFVRRGEPWLDPRVMPHVRALADP 409 
M.bovis_FbiC                TPDHVNPERPWPALDELAAVTAEAGYDMVQRLTAQPKYVQAGAAWIDPRVRGHVVALADP 420 
                            * **********   * *      *     **   *     *  * ****  ** *****                                                             
 
F0_synthase_contig1562      ------------------------------------------------------------ 385 
F0_synthase_contig2630      ------------------------------------------------------------ 0 
S.tat_FbiC                  VTGLAAAGALPAGRPWQEPEQL--PAATGRTDLHRTIDTEGRTGDRRGDFEEVYGDWTAL 457 
S.laur_FbiC                 ATGLADPDAVVRGLPWQEPDESFTELASGRTDLHRTIDTEGRTADRREDFDHVYGDWDAL 469 
M.bovis_FbiC                ATGLAR-DVNPVGMPWQEPDDV---ASWGRVDLGAAIDTQGRNTAVRSDLASAFGDWESI 476 
                             ****       * *****         ** **   *** **      *     ***                                                            
 
 
Figure 4.16: Alignment of amino acid sequences of FbiC (F0 synthase) from 
Mycobacterium species with candidate F0 synthases from S. tateyamensis and S. laurentii. 
M.bovis_FbiC: FbiC from Mycobacterium bovis BCG (WP_003406167);34 S.laur_FbiC: a 
FbiC from S. laurentii (BAU84049.1);
32 two potential fragments of a protein, 
F0_synthase_contig1562 and F0_synthase_contig2630, encoded in the S. tateyamensis 
draft genome that is/are a candidate FbiC; and S.tat_FbiC: a PCR product that was 
amplified from S. tateyamensis using sequences from F0_synthase_contig1562 and 
F0_synthase_contig2630. S.tat_FbiC shows 63.1% identity and 75.8% similarity to 
M.bovis_FbiC, and 76.2% identity and 84.2% similary to S.laur_FbiC. S.laur_FbiC shows 






F0_synthase_contig1562      ------------------------------------------------------------ 385 
F0_synthase_contig2630      ----------------------RAALAVAADDPTRLTDDQALALFAAEGEALDALCAVAD 38 
S.tat_FbiC                  REQVA------AIPPARLPGDVRAALAVAADDPTRLTDDQALALFAAEGEALDALCAVAD 511 
S.laur_FbiC                 REAAAPGLVPDVLAPERIDADTREALAVAADDPTRLTDAQALTLLHADGPALDALCRVAD 529 
M.bovis_FbiC                REQVHELA---VRAPERIDTDVLAALRSAERAPAGCTDGEYLALATADGPALEAVAALAD 533 
                            **            * *   *   **  *   *   **   * *  * * ** *    **             
 
F0_synthase_contig1562      ------------------------------------------------------------ 385 
F0_synthase_contig2630      AVRRDAVGETVTYCVTRNINFTNVCYTGCRFCAFAQRRTDADAYTLSLDQVADRAEQAWQ 98 
S.tat_FbiC                  AVRRDAVGETVTYCVTRNINFTNVCYTGCRFCAFAQRRTDADAYTLSLDQVADRAEQAWQ 571 
S.laur_FbiC                 DVRKSVVGDEVTYLVTRNINFTNVCYTGCRFCAFAQRRTDADAYTLSLEQVADRAAQAWD 589 
M.bovis_FbiC                SLRRDVVGDEVTFVVNRNINFTNICYTGCRFCAFAQRKGDADAYSLSVGEVADRAWEAHV 593 
                              *   **  **  * ******* *************  ***** **   *****                                                             
 
F0_synthase_contig1562      ------------------------------------------------------------ 385 
F0_synthase_contig2630      VGATEVCMQGGIHPDLPGTAYFDIARAVKERVPGMHVHAFSPMEVVNGAARTGLSIRDWL 158 
S.tat_FbiC                  VGATEVCMQGGIHPDLPGTAYFDIARAVKERVPGMHVHAFSPMEVVNGAARTGLSIRDWL 631 
S.laur_FbiC                 VGAVEVCMQGGIHPDLPGTAYFDIARAVKERVPGIHVHAFSPMEVVNGASRTGLSIREWL 649 
M.bovis_FbiC                AGATEVCMQGGIDPELPVTGYADLVRAVKARVPSMHVHAFSPMEIANGVTKSGLSIREWL 653 
                             ** ******** * ** * * *  **** ***  *********  **    ***** **                                                            
 
F0_synthase_contig1562      ------------------------------------------------------------ 385 
F0_synthase_contig2630      TAAQQAGLDTIPGTAAEILDDEVRWVLTKGKLPAATWVEVVSTAHELGIRSSATMMYGHV 218 
S.tat_FbiC                  TAAQQAGLDTIPGTAAEILDDEVRWVLTKGKLPAATWVEVVSTAHELGIRSSATMMYGHV 691 
S.laur_FbiC                 TAAKEAGLDSIPGTAAEILDDEVRWVLTKGKLPTATWTEVVTTAHELGIRSSSTMMYGHV 709 
M.bovis_FbiC                IGLREAGLDTIPGTAAEILDDEVRWVLTKGKLPTSLWIEIVTTAHEVGLRSSSTMMYGHV 713 
                                 **** ***********************   * * * **** * *** *******                                                             
 
F0_synthase_contig1562      ------------------------------------------------------------ 385 
F0_synthase_contig2630      DTPAHWLGHLRLLAGIQQRTGGFTEFVTLPFIHTNAPVYLAGIARPGPTHRDNRAVVAMA 278 
S.tat_FbiC                  DTPAHWLGHLRLLAGIQQRTGGFTEFVTLPFIHTNAPVYLAGIARPGPTHRDNRAVVAMA 751 
S.laur_FbiC                 DQPRHWLGHLRTLARIQQRTGGFTEFVTLPFVHTNAPVYLAGIARPGPTIRDNRAVTAMA 769 
M.bovis_FbiC                DSPRHWVAHLNVLRDIQDRTGGFTEFVPLPFVHQNSPLYLAGAARPGPSHRDNRAVHALA 773 
                            * * **  **  *  ** ********* *** * * * **** *****  ****** * *                                                             
 
F0_synthase_contig1562      ------------------------------------------------------------ 385 
F0_synthase_contig2630      RLLLHPHIPNIQTSWVKLGAAGAAEMLRSGANDLGGTLMEETISRMAGSAYGSYKSVRDL 338 
S.tat_FbiC                  RLLLHPHIPNIQTSWVKLGAAGAAEMLRSGANDLGGTLMEETISRMAGSAYGSYKSVRDL 811 
S.laur_FbiC                 RLLLHPYIPNIQTSWVKLGTEGAAEMLRSGANDLGGTLMEETISRMAGSSYGSYRSIRDL 829 
M.bovis_FbiC                RIMLHGRISHIQTSWVKLGVRRTQVMLEGGANDLGGTLMEETISRMAGSEHGSAKTVAEL 833 
                            *  **  *  *********      **  * ******************  **      *                                                             
 
F0_synthase_contig1562      ------------------------------------------------- 385 
F0_synthase_contig2630      EAIAAAAGRPARQRTTTYGEVPPE------------------------- 362 
S.tat_FbiC                  EAIAAAAGRPARQRTTTYGEVPPE------------------------- 835 
S.laur_FbiC                 AAIAEAAGRPSRLRTTLYGEVPEERQRAARDSDGHLPELLPLLPAEDGA 878 
M.bovis_FbiC                VAIAEGIGRPARQRTTTYALLAA-------------------------- 856 
                             ***   *** * *** *                                                     
 





Figure 4.17: PCR amplification of a candidate F0 synthase in S. tateyamensis. Primer pair 
HI24F/HI24R were used. (M) 1 kb molecular weight ladder and (1) S. tateyamensis. 
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4.3.5   Identification of potential thiopeptide biosynthetic gene clusters colocalized with 
TpnL 
 
 An in silico search for TpnL homologs in the NCBI database revealed potential 
thiopeptide biosynthetic gene clusters colocalized with a putative F420H2-dependent 
reductase (Figure 4.18). Two of these clusters appear to be capable of producing close 
structural homologs to 13-16, identified in Amycolatopsis saalfeldensis DSM 44993 
(A. saalfeldensis) and Micromonospora carbonacea DSM 43168 (DSM 43168). The TpnL 
homolog identified in A. saalfeldensis (SEO90151.1) shares 70% sequence identity (78% 
similarity) to TpnL. The associated gene cluster is identical in composition and 
organization to the tpn cluster, including homologs of tpnMN that are proposed to be 
involved in thioamidation of the peptide backbone (Figure 4.18 and Table 4.1). The core 
peptide sequence encoded in the A. saalfeldensis cluster (ASSSSCTTCICTCSCSS; 
SEO89922.1) is very similar to the sequence in TpnA and the thiostrepton precursor 
peptide TsrA.35 The putative thiopeptide biosynthetic gene cluster in DSM 43168 differs 
in organization from the tpn and S. saalfeldensis clusters, but does contain a full set of 
tpn/tsr-like genes (Figure 4.18 and Table 4.2), and also encodes homologs of TpnLMN, 
with the TpnL-like protein (SCF235261.1) bearing 52% identity (64% similarity) to TpnL. 
The core peptide sequence in DSM 43168 (SCF23644.1) differs from the thiopeptin 
sequence only at the first residue, is identical to the thiostrepton amino acid sequence, and 
is identical to that predicted for Sch 18640 1 (IASASCTTCICTCSCSS). Thus far, 1 has 
only been isolated from Micromonospora arborensis, and it is likely that DSM 43168 is 
another producer of this metabolite.36 The gene clusters identified in A. saalfeldensis and 
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DSM 43168 may therefore be involved in the generation of thioamidated series a and b 
thiopeptides, similar to the complex of 13-16 produced by S. tateyamensis. 
 In fact, work by Mitchell and coworkers was released at the time of this writing 
demonstrating that A. saalfeldensis produces saalfelduracin (34, Figure 4.19), a 
thioamidated series a thiopeptide.37 Unlike the thiopeptins which were isolated as a 
complex containing both dehydropiperidine and piperidine rings, only a piperidine-
containing 34 was isolated.26, 37-38 Mitchell and coworkers utilized a bioinformatic 
approach that focused on homologs of the YcaO-TfuA pair found in biosynthetic gene 
clusters of thioamidated metabolites to identify the thiopeptide gene cluster in 
A. saalfeldensis as a potential thioamidated thiopeptide producer. Therefore, a similar 
bioinformatic approach identifying TpnL-like proteins may be useful in the identification 
of yet unknown series a and series c (discussed below) thiopeptide biosynthetic gene 











Figure 4.18: The thiopeptin biosynthetic gene (tpn) cluster and possible thiopeptide 
biosynthetic gene clusters containing a homolog of tpnL. Two orfs in Micromonospora 
carbonacea var. africana ATCC 39149 are based on incomplete nucleotide data in the 
NCBI database are shown with dashes and dotted lines. The accession numbers are 
indicated below each species and the range of values are abbreviated by the “x” in the 



























Table 4.1: Deduced functions of the open reading frames in the predicted thiopeptide 




Description of Deduced Protein Tsr or Tpn  
Homologa 
SEO89824.1 2-Methyl-L-tryptophan aminotransferase TpnW 
(60/70) 
SEO89837.1 SnoaL-like cyclase TsrS 
(ACN52308.1; 67/77) 






SEO89888.1 Hypothetical protein  TsrO 
(ACN52305.1; 41/60) 
SEO89904.1 α/β-Hydrolase fold family protein TpnR 
(61/74) 
SEO89922.1 Thiopeptide precursor peptide  TsrA 
(ACN52291.1; 76/84) 
SEO89930.1 Thiopeptide macrocyclase TsrB 
(ACN52292.1; 65/74) 
SEO89952.1 LanB-type dehydratase glutamylation domain subunit TsrC 
(ACN52293.1; 51/63) 
SEO89971.1 LanB-type dehydratase glutamate elimination domain subunit TsrD 
(ACN52294.1; 60/74) 
SEO89991.1 Thiopeptide [4+2] cyclase TsrE 
(ACN52295.1; 74/84) 
SEO90009.1 Thiazoline dehydrogenase TsrF 
(ACN52296.1; 58/65) 
SEO90032.1 F-protein-leader peptide binding protein TsrG 
(ACN52297.1; 51/59) 
SEO90054.1 F-protein dependent cyclodehydratase TsrH 
(ACN52298.1; 61/69) 
SEO90075.1 4-(1-Hydroxyethyl)quinoline-2-carboxylic acid epoxygenase TsrI 
(ACN52299.1; 58/66) 
SEO90092.1 Adenylyltransferase TsrJ 
(ACN52300.1; 64/71) 
SEO90111.1 Isoleucine hydroxylase TsrK 
(ACN52301.1; 56/66) 
SEO90135.1 LanB-type dehydratase glutamylation domain subunit TsrL 
(ACN52302.1; 46/56) 
SEO90151.1 Flavin/deazaflavin oxidoreductase TpnL 
(66/75) 
SEO90172.1 YcaO domain-containing protein TpnM 
(77/84) 
SEO90188.1 TfuA-like protein TpnN 
(72/80) 
SEO90204.1 Tryptophan methyltransferase TsrM 
(ACN52303.1; 63/73) 
SEO90224.1 4-Acetyl-quinoline-2-carboxylic acid reductase TsrN 
(ACN52304.1; 53/63) 







Table 4.2: Deduced functions of the open reading frames in the predicted thiopeptide 




Description of Deduced Protein Tsr or Tpn  
Homologa 
SCF23835.1 Carboxylesterase TsrU 
(ACN52310.1; 51/64) 
SCF23822.1 Amidotransferase TsrT 
(ACN52309.1; 68/77) 
SCF23809.1 TfuA-like protein TpnN 
(57/65) 
SCF23793.1 YcaO domain-containing protein  TpnM 
(66/74) 
SCF23781.1 LanB-type dehydratase glutamylation domain subunit  TsrL 
(ACN52302.1; 47/56) 
SCF23767.1 Isoleucine hydroxylase TsrK 
(ACN52301.1; 56/68) 
SCF23754.1 Adenylyltransferase TsrJ 
(ACN52300.1; 60/69) 
SCF23740.1 4-(1-Hydroxyethyl)quinoline-2-carboxylic acid epoxygenase TsrI 
(ACN52299.1; 56/65) 
SCF23727.1 F-protein dependent cyclodehydratase TsrH 
(ACN52298.1; 60/69) 
SCF23715.1 F-protein-leader peptide binding protein TsrG 
(ACN52297.1; 41/51) 
SCF23702.1 SnoaL-like cyclase TsrS 
(ACN52308.1; 58/75) 














SCF23630.1b Thiopeptide macrocyclase TsrB 
(ACN52292.1; 54/66) 
 LanB-type dehydratase glutamylation domain subunit TsrC 
(ACN52293.1; 50/62) 
SCF23618.1 LanB-type dehydratase glutamate elimination domain subunit TsrD 
(ACN52294.1; 60/71) 
SCF23606.1 Thiopeptide [4+2] cyclase TsrE 
(ACN52295.1; 69/81) 
SCF23593.1 Thiazoline dehydrogenase TsrF 
(ACN52296.1; 56/63) 
SCF23580.1 F-protein-leader peptide binding protein TsrG 
(ACN52297.1; 51/58) 
SCF23564.1 Tryptophan methyltransferase TsrM 
(ACN52303.1; 66/75) 
SCF23550.1 4-Acetyl-quinoline-2-carboxylic acid reductase TsrN 
(ACN52304.1; 56/69) 
SCF23538.1 2-Methyl-L-tryptophan aminotransferase TpnW 
(31/40) 
SCF23526.1 Flavin/deazaflavin oxidoreductase TpnL 
(52/64) 
aNCBI accession numbers and % identity/similarity are given in parentheses. 






Figure 4.19: The structure of saalfelduracin 34, a thioamidated series a thiopeptide isolated 





To date, only one dihydroimidazopiperidine-containing series c thiopeptide has 
been identified, Sch 40832 3 (Figure 4.20) isolated from Micromonospora carbonacea var. 
africana ATCC 39149 (ATCC 39149).39 The genome sequence of ATCC 39149 contains 
a candidate biosynthetic gene cluster for this unusual thiopeptide (Figure 4.18), and the 
precursor peptide found encoded in this locus (EEP73621.1) includes a match for a 
predicted Sch 40832 core peptide (TSSSSCTTCICTCSCSS). Like 2 and 13-16, Sch 40832 
houses a second, quinaldic acid-containing macrocycle, and the genes encoding HEQ 
biosynthetic enzyme homologs are present in the proposed cluster (Figure 4.18; Table 4.3). 
The structure reported for Sch 40832 3 included a disaccharide tethered to the β-hydroxyl 
of Thr1, and a potential glycosyltransferase (EEP73625.1) is encoded in this cluster (Table 
4.3). In addition, methylation of the Cys15 sulfur and the methylhydroxylation of the 
dihydroimidazopiperidine ring found in 3 may be accomplished by actions of a putative 
methyltransferase (EEP73623.1) and a cytochrome P450 (EEP73622.1), respectively, that 
are encoded in this cluster (Table 4.3). The role of a putative NAD(P)-dependent 
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oxidoreductase (EEP73624.1) is unclear, but it may be involved in the formation or 
maturation of the dihydroimidazopiperidine ring. A homolog of TpnL (EEP73610.1) is 
present in the ATCC 39149 cluster, but there do not appear to be any homologs to TpnMN, 
the proposed thioamidation YcaO-TfuA-like proteins. Accordingly, the reported structure 
of Sch 40832 includes a piperidine ring but lacks a thioamide.39 The role of an F420H2-
dependent reductase in the biosynthesis of a series c thiopeptide is not entirely clear. It 
could reduce a dehydropiperidine precursor, forming a nascent piperidine subjected to 
additional oxidative modifications elaborating the central nitrogenous ring into the 
dihydroimidazopiperidine scaffold. Alternatively, the TpnL homolog could mediate an 





Figure 4.20: The structure of Sch 40832 3, a series c thiopeptide, produced by 
Micromonospora cabonacea var. africana ATCC 39149.39 The dihydroimidazopiperidine 








Table 4.3: Deduced functions of the open reading frames in the predicted thiopeptide 




Description of Deduced Protein Tsr or Tpn  
Homologa 
EEP73631.1 SnoaL-like cyclase TsrS 
(ACN52308.1; 61/77) 






EEP73628.1 2-Methyl-L-tryptophan aminotransferase TpnW 
(36/47) 
EEP73627.1 4-Acetyl-quinoline-2-carboxylic acid reductase TsrN 
(ACN52304.1; 48/62) 
EEP73626.1 Tryptophan methyltransferase TsrM 
(ACN52303.1; 59/68) 
EEP73625.1 Glycosyltransferase --- 
 
EEP73624.1 NAD(P)-dependent oxidoreductase --- 
 













EEP73620.1 Thiopeptide macrocyclase TsrB 
(ACN52292.1; 52/62) 
EEP73619.1 LanB-type dehydratase glutamylation domain subunit TsrC 
(ACN52293.1; 50/59) 
EEP73618.1 LanB-type dehydratase glutamate elimination domain subunit TsrD 
(ACN52294.1; 63/72) 
EEP73617.1 Thiopeptide [4+2] cyclase TsrE 
(ACN52295.1; 64/77) 
EEP73616.1b Thiazoline dehydrogenase TsrF 
(ACN52296.1; 47/57) 
Orf1c F-protein-leader peptide binding protein TsrG 
(ACN52297.1; 52/61) 
EEP73615.1 F-protein dependent cyclodehydratase TsrH 
(ACN52298.1; 56/64) 
EEP73614.1 4-(1-Hydroxyethyl)quinoline-2-carboxylic acid epoxygenase TsrI 
(ACN52299.1; 53/62) 
EEP73613.1 Adenylyltransferase TsrJ 
(ACN52300.1; 61/69) 
EEP73612.1 Isoleucine hydroxylase TsrK 
(ACN52301.1; 50/64) 
EEP73611.1 LanB-type dehydratase glutamylation domain subunit  TsrL 
(ACN52302.1; 39/49) 
EEP73610.1 Flavin/deazaflavin oxidoreductase TpnL 
(50/61) 
aNCBI accession numbers and % identity/similarity are given in parentheses. 
bEEP73616.1 is deposited to GenBank with incomplete nucleotide sequence. 





Actinoalloteichus hoggarensis DSM 45943 (A. hoggarensis) also identifies with a 
putative thiopeptide biosynthetic gene cluster harboring a TpnL-like protein, and contains 
many similarities to the components of the ATCC 39149 biosynthetic gene cluster (Figure 
4.18, Tables 4.3 and 4.4). The A. hoggarensis core peptide (WP_093941958.1) is identical 
to the proposed Sch 40832 core peptide of ATCC 39149. Both A. hoggarensis and ATCC 
39149 gene clusters encode a putative glycosyltransferase 
(WP_093941956.1/EEP73625.1), methyltransferase (WP_093941975.1/EEP73623.1), 
cytochrome P450 (WP_093941957.1/EEP73622.1), and an NAD(P)-dependent 
oxidoreductase (WP_093944483.1/ EEP73624.1), which may represent a set of enzymes 
required in the formation of series c thiopeptides. The A. hoggarensis cluster, however, 
also includes homologs to the proposed TpnMN thioamidating system. It is therefore 
possible that A. hoggarensis may generate another series c thiopeptide bearing a thioamide. 
In addition, the A. hoggarensis biosynthetic gene cluster contains additional encoded 
products (WP_093944484.1, WP_093941974.1, WP_093941976.1) not found in the 
ATCC 39149 biosynthetic gene cluster, which may be involved in additional modifications 












Table 4.4: Deduced functions of the open reading frames in the predicted thiopeptide 






Tsr or Tpn  
Homologa 
WP_093944483.1 Gfo/Idh/MocA family oxidoreductase --- 
 





WP_093941957.1 Cytochrome P450 --- 
 




WP_093941959.1 Thiopeptide macrocyclase TsrB 
(ACN52292.1; 60/72) 
WP_093941960.1 LanB-type dehydratase glutamylation domain subunit TsrC 
(ACN52293.1; 47/58) 
WP_093941961.1 LanB-type dehydratase glutamate elimination domain subunit TsrD 
(ACN52294.1; 57/71) 
WP_093941962.1 Thiopeptide [4+2] cyclase TsrE 
(ACN52295.1; 66/78) 
WP_093941963.1 Thiazoline dehydrogenase TsrF 
(ACN52296.1; 51/60) 
WP_093941964.1 F-protein-leader peptide binding protein TsrG 
(ACN52297.1; 45/54) 
WP_093941965.1 F-protein dependent cyclodehydratase TsrH 
(ACN52298.1; 52/62) 
WP_093941966.1 4-(1-Hydroxyethyl)quinoline-2-carboxylic acid epoxygenase TsrI 
(ACN52299.1; 55/65) 
WP_093941967.1 Adenylyltransferase TsrJ 
(ACN52300.1; 62/71) 
WP_093944485.1 Carboxymethyltransferase  TsrP 
(ACN52306.1; 47/55) 
WP_093941968.1 3-(2-Methylindolyl)pyruvate dehydrogenase TsrQ 
(ACN52307.1; 54/69) 
WP_093941969.1 SnoaL-like cyclase TsrS 
(ACN52308.1; 52/68) 
WP_093941970.1 Isoleucine hydroxylase TsrK 
(ACN52301.1; 52/63) 
WP_093941971.1 LanB-type dehydratase glutamylation domain subunit  TsrL 
(ACN52302.1; 40/48) 
WP_093941972.1 Flavin/deazaflavin oxidoreductase TpnL 
(45/60) 
WP_093944486.1 YcaO domain-containing protein  TpnM 
(62/70) 
WP_093941973.1 TfuA-like protein TpnN 
(48/59) 
WP_093941974.1 Peptidase --- 
 
WP_093941975.1 FkbM family methyltransferase --- 
 
WP_093941976.1 SGNH/GDSL hydrolase family protein --- 
 





Several other homologs of TpnL were identified in the NCBI database, only a few 
of which appear to be involved in thiopeptide biosynthesis. A phylogenetic analysis of 
TpnL was conducted alongside its homologs and established F420H2-dependent FDOR-Bs 
from Mycobacterium species and Streptomyces rimosus1, 7, 9, 12-13, 40 The TpnL-like proteins 
affiliated with a known or predicted thiopeptide biosynthetic gene cluster are in a distinct 
clade from the other FDOR-B proteins (Figure 4.21). The two proteins that may be 
involved in biosynthesis of dihydroimidazopiperidine-containing (series c) thiopeptides 
form a separate subclade from the homologs identified from bacteria that are or may be 






Figure 4.21: Phylogenetic tree of TpnL and other F420-dependent FDOR-B homologs. 
TpnL homologs colocalized with predicted thiopeptide biosynthetic gene clusters are 
shown in blue, and other known and putative F420-dependent FDOR-Bs are shown in black. 
The F420-dependent FDOR-Bs from Actinobacteria that have been biochemically 
characterized are indicated with a bracket. The branch distances are indicated at the nodes 
and are based on the number of substitutions in the amino acid sequences between 
homologs, an indicator of genetic divergence. The scale bar represents ten amino acid 
substitutions per 100 amino acid residues. Accession numbers for the sequences used are 




A defining characteristic of thiopeptides is the core macrocycle linked through a 
nitrogenous heterocycle derived from two Dha residues via a formal [4+2] cycloaddition.22 
Series d thiopeptides utilize a dedicated pyridine synthase to catalyze this cyclization, 
followed by dehydration and elimination of the leader peptide.41 A similar process might 
also lead to the core macrocycle of series a and b thiopeptides, although it is not yet 
understood how this permits retention of the N-terminal portion of the peptide and a more 
reduced ring system. There are, however, no obvious reductase candidates in either the 2 
or siomycin biosynthetic gene clusters, leaving the origin of the dehydropiperidine ring 
enigmatic.35, 42 Identification of TpnL as a dehydropiperidine reductase demonstrates that 
the series a thiopeptide piperidine originates from the reduction of a series b thiopeptide 
intermediate. TpnL does accept thiostrepton A 2, a mature metabolite bearing both the core 
macrocycle and the quinaldic acid loop, as a substrate. It is not yet known, however, if 
TpnL would act upon a dehydropiperidine-containing intermediate in which the second, 
quinaldic acid-containing, macrocycle has not yet been installed.43-44 The TpnL-dependent 
reduction shown here occurs independent of additional ancillary recognition elements such 
as the leader peptide, in contrast to many modifications in thiopeptide biosynthesis that do 
require the presence of the leader peptide.22 A similar transformation is expected to be 
carried out by TpnL on a dehydropiperidine-containing biosynthetic intermediate of 
thiopeptin in S. tateyamensis. Gene deletion experiments of tpnL and other thiopeptide 
biosynthetic genes in S. tateayamensis or in S. laurentii HI1 (the S. laurentii strain that 
expresses TpnL), and a deletion experiment of the tpnL homolog in A. saalfeldensis are 
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needed to discern the exact timing of this modification in thiopeptide biosynthesis and 
substrate specificity of this enzyme.  
The activity of TpnL appears to be subject to substrate inhibition by thiostrepton A 
at concentrations above 2 μM. A majority of F420 in the TpnL assay appears to be reduced 
during the course of the activity assay and increasing the concentration of available F420H2 
did not alter the activity of TpnL. Further kinetic experiments that alter temperature and 
pH are needed to better describe the non-Michaelis-Menten behavior of TpnL activity. In 
addition, structural characterization of TpnL may reveal insights into the binding mode of 
the substrates with TpnL and the catalytic mechanism of the dehydropiperidine reduction. 
Kinetic and structural characterization of TpnL may help explain the apparent substrate 
inhibition that was observed. 
A few TpnL homologs were found to colocalize with other predicted thiopeptide 
biosynthetic gene clusters. One of which was identified in M. carbonacea var. africana 
ATCC 39149, a known producer of the series c thiopeptide Sch 40832 3. The encoded core 
peptide sequence in this gene cluster matches the predicted core peptide sequence of Sch 
40832 and it is likely that this gene cluster is involved in its biosynthesis.  The role of the 
TpnL homolog in Sch 40832 biosynthesis is unclear and biosynthetic characterizations of 
the TpnL-like protein and other encoded products of the ATCC 39149 gene cluster are 
required.  
There is a recent surge of interest in cofactor F420 for its involvement in 
mycobacterial virulence. Yet, our understanding of deazaflavin-dependent reactions is 
limited, especially in secondary metabolism. TpnL demonstrates the first known 
involvement of cofactor F420 in thiopeptide biosynthesis or RiPP biosynthesis. In addition 
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to TpnL, OxyR, the F420-dependent reductase in oxytetracycline biosynthesis is one of the 
few characterized examples of F420 in secondary metabolism.
9 Discovery of novel F420-
dependent proteins may reveal additional chemical modifications that are attributed to this 




1. Ahmed, F. H.; Carr, P. D.; Lee, B. M.; Afriat-Jurnou, L.; Mohamed, A. E.; Hong, 
N. S.; Flanagan, J.; Taylor, M. C.; Greening, C.; Jackson, C. J., Sequence-structure-
function classification of a catalytically diverse oxidoreductase superfamily in 
mycobacteria. J. Mol. Biol. 2015, 427, 3554-3571. 
 
2. Greening, C.; Ahmed, F. H.; Mohamed, A. E.; Lee, B. M.; Pandey, G.; Warden, A. 
C.; Scott, C.; Oakeshott, J. G.; Taylor, M. C.; Jackson, C. J., Physiology, 
biochemistry, and applications of F420- and F0-dependent redox reactions. 
Microbiol. Mol. Biol. Rev. 2016, 80, 451-493. 
 
3. stHu, Y.; Jiang, F.; Guo, Y.; Shen, X.; Zhang, Y.; Zhang, R.; Guo, G.; Mao, X.; 
Zou, Q.; Wang, D. C., Crystal structure of HugZ, a novel heme oxygenase from 
Helicobacter pylori. J. Biol. Chem. 2011, 286, 1537-1544. 
 
4. Biswal, B. K.; Au, K.; Cherney, M. M.; Garen, C.; James, M. N., The molecular 
structure of Rv2074, a probable pyridoxine 5'-phosphate oxidase from 
Mycobacterium tuberculosis, at 1.6 Å resolution. Acta. Crystallogr. Sect. F Struct. 
Biol. Cryst. Commun. 2006, 62, 735-742. 
 
5. Canaan, S.; Sulzenbacher, G.; Roig-Zamboni, V.; Scappuccini-Calvo, L.; 
Frassinetti, F.; Maurin, D.; Cambillau, C.; Bourne, Y., Crystal structure of the 
conserved hypothetical protein Rv1155 from Mycobacterium tuberculosis. FEBS 
Lett. 2005, 579, 215-221. 
 
6. di Salvo, M. L.; Contestabile, R.; Safo, M. K., Vitamin B6 salvage enzymes: 
mechanism, structure and regulation. Biochem. Biophys. Acta, Proteins Proteomics 
2011, 1814, 1597-1608. 
 
7. Greening, C.; Jirapanjawat, T.; Afroze, S.; Ney, B.; Scott, C.; Pandey, G.; Lee, B. 
M.; Russell, R. J.; Jackson, C. J.; Oakeshott, J. G.; Taylor, M. C.; Warden, A. C., 
Mycobacterial F420H2-dependent reductases promiscuously reduce diverse 




8. Oyugi, M. A.; Bashiri, G.; Baker, E. N.; Johnson-Winters, K., Investigating the 
reaction mechanism of F420-dependent glucose-6-phosphate dehydrogenase from 
Mycobacterium tuberculosis: kinetic analysis of the wild-type and mutant enzymes. 
Biochemistry 2016, 55, 5566-5577. 
 
9. Wang, P.; Bashiri, G.; Gao, X.; Sawaya, M. R.; Tang, Y., Uncovering the enzymes 
that catalyze the final steps in oxytetracycline biosynthesis. J. Am. Chem. Soc. 2013, 
135, 7138-7141. 
 
10. Purwantini, E.; Mukhopadhyay, B., Conversion of NO2 to NO by reduced 
coenzyme F420 protects mycobacteria from nitrosative damage. Proc. Natl. Acad. 
Sci. U.S.A. 2009, 106, 6333-6338. 
 
11. Guo, Y.; Guo, G.; Mao, X.; Zhang, W.; Xiao, J.; Tong, W.; Liu, T.; Xiao, B.; Liu, 
X.; Feng, Y.; Zou, Q., Functional identification of HugZ, a heme oxygenase from 
Helicobacter pylori. BMC Microbiol. 2008, 8, 226. 
 
12. Ahmed, F. H.; Mohamed, A. E.; Carr, P. D.; Lee, B. M.; Condic-Jurkic, K.; O'Mara, 
M. L.; Jackson, C. J., Rv2074 is a novel F420H2-dependent biliverdin reductase in 
Mycobacterium tuberculosis. Protein Sci. 2016, 25, 1692-1709. 
 
13. Mashalidis, E. H.; Gittis, A. G.; Tomczak, A.; Abell, C.; Barry, C. E., 3rd; Garboczi, 
D. N., Molecular insights into the binding of coenzyme F420 to the conserved protein 
Rv1155 from Mycobacterium tuberculosis. Protein Sci. 2015, 24, 729-740. 
 
14. Liu, Y.; Liu, J.; Tetzlaff, W.; Paty, D. W.; Cynader, M. S., Biliverdin reductase, a 
major physiologic cytoprotectant, suppresses experimental autoimmune 
encephalomyelitis. Free Radic. Biol. Med. 2006, 40, 960-967. 
 
15. Barañano, D. E.; Rao, M.; Ferris, C. D.; Snyder, S. H., Biliverdin reductase: A major 
physiologic cytoprotectant. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 16093-16098. 
 
16. Doré, S.; Takahashi, M.; Ferris, C. D.; Hester, L. D.; Guastella, D.; Snyder, S. H., 
Bilirubin, formed by activation of heme oxygenase-2, protects neurons against 
oxidative stress injury. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 2445-2450. 
 
17. Bashiri, G.; Squire, C. J.; Baker, E. N.; Moreland, N. J., Expression, purification 
and crystallization of native and selenomethionine labeled Mycobacterium 
tuberculosis FGD1 (Rv0407) using a Mycobacterium smegmatis expression system. 
Protein Expr. Purif. 2007, 54, 38-44. 
 
18. Bashiri, G.; Rehan, A. M.; Greenwood, D. R.; Dickson, J. M.; Baker, E. N., 
Metabolic engineering of cofactor F420 production in Mycobacterium smegmatis. 




19. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 
1976, 72, 248-254. 
 
20. Mahanta, N.; Liu, A.; Dong, S.; Nair, S. K.; Mitchell, D. A., Enzymatic 
reconstitution of ribosomal peptide backbone thioamidation. Proc. Natl. Acad. Sci. 
U.S.A. 2018, 115, 3030-3035. 
 
21. Taylor, M. C.; Jackson, C. J.; Tattersall, D. B.; French, N.; Peat, T. S.; Newman, J.; 
Briggs, L. J.; Lapalikar, G. V.; Campbell, P. M.; Scott, C.; Russell, R. J.; Oakeshott, 
J. G., Identification and characterization of two families of F420H2-dependent 
reductases from Mycobacteria that catalyse aflatoxin degradation. Mol. Microbiol. 
2010, 78, 561-575. 
 
22. Hudson, G. A.; Zhang, Z.; Tietz, J. I.; Mitchell, D. A.; van der Donk, W. A., In vitro 
biosynthesis of the core scaffold of the thiopeptide thiomuracin. J. Am. Chem. Soc. 
2015, 137, 16012-16015. 
 
23. Zhang, Z.; Hudson, G. A.; Mahanta, N.; Tietz, J. I.; van der Donk, W. A.; Mitchell, 
D. A., Biosynthetic timing and substrate specificity for the thiopeptide thiomuracin. 
J. Am. Chem. Soc. 2016, 138, 15511-15514. 
 
24. Cheeseman, P.; Toms-Wood, A.; Wolfe, R. S., Isolation and properties of a 
fluorescent compound, factor 420, from Methanobacterium strain M.o.H. J. 
Bacteriol. 1972, 112, 527-531. 
 
25. Mohamed, A. E.; Ahmed, F. H.; Arulmozhiraja, S.; Lin, C. Y.; Taylor, M. C.; 
Krausz, E. R.; Jackson, C. J.; Coote, M. L., Protonation state of F420H2 in the 
prodrug-activating deazaflavin dependent nitroreductase (Ddn) from 
Mycobacterium tuberculosis. Mol. Biosyst. 2016, 12, 1110-1113. 
 
26. Miyairi, N.; Miyoshi, T.; Aoki, H.; Kosaka, M.; Ikushima, H., Thiopeptin, a new 
feed additive antibiotic: microbiological and chemical studies. Antimicrob. Agents 
Chemother. 1972, 1, 192-196. 
 
27. Ryan, P. C.; Lu, M.; Draper, D. E., Recognition of the highly conserved GTPase 
center of 23 S ribosomal RNA by ribosomal protein L11 and the antibiotic 
thiostrepton. J. Mol. Biol. 1991, 221, 1257-1268. 
 
28. Bashiri, G.; Squire, C. J.; Moreland, N. J.; Baker, E. N., Crystal structures of F420-
dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of 
the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and 
substrate binding. J. Biol. Chem. 2008, 283, 17531-17541. 
 
29. Zhang, F.; Kelly, W. L., Saturation mutagenesis of TsrA Ala4 unveils a highly 
mutable residue of thiostrepton A. ACS Chem. Biol. 2015, 10, 998-1009. 
169 
 
30. Kelly, J.; Kutscher, A. H.; Tuot, I. F., Thiostrepton, a new antibiotic: tube dilution 
sensitivity studies. Oral surgery, oral medicine, and oral pathology 1959, 12, 1334-
1339. 
 
31. Choi, K. P.; Bair, T. B.; Bae, Y. M.; Daniels, L., Use of transposon Tn5367 
mutagenesis and a nitroimidazopyran-based selection system to demonstrate a 
requirement for fbiA and fbiB in coenzyme F420 biosynthesis by Mycobacterium 
bovis BCG. J. Bacteriol. 2001, 183, 7058-7066. 
 
32. Doi, K.; Fujino, Y.; Nagayoshi, Y.; Ohshima, T.; Ogata, S., Complete genome 
sequence of thiostrepton-producing Streptomyces laurentii ATCC 31255. Genome 
Announc. 2016, 4, e00360-16. 
 
33. Bashiri, G.; Rehan, A. M.; Sreebhavan, S.; Baker, H. M.; Baker, E. N.; Squire, C. 
J., Elongation of the poly-γ-glutamate tail of F420 requires both domains of the 
F420:γ-glutamyl ligase (FbiB) of Mycobacterium tuberculosis. J. Biol. Chem. 2016, 
291, 6882-6894. 
 
34. Choi, K. P.; Kendrick, N.; Daniels, L., Demonstration that fbiC is required by 
Mycobacterium bovis BCG for coenzyme F420 and F0 biosynthesis. J. Bacteriol. 
2002, 184, 2420-2428. 
 
35. Kelly, W. L.; Pan, L.; Li, C., Thiostrepton biosynthesis: prototype for a new family 
of bacteriocins. J. Am. Chem. Soc. 2009, 131, 4327-4334. 
 
36. Puar, M. S.; Ganguly, A. K.; Afonso, A.; Brambilla, R.; Mangiaracina, P.; Sarre, 
O.; MacFarlane, R. D., Sch 18640. A new thiostrepton-type antibiotic. J. Am. Chem. 
Soc. 1981, 103, 5231-5233. 
 
37. Schwalen, C. J.; Hudson, G. A.; Kille, B.; Mitchell, D. A., Bioinformatic expansion 
and discovery of thiopeptide antibiotics. J. Am. Chem. Soc. 2018, 140, 9494–9501. 
 
38. Hensens, O. D.; Albers-Schonberg, G., Total structure of the highly modified 
peptide antibiotic components of thiopeptin. J. Antibiot. 1983, 36, 814-831. 
 
39. Puar, M. S.; Chan, T. M.; Hegde, V.; Patel, M.; Bartner, P.; Ng, K. J.; Pramanik, B. 
N.; MacFarlane, R. D., Sch 40832: a novel thiostrepton from Micromonospora 
carbonacea. J. Antibiot. 1998, 51, 221-224. 
 
40. Manjunatha, U. H.; Boshoff, H.; Dowd, C. S.; Zhang, L.; Albert, T. J.; Norton, J. 
E.; Daniels, L.; Dick, T.; Pang, S. S.; Barry, C. E., 3rd, Identification of a 
nitroimidazo-oxazine-specific protein involved in PA-824 resistance in 
Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 431-436. 
 
41. Cogan, D. P.; Hudson, G. A.; Zhang, Z.; Pogorelov, T. V.; van der Donk, W. A.; 
Mitchell, D. A.; Nair, S. K., Structural insights into enzymatic [4+2] aza-
170 
 
cycloaddition in thiopeptide antibiotic biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 
2017, 114, 12928-12933. 
 
42. Liao, R.; Duan, L.; Lei, C.; Pan, H.; Ding, Y.; Zhang, Q.; Chen, D.; Shen, B.; Yu, 
Y.; Liu, W., Thiopeptide biosynthesis featuring ribosomally synthesized precursor 
peptides and conserved posttranslational modifications. Chem. Biol. 2009, 16, 141-
147. 
 
43. Li, C.; Zhang, F.; Kelly, W. L., Mutagenesis of the thiostrepton precursor peptide at 
Thr7 impacts both biosynthesis and function. Chem. Commun. 2012, 48, 558-560. 
 
44. Zheng, Q.; Wang, S.; Duan, P.; Liao, R.; Chen, D.; Liu, W., An α/β-hydrolase fold 
protein in the biosynthesis of thiostrepton exhibits a dual activity for endopeptidyl 
hydrolysis and epoxide ring opening/macrocyclization. Proc. Natl. Acad. Sci. U.S.A. 

































 The thiopeptin biosynthetic gene (tpn) cluster was identified in Streptomyces 
tateyamensis ATCC 21389 (S. tateyamensis), a producer of the antibiotic complex, 
thiopeptin (13-16).1-2 To confirm the role of the tpn cluster in thiopeptin biosynthesis, the 
transaminase activity of TpnW was demonstrated in vitro. TpnW was able to convert 
2-methyl-L-tryptophan to 3-(2-methylindolyl)pyruvate in the presence of aromatic α-keto 
acid donors. This transamination is the second step of HEQ biosynthesis, and HEQ is a 
component required to form the second macrocycle of thiopeptin. While most of the 23 
open reading frames in the tpn cluster (tpnA-W) encode homologs of known thiopeptide 
biosynthetic proteins, the functions of TpnLMN were not immediately clear.3 To confirm 
the involvement of the tpn cluster in thiopeptin biosynthesis and to investigate the roles of 
tpnLMNR, gene inactivation studies of tpnLMNR in S. tateyamensis were pursued. 
S. tateyamensis, however, was recalcitrant to genetic modifications. Neither the 
interspecies conjugation of S. tateyamensis with E. coli nor S. tateyamensis protoplast 
transformation were able to be optimized. In addition, thiopeptin production by 
S. tateyamensis became difficult to reproduce, making the results of the S. tateyamensis 
mutants difficult to interpret. 
 To circumvent obstacles encountered with genetic modifications to S. tateyamensis, 
TpnLMNR were expressed in Streptomyces laurentii ATCC 31255 (S. laurentii), a 
producer of thiostrepton A 2, a thiopeptide antibiotic with a highly similar structure to 
thiopeptin.4 S. laurentii HI1, a strain that expresses TpnL, produced thiostrepton Aa 31, a 
piperidine-containing analog of 2. The piperidine modification of thiostrepton Aa 31 did 
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not significantly alter either the aqueous solubility or antibacterial activities of the analog 
against the strains evaluated. S. laurentii HI6, a strain that coexpresses TpnMN, produced 
a metabolite with the same mass as a thioamidated thiostrepton analog 32. Isolation and 
structural characterization of this metabolite is needed to confirm the thioamide 
modification that is predicted to be installed by TpnMN. 
 TpnL is homologous to enzymes of the flavin/deazaflavin oxidoreductase subgroup 
B (FDOR-B) and TpnL has a conserved lysine residue (K55) that is present in most F420-
dependent FDOR-Bs. Accordingly, TpnL was found to preferentially bind the deazaflavin 
cofactor F420 over flavin cofactors. TpnL activity was demonstrated in the presence of F420, 
F420-dependent glucose-6-phosphate dehydrogenase, glucose-6-phosphate, and 
thiostrepton A 2. TpnL was able to reduce the dehydropiperine ring of 2 to the piperidine 
ring of thiostrepton Aa 31. TpnL activity, however, appeared to be strongly inhibited by 
thiostrepton A 2 above 2 μM. While TpnL did accept 2, a mature thiopeptide as a substrate, 
further characterization is required to determine if TpnL accepts a dehydropiperidine-
containing biosynthetic intermediate in which the quindalic acid-containing macrocycle 
has not yet been installed. Gene inactivation studies in S. laurentii HI1 or heterologous 
expression of TpnL in S. laurentii mutants that have one or more thiostrepton biosynthetic 
genes inactivated may shed light on the timing of this modification and the substrate 
specificity of TpnL. Structural characterization of TpnL may reveal the binding mode of 
F420H2 and 2, and possibly illuminate a structural mechanism for the substrate inhibition of 
TpnL activity. 
 TpnL homologs were found to colocalize with other predicted thiopeptide 
biosynthetic gene clusters. One of these clusters was identified in M. carbonacea var 
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africana, a known producer of Sch 40832, a series c thiopeptide. The encoded core peptide 
sequence in this gene cluster matches the predicted core peptide sequence of Sch 40832 
and it is likely that this gene cluster is involved in its biosynthesis. A phylogenetic analysis 
of TpnL-like proteins showed that the TpnL homologs predicted to be involved in series a 
or series c thiopeptide biosynthesis formed their own separate clades. Therefore, genome 
mining for TpnL-like proteins may be useful in identifying series a and series c thiopeptide 
biosynthetic gene clusters as more microbial genomes become available on the database. 
 The characterization of TpnL as an F420H2-dependent dehydropiperidine reductase 
establishes the basis for a series a thiopeptide and TpnL is the first known instance of a 
F420-dependent enzyme involved in the biosynthesis of ribosomally-translated and post-
translationally modified peptides. Further characterization of TpnL will be needed to 
determine whether this reduction reflects the terminal step in series a thiopeptide 
biosynthesis or if the true biological substrate is an earlier intermediate. Regardless, TpnL 
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APPENDIX A: PRIMERS, PLASMIDS, STRAINS, AND PROTEINS  




Table A.1: Primers used in this study. 





Primers for the amplification of a fragment 






Primers for the amplification of a fragment 






Primers for the amplification of a fragment 









Primers for the amplification of tpnA and 
flanking regions. The HindIII restriction 











Primers for the disruption of tpnA in 
pGM-tpnA.  Underlined regions are 
homologous to tpnA. Regions that are not 
underlined are homologous to the 





Primers for the confirmation of 





Primers for the confirmation of 








Primers for the amplification of tpnL and 
flanking regions. The HindIII restriction 











Primers for the disruption of tpnL in 
pGM-tpnL.  Underlined regions are 
homologous to tpnL. Regions that are not 
underlined are homologous to the 








Primers for the amplification of tpnM and 
flanking regions. The HindIII restriction 











Primers for the disruption of tpnM in 
pGM-tpnM.  Underlined regions are 
homologous to tpnM. Regions that are not 
underlined are homologous to the 
aac(3)IV/oriT cassette of pIJ773. 
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Table A.1 (continued) 








Primers for the amplification of tpnN and 
flanking regions. The HindIII restriction 











Primers for the disruption of tpnN in 
pGM-tpnN.  Underlined regions are 
homologous to tpnN. Regions that are not 
underlined are homologous to the 








Primers for the amplification of tpnR and 
flanking regions. The HindIII restriction 











Primers for the disruption of tpnR in 
pGM-tpnR.  Underlined regions are 
homologous to tpnR. Regions that are not 
underlined are homologous to the 






Primers for the amplification of tpnA for 
genetic complementation in 
S. tateyamensis HI1. The NdeI and EcoRI 













Primers for the amplification of tpnW for 
expression in E. coli. The NdeI and EcoRI 














Primers for the amplification of tpnL for 
expression in S. laurentii. The NdeI 







Primers for the amplification of tpnM for 
expression in S. laurentii. The NdeI 







Primers for the amplification of tpnN for 
expression in S. laurentii. The NdeI 





Primers for the amplification of tpnR for 








Primers for the amplification of tpnL for 
expression in E. coli. The NdeI and HindIII 





Primers for the amplification of an F0-
synthase candidate in S. tateyamensis. 
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Table A.2: Strains and plasmids used in this study 
 
Strain/Plasmid Description Reference or 
Source 
E. coli strains   
BL21(DE3) Host for protein expression  
BW25113/pKD46 Host for PCR-targeted disruption of a gene from  
a plasmid 
1 
EPI300 Host for inducing high copy number of a fosmid Epicenter (Lucigen) 




S. laurentii ATCC 31255 Wild type, thiostrepton A producer ATCC 
S. laurentii HI0 S. laurentii containing pSET1520 This study 
S. laurentii HI1 S. laurentii containing pSET1520-tpnL This study 
S. laurentii HI2 S. laurentii containing pSET1520-tpnM This study 
S. laurentii HI3 S. laurentii containing pSET1520-tpnN This study 
S. laurentii HI4 S. laurentii containing pSET1520-tpnR This study 
S. laurentii HI5 S. laurentii containing pSET1520-tpnLM This study 
S. laurentii HI6 S. laurentii containing pSET1520-tpnMN This study 
S. laurentii HI7 S. laurentii containing pSET1520-tpnLMN This study 
S. tateyamensis ATCC 
21389 
Wild type, thiopeptin producer ATCC 
S. tateyamensis HI1 S. tateyamensis tpnA mutant This study 
   
Plasmids   
HI2B7 pCC1FOS fosmid containing a fragment (tpnW-tpnJ) 
of the tpn gene cluster 
This study 
HI2G2 pCC1FOS fosmid containing a fragment (tpnF-tpnP) 
of the tpn gene cluster 
This study 
JP8D9 pCC1FOS fosmid of the S. laurentii genomic fosmid 
library 
3 
pCC1FOS Fosmid used for genomic library construction Lucigen 
pET28b(+) Vector for protein expression in E. coli Novagen 
pET28b-tpnL Plasmid for TpnL expression in E. coli This study 
pET28b-tpnW Plasmid for TpnW expression in E. coli This study 
pGM160HKss 
 
A derivative of pGM160HK, in which the ampicillin 
resistance gene was replaced by the spectinomycin-
streptomycin resistance cassette. It is a conjugal and 
temperature-sensitive E. coli-Streptomyces shuttle 
vector 
4 
pGM-dtpnA pGM-tpnA with an aac(3)IV/oriT inserted at tpnA This study 
pGM-dtpnL pGM-tpnL with an aac(3)IV/oriT inserted at tpnL This study 
pGM-dtpnM pGM-tpnM with an aac(3)IV/oriT inserted at tpnM This study 
pGM-dtpnN pGM-tpnN with an aac(3)IV/oriT inserted at tpnN This study 
pGM-dtpnR pGM-tpnR with an aac(3)IV/oriT inserted at tpnR This study 
pGM-tpnA pGM160HKss containing tpnA and flanking regions This study 
pGM-tpnL pGM160HKss containing tpnL and flanking regions This study 
pGM-tpnM pGM160HKss containing tpnM and flanking regions This study 
pGM-tpnN pGM160HKss containing tpnN and flanking regions This study 
pGM-tpnR pGM160HKss containing tpnR and flanking regions This study 
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Table A.2 (contined) 
   
pSET1520 Derivative of pSET152 with a ermE* and RBS of 
pET-series vector inserted into an MCS site 
5 
pSET1520-TpnL Integrative plasmid for tpnL expression in S. laurentii This study 
pSET1520-TpnLM Integrative plasmid for tpnLM expression in 
S. laurentii 
This study 
pSET1520-TpnLMN Integrative plasmid for tpnLMN expression in 
S. laurentii 
This study 
pSET1520-TpnM Integrative plasmid for tpnM expression in 
S. laurentii 
This study 
pSET1520-TpnMN Integrative plasmid for tpnMN expression in 
S. laurentii 
This study 
pSET1520-TpnN Integrative plasmid for tpnN expression in 
S. laurentii 
This study 
pSET1520-TpnR Integrative plasmid for tpnR expression in 
S. laurentii 
This study 
pSET1520ss Derivative of pSET152, with a ermE* and RBS of 
pET-series vector inserted into MCS site, and 
apramycin resistance gene replaced by 
spectinomycin/streptomycin resistance gene 
6 
pSET1520ss-TpnA pSET1520ss containing a functional tpnA This study 
pSC-B-amp/kan A routine vector from StrataClone Blunt PCR 





pSC-B-amp/kan containing tpnL; an EcoRI site is 3’ 
to the stop codon of tpnL 
This study 
pTpnL pSC-B-amp/kan containing tpnL and flanking regions This study 
pTpnM pSC-B-amp/kan containing tpnM and flanking 
regions 
This study 
pTpnN pSC-B-amp/kan containing tpnN and flanking regions This study 
pTpnR pSC-B-amp/kan containing tpnR and flanking regions This study 
ptpnW pSC-B-amp/kan containing tpnW and flanking 
regions 
This study 














Table A.3: NCBI accession numbers of proteins used to construct the TpnL homolog 
phylogenetic tree. 
 
Source organism Accession number Homology 
to TpnLa 
Actinoalloteichus hoggarensis sp. nov. DSM 45943 WP_093941972.1 45/60 
Amycolatopsis saalfeldensis DSM 44993 SEO90151.1 70/78 
Chloroflexi bacterium RBG_13_68_17 OGO13680.1 53/64 
Jiangella alkaliphila DSM 45079 SDU67749.1 46/55 
Jiangella sp. DSM 45060 SDT24520.1 45/56 
Micromonospora carbonacea DSM 43168 SCF23526.1 53/62 
Micromonospora carbonacea var. africana ATCC 39149 EEP73611.1 50/61 
Mycobacterium smegmatis MC2 155 YP_888093.1 19/29 
Mycobacterium tuberculosis H37Rv NP_217507.1 24/34 
Mycobacterium tuberculosis H37Rv WP_003898745.1 18/29 
Mycobacterium tuberculosis H37Rv WP_003899157.1 18/24 
Streptacidiphilus anmyonensis sp. nov NBRC 103185 WP_042427374.1 52/60 
Streptomyces hygroscopicus XM201 AQW53324.1 41/52 
Streptomyces rimosus ATCC 10970 L8EYU3.1 22/28 
Streptomyces sp. GP55 PKV74444.1 48/62 
Streptomyces viridochromogenes NRRL 3413 KOG13857.1 32/50 
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Figure B.1: HPLC-MS analysis of a crude culture extract from S. tateyamensis. (a) 
Extracted ion chromatogram of m/z 842 for thiopeptin A1a 13 (calculated [M+2H]
2+ m/z = 
842.2) and the mass spectrum at tR = 32.16 min (inset). (b) Extracted ion chromatogram of 
m/z 835 for thiopeptin Ba 14 (calculated [M+2H]
2+ m/z = 835.2) and the mass spectrum at 
tR = 29.60 min (inset). (c) Extracted ion chromatogram of m/z 841 for thiopeptin A1b 15 
(calculated [M+2H]2+ m/z = 841.2) and the mass spectrum at tR = 33.92 min (inset). 
(d) Extracted ion chromatogram of m/z 834 for thiostrepton Bb 16 (calculated [M+2H]
2+ 
m/z = 834.2) and the mass spectrum at tR = 29.16 min (inset).  (e) Total ion chromatogram 








Figure B.2: HPLC-MS analysis of a crude culture extract from S. tateyamensis HI1. (a) 
Extracted ion chromatogram of m/z 842 for thiopeptin A1a 13 (calculated [M+2H]
2+ m/z = 
842.2). (b) Extracted ion chromatogram of m/z 835 for thiopeptin Ba 14 (calculated 
[M+2H]2+ m/z = 835.2). (c) Extracted ion chromatogram of m/z 841 for thiopeptin A1b 15 
(calculated [M+2H]2+ m/z = 841.2). (d) Extracted ion chromatogram of m/z 834 for 
thiostrepton Bb 16 (calculated [M+2H]
2+ m/z = 834.2).  (e) Total ion chromatogram of the 














Figure B.3: HPLC-MS analyses of the in vitro reconstitution of TpnW transamination 
activity after 30 minute reaction time. (a) Extracted ion chromatogram of m/z 203 L-
tryptophan 17 (calculated [M-H]- m/z = 203.1) and 3-indolylpyruvate 30 (calculated [M-
H]- m/z = 202.1) and the mass spectrum at tR = 23.82 min (inset) from the 3-indolylpyruvate 
30 standard. (b) Extracted ion chromatogram of m/z 217 for 3-(2-methylindolyl)pyruvate 
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19 (calculated [M-H]- m/z = 216.1) and 2-methyl-L-tryptophan 18 (calculated [M-H]- m/z 
= 217.1) and the mass spectrum at tR~26.93 min (inset) from the 30 standard. (c) Extracted 
ion chromatogram of m/z 203 and the mass spectrum at tR = 23.76 min (inset) in the reaction 
mixture lacking TpnW. (d) Extracted ion chromatogram of m/z 217 and the mass spectrum 
at tR = 11.97 min and tR ~26.30 min (inset) in the reaction mixture lacking TpnW. (e) 
Extracted ion chromatogram of m/z 203 and the mass spectrum at tR = 7.84 min and tR 
~23.80 min (inset) in the reaction mixture containing TpnW. (f) Extracted ion 
chromatogram of m/z 217 and the mass spectrum at tR = 12.05 min and tR ~26.84 min (inset) 
in the reaction mixture containing TpnW. The compound indicated by (▼) was observed 
in all reactions and has an identical m/z with 30 but has a slightly earlier tR. ▼may be a 



























Figure B.4: HPLC-MS analyses of the crude culture extract from S. laurentii. (a) Extracted 
ion chromatogram of m/z 833 thiostrepton A 2 (calculated [M+2H]+ m/z = 832.8) and the 
mass spectra at tR = 22.79 min and tR = 28.28 min (inset). (b) Extracted ion chromatogram 
of m/z 834 piperidine-containing thiostrepton analog 31 (calculated [M+2H]+ m/z = 833.8). 
(c) Extracted ion chromatogram of m/z 841 thioamide-containing thiostrepton analog 32 
(calculated [M+2H]+ m/z = 840.7). (d) Extracted ion chromatogram of m/z 842 piperidine 
and thioamide-containing thiostrepton analog 33 (calculated [M+2H]+ m/z = 841.8). (e) 













Figure B.5: HPLC-MS analyses of the crude culture extract from S. laurentii HI0, which 
houses the empty pSET1520 vector. (a) Extracted ion chromatogram of m/z 833 
thiostrepton A 2 (calculated [M+2H]+ m/z = 832.8) and the mass spectra at tR = 22.28 min 
and tR = 27.47 min (inset). (b) Extracted ion chromatogram of m/z 834 piperidine-
containing thiostrepton analog 31 (calculated [M+2H]+ m/z = 833.8). (c) Extracted ion 
chromatogram of m/z 841 thioamide-containing thiostrepton analog 32 (calculated 
[M+2H]+ m/z = 840.7). (d) Extracted ion chromatogram of m/z 842 piperidine and 
thioamide-containing thiostrepton analog 33 (calculated [M+2H]+ m/z = 841.8). (e) Total 












Figure B.6: HPLC-MS analyses of the crude culture extract from S. laurentii HI1, a strain 
that expresses TpnL. (a) Extracted ion chromatogram of m/z 833 thiostrepton A 2 
(calculated [M+2H]+ m/z = 832.8) and the mass spectra at tR = 22.28 min and tR = 27.77 
min (inset). (b) Extracted ion chromatogram of m/z 834 piperidine-containing thiostrepton 
analog 31 (calculated [M+2H]+ m/z = 833.8) and the mass spectra at tR = 20.30 and tR = 
24.91 min (inset). (c) Extracted ion chromatogram of m/z 841 thioamide-containing 
thiostrepton analog 32 (calculated [M+2H]+ m/z = 840.7). (d) Extracted ion chromatogram 
of m/z 842 piperidine and thioamide-containing thiostrepton analog 33 (calculated 
[M+2H]+ m/z = 841.8). (e) Total ion chromatogram of the crude culture extract from 






Figure B.7: HPLC-MS analyses of the crude culture extract from S. laurentii HI2, a strain 
that expresses TpnM. (a) Extracted ion chromatogram of m/z 833 thiostrepton A 2 
(calculated [M+2H]+ m/z = 832.8) and the mass spectra at tR = 22.35 min and tR = 27.69 
min (inset). (b) Extracted ion chromatogram of m/z 834 piperidine-containing thiostrepton 
analog 31 (calculated [M+2H]+ m/z = 833.8). (c) Extracted ion chromatogram of m/z 841 
thioamide-containing thiostrepton analog 32 (calculated [M+2H]+ m/z = 840.7). (d) 
Extracted ion chromatogram of m/z 842 piperidine and thioamide-containing thiostrepton 
analog 33 (calculated [M+2H]+ m/z = 841.8). (e) Total ion chromatogram of the crude 












Figure B.8: HPLC-MS analyses of the crude culture extract from S. laurentii HI3, a strain 
that expresses TpnN. (a) Extracted ion chromatogram of m/z 833 thiostrepton A 2 
(calculated [M+2H]+ m/z = 832.8) and the mass spectra at tR = 22.28 min and tR = 27.84 
min (inset). (b) Extracted ion chromatogram of m/z 834 piperidine-containing thiostrepton 
analog 31 (calculated [M+2H]+ m/z = 833.8). (c) Extracted ion chromatogram of m/z 841 
thioamide-containing thiostrepton analog 32 (calculated [M+2H]+ m/z = 840.7). (d) 
Extracted ion chromatogram of m/z 842 piperidine and thioamide-containing thiostrepton 
analog 33 (calculated [M+2H]+ m/z = 841.8). (e) Total ion chromatogram of the crude 












Figure B.9: HPLC-MS analyses of the crude culture extract from S. laurentii HI4, a strain 
that expresses TpnR. (a) Extracted ion chromatogram of m/z 833 thiostrepton A 2 
(calculated [M+2H]+ m/z = 832.8) and the mass spectra at tR = 22.28 min and tR = 27.69 
min (inset). (b) Extracted ion chromatogram of m/z 834 piperidine-containing thiostrepton 
analog 31 (calculated [M+2H]+ m/z = 833.8). (c) Extracted ion chromatogram of m/z 841 
thioamide-containing thiostrepton analog 32 (calculated [M+2H]+ m/z = 840.7). (d) 
Extracted ion chromatogram of m/z 842 piperidine and thioamide-containing thiostrepton 
analog 33 (calculated [M+2H]+ m/z = 841.8). (e) Total ion chromatogram of the crude 






Figure B.10: HPLC-MS analyses of the crude culture extract from S. laurentii HI5, a strain 
that coexpresses TpnLM. (a) Extracted ion chromatogram of m/z 833 thiostrepton A 2 
(calculated [M+2H]+ m/z = 832.8) and the mass spectra at tR = 22.79 min and tR = 28.42 
min (inset). (b) Extracted ion chromatogram of m/z 834 piperidine-containing thiostrepton 
analog 31 (calculated [M+2H]+ m/z = 833.8) and the mass spectra at tR = 20.89 min and tR 
= 25.42 min (inset). (c) Extracted ion chromatogram of m/z 841 thioamide-containing 
thiostrepton analog 32 (calculated [M+2H]+ m/z = 840.7). (d) Extracted ion chromatogram 
of m/z 842 piperidine and thioamide-containing thiostrepton analog 33 (calculated 
[M+2H]+ m/z = 841.8). (e) Total ion chromatogram of the crude culture extract from 











Figure B.11: HPLC-MS analyses of the crude culture extract from S. laurentii HI6, a strain 
that coexpresses TpnMN. (a) Extracted ion chromatogram of m/z 833 thiostrepton A 2 
(calculated [M+2H]+ m/z = 832.8) and the mass spectrum at tR = 27.84 (inset). (b) Extracted 
ion chromatogram of m/z 834 piperidine-containing thiostrepton analog 31 (calculated 
[M+2H]+ m/z = 833.8). (c) Extracted ion chromatogram of m/z 841 thioamide-containing 
thiostrepton analog 32 (calculated [M+2H]+ m/z = 840.7) and the mass spectrum at tR = 
22.35 (inset). (d) Extracted ion chromatogram of m/z 842 piperidine and thioamide-
containing thiostrepton analog 33 (calculated [M+2H]+ m/z = 841.8). (e) Total ion 











Figure B.12: HPLC-MS analyses of the crude culture extract from S. laurentii HI7, a strain 
that coexpresses TpnLMN. (a) Extracted ion chromatogram of m/z 833 thiostrepton A 2 
(calculated [M+2H]+ m/z = 832.8) and the mass spectra at tR = 22.79 and tR = 28.43 min 
(inset). (b) Extracted ion chromatogram of m/z 834 piperidine-containing thiostrepton 
analog 31 (calculated [M+2H]+ m/z = 833.8) and the mass spectra at tR = 20.81 and tR = 
25.50 min (inset). (c) Extracted ion chromatogram of m/z 841 thioamide-containing 
thiostrepton analog 32 (calculated [M+2H]+ m/z = 840.7). (d) Extracted ion chromatogram 
of m/z 842 piperidine and thioamide-containing thiostrepton analog 33 (calculated 
[M+2H]+ m/z = 841.8) and the mass spectrum at tR = 29.01 min (inset). (e) Total ion 












Figure B.13: MS analyses of thiostrepton Aa 31. (a) ESI-MS analysis of thiostrepton Aa 
































Figure B.14: The proposed structures of fragments of thiostrepton Aa 31 following 
MS/MS of parent ion m/z 833.8. 
 
Fragment Expected Observed 
1.     [M+Na]+ 





2.     [M+H]+ 





3.     [M+Mn]2+ 860.7269 860.7206 
4.     [M-Dha3-OH+2H]2+ 790.8 790.8 
5.     [M-Dha17-Dha16+2H]2+ 764.8 764.8 
6.     [M-Ile1-Ala2+H]+ 1482.4 1482.4 
7a.   [M-Q+H]+ 1433.4 1433.4 
7b.   [M-Q-OH+H]+ 1416.4 1416.4 
8.     [M-Ile1-Ala2-Dha3+H]+ 1413.4 1413.3 
9a.   [M-Q-Ile1-Ala2+H]+ 1249.3 1249.4 
9b.   [M-Q-Ile1-Ala2-OH+H]+ 1232.3 1232.3 
9c.   [M-Q-Ile1-Ala2-OH-H2O+H]+ 1214.3 1214.3 
10a. [M-Q-Ile1-Ala2-Dha3+H]+ 1180.3 1180.3 
10b. [M-Q-Ile1-Ala2-Dha3-OH+H]+ 1163.3 1163.3 
11.   [M-Q-Ile1-Ala2-Dha3-Dha17+H]+ 1111.3 1111.3 
12a. [M-Q-Ile1-Ala2-Dha3-Ala4+H]+ 1109.3 1109.3 
12b. [M-Q-Ile1-Ala2-Dha3-Ala4-OH+H]+ 1094.3 1094.3 
13.   [M-CO+2H]2+ 819.8 819.8 
14.   [M-OH-H2O+2H]2+ 816.3 816.3 
15.   [M-2H2O+2H]2+ 815.8 815.8 
16.   [M-CO-OH+2H]2+ 811.3 811.3 
17a. [M-IIe1(CO)-Ala2+2H]2+ 784.2 784.3 
17b. [M-IIe1(CO)-Ala2-OH+2H]2+ 775.7 775.8 
18.   [M-IIe1(CO)-Ala2-Dha3-OH+2H]2+ 741.2 741.3 
19.   [M-Ile1(CO)-Ala2-Dha3-Dha17+2H]2+ 715.2 715.3 

























Table B.2: 1H and 13C NMR assignments of thiostrepton Aa 31. 
Position δc [ppm]; 
mult. 
δH [ppm]; 
(mult, J in Hz) 
HMBCa COSYb 
Ile1     
Ile1-1 173.7; C q    
Ile1-2 65.6; CH 3.12 (t, 4.6) Ile1-1; Ile1-3; Ile1-4; Q-8 Ile1-3; Ile1-NH 
Ile1-3 37.8; CH 1.76-1.73 (m)  Ile1-2; Ile1-4-HA; Ile1-4-HB; Ile1-6 
Ile1-4 24.0; CH2 HA: 1.41-1.37 (m) 
HB: 1.21-1.13 (m) 
Ile1-3; Ile1-5; Ile1-6 
Ile1-2; Ile1-3; Ile1-5; Ile1-6 
Ile1-3; Ile1-4-HB; Ile1-5 
Ile1-3; Ile1-4-HA; Ile1-5 
Ile1-5 11.5; CH3 0.81 (t, 7.3) Ile1-3; Ile1-4 Ile1-4-HA; Ile1-4-HB 
Ile1-6 15.7; CH3 0.92 (d, 6.7) Ile1-2; Ile1-3; Ile1-4 Ile1-3 
Ile1-NH  2.39 (br s)  Ile1-2; Q-8 
     
Ala2     
Ala2-1 172.3; C q    
Ala2-2 48.6; CH 4.48 (m) Ala2-1 Ala2-3; Ala2-NH 
Ala2-3 18.1; CH3 1.27 (d, 7.0) Ala2-1; Ala2-2 Ala2-2 
Ala2-NH  8.53 (d, 4.2) Ile1-1; Ala2-2 Ala2-2 
     
Dha3     
Dha3-1 164.3; C q    
Dha3-2 135.7; C q    
Dha3-3 108.5; CH2 HA: 5.66 (s) 




Dha3-NH  7.91 (s)   
     
Ala4     
Ala4-1 172.0; C q    
Ala4-2 49.1; CH 4.60 (br s)  Ala4-3; Ala4-NH 
Ala4-3 16.6; CH3 1.30 (d, 8.1) Ala4-1; Ala4-2 Ala4-2 
Ala4-NH  8.45 (br s)  Ala4-2 
     







HA: 2.12-2.08 (m) 





Pip-2; Pip-3-HB; Pip-4-HA; Pip-4-HB 
Pip-2; Pip-3-HA; Pip-4-HA; Pip-4-HB 
Pip-4 30.6; CH2 HA: 3.06-3.02 (m) 
HB: 2.63-2.58 (m) 
Pip-2; Pip-6 Pip-3-HA; Pip-3-HB; Pip-4-HB 
Pip-3-HA; Pip-3-HB; Pip-4-HA 
Pip-5 
Pip-5-NH 
60.5; C q  
9.43 (br s) 
  
Pip-6 65.9; CH 4.76 (br s)  Pip-NH 
Pip-NH  4.05 (br s) Pip-5 Pip-2; Pip-3-HA; Pip-6 
     
Thz6      
Thz6-1 159.7; C q    
Thz6-2 148.6; C q    
Thz6-3 124.7; CH 8.00 (s) Thz6-1; Thz6-2; Thz6-4  
Thz6-4 173.7; C q    
     
Thr7     
Thr7-1 168.1; C q    
Thr7-2 56.7; CH 4.63 (dd, 7.5, 4.3) Thr7-1; Thr7-3; Thr7-4 Thr7-3; Thr7-NH 
Thr7-3 66.2; CH 4.01- 3.97 (m)  Thr7-2; Thr7-3-OH; Thr7-4 
Thr7-3-OH  5.23 (d, 2.1)  Thr7-3 
Thr7-4 17.0; CH3 0.82 (d, 7.0) Thr7-2; Thr7-3 Thr7-3 
Thr7-NH  7.81 (br s)  Thr7-2 
     
Dhb8     
Dhb8-2 129.9; C q    
Dhb8-3 134.9; CH 6.40 (q, 6.7) Dhb8-2; Dhb8-4; Tzn9-4 Dhb8-4 
Dhb8-4 13.9; CH3 1.77 (d, 6.9) Dhb8-2; Dhb8-3; Tzn9-4 Dhb8-3; Dhb8-NH 
Dhb8-NH  9.21 (s) Thr7-1 Dhb8-4 
     
Tzn9     
Tzn9-1 170.9; C q    
Tzn9-2 77.6; CH 5.31 (t, 8.2) Thz9-1; Thz9-4; Dhb8-2 Tzn9-3-HA; Tzn9-3-HB 
Tzn9-3 35.2; CH2 HA: 3.65 (t, 10.2) 
HB: 3.51-3.47 (m) 




Tzn9-4 168.5; C q    
     
197 
 
Ile10     
Ile10-2 57.4; CH 5.37 (d, 8.9) Tzn9-1; Ile10-3; Ile10-4;  
Ile10-6; Thz11-4 
Ile10-NH 
Ile10-3 74.9; C q    
Ile10-3-OH  5.47 (br s) Ile10-2; Ile10-3; Ile10-4;  
Ile10-6 
 
Ile10-4 67.8; CH 3.56 (dq, 5.8, 5.7) Ile10-3 Ile10-4-OH; Ile10-5 
Ile10-4-OH  4.70 (d, 3.0) Ile10-5 Ile10-4 
Ile10-5 16.5; CH3 1.06 (d, 6.1) Ile10-3; Ile10-4 Ile10-4 
Ile10-6 17.5; CH3 0.76 (s) Ile10-2; Ile10-3; Ile10-4  
Ile10-NH  8.78 (br s)  Ile10-2 
     
Thz11     
Thz11-1 160.1; C q    
Thz11-2 146.5; C q    
Thz11-3 127.2; CH 8.39 (s) Thz11-1; Thz11-2; Thz11-4  
Thz11-4 167.9; C q    
     
Thr12     
Thr12-2 53.3; CH 5.60 (t, 5.4)  Thr12-3; Thr12-NH 
Thr12-3 70.1; CH 5.48-5.45 (m)  Thr12-2; Thr12-4 
Thr12-4 13.9; CH3 0.68 (br s)  Thr12-3 
Thr12-NH  7.89 (br s)  Thr12-2 
     
Thz13     




165.1; C q 
7.94 (s) Thz13-4  
     
Thz15     
Thz15-1 159.3; C q    
Thz15-2 148.2; C q    
Thz15-3 125.3; CH 8.36 (s) Thz15-1; Thz15-2; Thz15-4  
Thz15-4 175.6; C q    
     
Dha16     
Dha16-1 162.0; C q    
Dha16-2 134.9; C q    
Dha16-3 104.9; CH2 HA: 6.34 (s) 





Dha16-NH  9.89 (s) Thz15-1; Dha16-1; Dha16-3 Dha16-3-HB 
     
Dhb17     
Dha17-1 165.1; C q    
Dha17-2 135.0; C q    
Dha17-3 105.8; CH2 HA: 6.04 (s) 





Dha17-NH  9.39 (s) Dha16-1; Dha17-1; Dha17-3 Dha17-3-HA; Dha17-3-HB 
Dha17-NH2  HA: 7.94 (s) 





     
Q     
Q-1 164.3; C q    
Q-2 144.1; C q    
Q-3 121.5; CH 8.17 (s) Q-1; Q-2; Q-5; Q-11  
Q-4 
Q-5 
151.5; C q 




Q-6 120.9; CH 6.86 (dd, 10.2, 1.0) Q-4; Q-5; Q-8; Q-7; Q-9; Q-10 Q-7; Q-8 
Q-7 135.2; CH 6.36-6.34 (m) Q-5; Q-8; Q-9 Q-6; Q-8 
Q-8 59.9; CH 3.51-3.47 (m) Q-6; Q-7; Q-9 Ile1-NH; Q-6; Q-7; Q-9 
Q-9 73.2; CH 4.68-4.66 (m) Q-5; Q-7; Q-8; Q-10 Q-8; Q-9-OH 
Q-9-OH  5.11 (s) Q-8; Q-9; Q-10 Q-9 
Q-10 156.0; C q    
Q-11 64.1; CH 5.08 (dq, 5.7, 5.5) Q-2; Q-3; Q-4; Q-12 Q-11-OH; Q-12 
Q-11-OH  5.59 (d, 4.2) Q-4; Q-11; Q-12 Q-11 
Q-12 24.6; CH3 1.31 (d, 6.6) Q-4; Q-11 Q-11 
 
a HMBC correlations are from the proton to the indicated carbon.  
































Table B.3: 1H-1H ROESY correlations of the piperidine moiety of thiostrepton Aa 31. 
Correlations used for the assignment of the configuration at Pip-2 is shown in blue. 
 
 δH [ppm]; 
(mult, J in Hz) 
ROESY correlation 
Pip   
Pip-2 4.68-4.66 (m) Pip-3-HA; Pip-4-HB; Pip-NH 
Pip-3 HA: 2.12-2.08 (m) 
HB: 1.70-1.65 (m) 
Pip-2-H; Pip-3-HB; Pip-4-HB 
Pip-3-HA; Pip-4-HA 
Pip-4 HA: 3.06-3.02 (m) 
HB: 2.63-2.58 (m) 
Pip-4-HB; Pip-3-HB 
Pip-2-H; Pip-3-HA; Pip-4-HA; Pip-6-H 
Pip-5   
Pip-5-NH 9.43 (br s)  
Pip-6 4.76 (br s) Pip-4-HB; Pip-NH 




Figure B.22: The configuration of the piperidine moiety of thiostrepton Aa 31 overlaid 
with ROESY correlations. Correlations used for the assignment of the configuration at Pip-













Figure B.23: 1H-1H ROESY NMR spectrum of thiostrepton Aa 31 (800 MHz, DMSO-d6, 
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Figure B.24: Growth inhibition of Bacillus sp. by thiostrepton A 2 and Aa 31.  Results from 
three trials are shown. The MIC of thiostrepton A 2 was determined to be: (a) 0.0253 
µg/mL, (b) 0.0231 µg/mL, and (c) 0.0182 µg/mL. The MIC of thiostrepton Aa 31 was 
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Figure B.25: Growth inhibition of vancomycin-resistant Enterococcus faecium (VRE) by 
thiostrepton A 2 and Aa 31.  Results from two trials are shown. The MIC of thiostrepton A 
2 was determined to be: (a) 0.0126 µg/mL and (b) 0.0268 µg/mL.  The MIC of thiostrepton 
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Figure B.26: Growth inhibition of methicillin-resistant Staphylococcus aureus (MRSA) 
by thiostrepton A 2 and Aa 31.  The MIC of thiostrepton A 2 was determined to be: (a) 
0.0519 µg/mL, (b) 0.0166 µg/mL, (c) 0.1562 µg/mL, and (d) 0.0195 µg/mL.  The MIC of 
thiostrepton Aa 31 was determined to be: (a) 0.1027 µg/mL, (b) 0.0334 µg/mL, (c) 0.2184 
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Figure B.27: Inhibition of prokaryotic ribosomal translation by thiostrepton A 2 and 









Figure B.28: HPLC-MS analyses of the in vitro reconstitution of TpnL activity after 1-hour 
incubation. (a) Extracted ion chromatogram of m/z 833 for thiostrepton A 2 (calculated 
[M+2H]2+ m/z = 832.8) and the mass spectrum at tR = 27.15 min (inset) of a reaction lacking 
TpnL. (b) Extracted ion chromatogram of m/z 834 for thiostrepton Aa 31 (calculated 
[M+2H]2+ m/z = 833.8) and the mass spectrum at tR = 27.08 min (inset) of a reaction lacking 
TpnL. (c) Extracted ion chromatogram of m/z 833 for thiostrepton A 2 and the mass 
spectrum at tR = 27.08 min (inset) of a reaction containing TpnL. (d) Extracted ion 
chromatogram of m/z 834 for thiostrepton Aa 31 and the mass spectrum at tR = 24.66 min 
(inset) of a reaction containing TpnL. 
 
 
